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ABSTRACT 
 Salt-sensitive hypertension, a key component of essential hypertension, affects 
approximately 50% of hypertensive patients and dramatically increases the risk of 
adverse cardiovascular events. Excess dietary sodium intake is an established cause of 
hypertension, but there remains no clear understanding of the central molecular pathways 
acting to facilitate sodium homeostasis and normotension in salt-resistant phenotypes, or 
potential derangements in these antihypertensive systems in salt-sensitive hypertension. 
Therefore, there exists a critical need to elucidate the neural mechanisms that account for 
the phenotypic difference between salt-resistance and salt-sensitivity. The current studies 
hypothesize that hypothalamic paraventricular nucleus (PVN) Gαi2 proteins mediate the 
central responses activated to counter the development of salt-sensitive hypertension. 
 Salt-resistant (Sprague-Dawley, Dahl salt-resistant, Brown Norway) and salt-
sensitive (Dahl salt-sensitive, 8-congenic Dahl salt-sensitive) rat phenotypes were utilized 
to investigate the role of central Gαi2 proteins in the physiological regulation of blood 
pressure in response to acute and chronic challenges to sodium homeostasis.  
 Salt-resistant animals remain normotensive following chronic high salt intake and 
exhibit an endogenous site-specific increase in PVN Gαi2 proteins. Exogenous 
		 vi 
oligodeoxynucleotide-mediated downregulation of Gαi2 proteins throughout the brain 
evokes rapid renal nerve-dependent hypertension, sodium retention, and 
sympathoexcitation in animals typically salt-resistant. In salt-sensitive animals, Gαi2 
protein downregulation exacerbated salt-sensitive hypertension via a renal nerve-
dependent mechanism. Central Gαi2 protein downregulation also resulted in prolonged 
elevated blood pressure mediated by an attenuated activation of parvocellular PVN 
neurons. The PVN is the critical brain site at which the antihypertensive compensatory 
action of Gαi2 protein mediated signal transduction influences blood pressure regulation.  
PVN Gαi2 protein-mediated signal transduction represents a conserved central 
molecular pathway mediating sympathoinhibitory renal nerve-dependent responses 
evoked to maintain sodium homeostasis and a salt-resistant phenotype. This also 
differentially influences PVN parvocellular neuronal activation, sympathetic outflow, and 
arterial pressure in response to sodium challenges, independently of actions on 
magnocellular neurons and vasopressin release. Impairment of this signaling mechanism 
contributes to the development of salt-sensitive hypertension. Collectively, this work 
highlights the complex interaction between the CNS and kidney, and the role of the 
sympathetic nervous system, in the short and long-term regulation of blood pressure. 
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PREFACE 
All experiments outlined in this dissertation are organized in the format of 
published manuscripts or submitted manuscripts.  
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CHAPTER ONE: Introduction 
Hypertension 
Hypertension, or high blood pressure, is a global public health issue (WHO, 
2013). Approximately 9.4 million deaths worldwide every year can be attributed to 
complications of hypertension (Lim et al., 2012) and it is the leading global non-
communicable cause of mortality and number one risk factor for disability-adjusted life 
years (Danaei et al., 2011; Lim et al., 2012; Lozano et al., 2012; Murray et al., 2012). In 
the US alone, hypertension affects 1 in 3 adults and is predicted to be the leading global 
cause of death and disability by 2020 (Danaei et al., 2011; Lim et al., 2012; Lozano et al., 
2012; Mozaffarian et al., 2016), with annual projected healthcare costs estimated to reach 
$274 billion by 2030 (Go et al., 2013). The health and economic burden of hypertension 
is so great because it exacerbates a range of cardiovascular pathologies, including heart 
disease and stroke, as well as kidney failure and premature disability and mortality. It is 
the single largest risk factor for stroke, myocardial infarction, congestive heart failure, 
and chronic kidney disease (Kannel, 2000; Lifton et al., 2001; Luzardo et al., 2015). The 
global reach of this disease is somewhat astronomical and very much a public health 
burden, and a better understanding of the disease is needed to treat and prevent this trend 
from continuing to increase. 
As a heterogeneous disease, the pathogenesis of hypertension has remained 
elusive, but likely involves the complex integration of multiple regulatory systems. 
Hypertension in the early stages typically presents without symptoms, and thus many 
people go undiagnosed. Current therapies are also less than adequate due to our 
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incomplete understanding of the pathogenesis of hypertension.  
Salt-Sensitive Hypertension 
Especially damaging is salt-sensitive hypertension, defined as an exaggerated 
pressor response to dietary salt intake (Weinberger et al., 1986; Morimoto et al., 1997), 
which affects approximately 50% of hypertensive patients (Kotchen et al., 2013) and 
dramatically increases the risk of adverse cardiovascular events (Morimoto et al., 1997; 
Weinberger et al., 2001; Appel et al., 2011). The Centers for Disease Control and 
Prevention recommends limiting sodium to less than 2,300 mg a day (at the upper limit), 
while the average American consumes 3,400 mg a day. This represents excess 
consumption by 95% of men and 75% of women in the US—a significant proportion of 
individuals for which this could be relatively easy to control.  
A direct association between sodium intake and elevated blood pressure is evident 
in epidemiological studies (Strazzullo et al., 2009; Appel et al., 2011; Kotchen et al., 
2013). In salt-resistant subjects, neural and humoral sodium-retaining mechanisms are 
suppressed to facilitate normotension during high salt intake (Lohmeier et al., 1999; 
Brooks et al., 2005; Osborn et al., 2008; Johns et al., 2011). In contrast, dietary salt intake 
evokes increased sympathetic nervous system (SNS) activity and renal sodium retention 
in salt-sensitive subjects (Bayorh et al., 1998; Huang et al., 2001), resulting in 
hypertension (Blaustein et al., 2012; DiBona, 2013) (Fig. 1). Despite the relationship 
between dietary salt intake and the development of hypertension (Meneton et al., 2005; 
Luzardo et al., 2015)—epidemiological, experimental, and interventional observations 
have demonstrated a link between salt and blood pressure—skepticism still remains due 
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to a lack of causative evidence. 
 
Figure 1. Blood Pressure Changes in Salt-Sensitive versus Salt-Resistant Individuals 
Changes in blood pressure over time in salt-sensitive versus salt-resistant individuals following 
(A) acute or (B) chronic sodium intake. 
There is currently no clear understanding of the central molecular pathways acting 
to facilitate sodium homeostasis and normotension in salt-resistant phenotypes, or 
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potential derangements in these systems in salt-sensitive phenotypes. A paucity of 
knowledge exists around the sodium-sensitive mechanisms that operate between the brain 
(Ji et al., 2008; Fujita and Fujita, 2013; Noda and Sakuta, 2013; Stocker et al., 2013a) and 
the kidney (Ji et al., 2008; Mu et al., 2011; Terker et al., 2014) to facilitate sodium 
homeostasis and long-term blood pressure regulation. Therefore, there exists a critical 
need to elucidate the neural mechanisms that account for the phenotypic difference 
between salt-resistance and salt-sensitivity. Delineating these mechanisms will likely 
identify new therapeutics for hypertension. 
Salt and the Nervous System 
Recent work has explored the role of brain mechanisms in both the short (i.e., 
initiation) and long-term (i.e., maintenance) control of blood pressure. Highlighting the 
importance of central pathways involved in blood pressure regulation, it has been 
suggested that more than 50% of clinical hypertension cases can be categorized as 
neurogenic essential hypertension (Parati and Esler, 2012). Among multiple proposed 
mechanisms, impaired SNS activity has been hypothesized to play a critical role in the 
development of salt-sensitive hypertension (Brooks et al., 2005; Osborn et al., 2009; 
Fujita and Fujita, 2013)—a theory gaining traction following reports of increased SNS 
activity in animal models of salt-sensitive hypertension (Kandlikar and Fink, 2011a; Foss 
et al., 2013) and salt-sensitive humans (Yatabe et al., 2010). The central nervous system 
(CNS), a key regulator of sympathetic nerve activity and blood pressure, plays a critical 
role in sodium-induced sympathoexcitation and hypertension (Fujita and Fujita, 2016).  
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Exaggerated sympathetic nerve activity (SNA) significantly contributes to salt-
sensitive cardiovascular disease. Support for this SNS component in salt-sensitive 
hypertension arises from multiple lines of evidence: 1) population studies that indicate 
that normotensive humans with greater salt intake are at an increased risk for an adverse 
cardiovascular event (Cook et al., 2007; Strazzullo et al., 2009; Cook et al., 2014), 2) 
acute and chronic elevations in sodium concentration activate the SNS (Stocker et al., 
2010; Stocker et al., 2013a), and 3) elevated SNA in multiple animal models of 
hypertension (Bayorh et al., 1998; Kandlikar and Fink, 2011a; Ando, 2014). Despite this, 
many of the mechanistic details of precisely how the body recognizes sodium and the 
neural circuitry mediating subsequent sympathetic nerve discharge remain largely 
unexplored. 
There is an emerging role for plasma or cerebrospinal fluid (CSF) hypernatremia 
as a key mediator of sympathoexcitation and elevated blood pressure (Toney & Stocker, 
2010). Recent work suggests that dietary salt, via elevations in plasma or CSF sodium, 
may modulate sympathetic neuron responsiveness and act to increase the gain of central 
sympathetic networks (Simmonds et al., 2014). Dietary salt, independent of elevations in 
blood pressure, works through the forebrain hypothalamus to modulate centrally-
mediated cardiovascular reflexes and alter the functional regulation of SNA (Simmonds 
et al., 2014). It has been suggested that a reduction in GABAergic function of 
hypothalamic paraventricular nucleus (PVN) neurons acts as a potential mechanism by 
which elevations in sodium result in increased SNA (Patel, 2000). There has also been 
emphasis on the ability of PVN neurons to differentially control sympathetic outflow to 
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distinct end organs (Stocker et al., 2013b). Nonetheless, the integrated sodium-sensitive 
mechanisms that operate between the brain and the kidney to facilitate sodium 
homeostasis and normotension in salt-resistant phenotypes remain to be established. 
Neural Sites of Sodium Sensing 
The precise mechanism by which the body detects elevations in total body sodium 
is poorly understood. Alterations in body fluid osmolality/sodium concentration have 
been postulated to be sensed by two nervous system mechanisms: 1) Osmo- and sodium-
sensitive neurons localized primarily at the anteroventral third ventricle (AV3V) 
circumventricular (CVO) organs or 2) mechano- and chemosensitive renal afferent nerve 
terminals localized at the renal pelvis. These sodium-sensitive mechanisms influence 
sympathetic nervous system regulation of sodium homeostasis and blood pressure 
through undetermined circuitry. 
Neurons of the AV3V region are intrinsically osmo- and sodium-sensitive and act 
as an important site of exchange between the CNS and peripheral blood flow due to the 
extensive vasculature and lack of a normal blood brain barrier (McKinley et al., 1998; 
Ganong, 2000). Notably, CVO neurons have direct projections to the PVN that are active 
in cardiovascular responses and osmoregulation (Gordon et al., 1982; Ganong, 2000) 
(Fig. 2A, B). Under physiological conditions, the neurons of the PVN are largely 
influenced by the CVOs of the AV3V region, which monitor the extracellular osmotic 
pressure of the systemic circuit (Larsen and Mikkelsen, 1995). Lesions of the AV3V 
structures—specifically the median preoptic nucleus (MnPO) and organum vasculosum 
of the lamina terminalis (OVLT)—significantly attenuates the functional output of PVN 
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neurons to the hypertonic saline injection model of “acute” stress (Ramsay et al., 1983; 
Leng et al., 1992). Numerous studies have utilized cFos immunoreactivity to functionally 
identify central afferent structures of the AV3V region that convey information of 
hyperosmotic stress to the PVN (Larsen and Mikkelsen, 1995; Dampney and Horiuchi, 
2003). Evidence also suggests that sympathoexcitatory effects of acute hypernatremia are 
in part, mediated by CVO neuronal projections to preganglionic neurons, via the PVN, to 
alter blood pressure (Chen and Pan, 2006; Stocker et al., 2013a). These data highlight the 
CVOs as a candidate brain region responsible for sensing salt and initiating endogenous, 
counter-regulatory actions. 
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Figure 2. Neuroanatomy of the Circumventricular Organs and Paraventricular Nucleus of 
the Hypothalamus  
(A) Circumventricular organ projections to the paraventricular nucleus of the hypothalamus and 
(B) location of the hypothalamic paraventricular nucleus in the coronal plane of a rat brain 
(Paxinos and Watson, 1998). 
 
Further, increasing attention is focusing on the role of the renal sympathetic 
nerves in blood pressure regulation following reports that catheter-based renal nerve 
ablation attenuates hypertension in human subjects (Esler et al., 2012; Krum et al., 2014). 
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Despite these recent advances, it is widely acknowledged that the CNS mechanisms that 
modulate central sympathetic outflow to the kidney to facilitate sodium homeostasis and 
blood pressure regulation require further investigation (Brooks et al., 2005; Ellison and 
Brooks, 2011; Stocker et al., 2013a). A key mechanistic question that remains is whether 
renal denervation (RDNX) lowers blood pressure secondary to ablation of the afferent or 
efferent renal nerves (Foss et al., 2016).  
The afferent renal nerves project to the central nervous system via supraspinal 
integration. The cell bodies of the afferent renal nerves are located in ipsilateral dorsal 
root ganglia (DRG) from T6 to L4 (Donovan et al., 1983; Weiss and Chowdhury, 1998), 
with very few derived from the contralateral DRG. Within the spinal cord, they project to 
the ipsilateral dorsal horn in laminae I, III-V (Ciriello and Calaresu, 1983), where they 
synapse with interneurons projecting to sites within the CNS associated with 
cardiovascular regulation, including the PVN (Solano-Flores et al., 1997). 
The renal nerves act as a negative feedback circuit, also known as the renorenal 
reflex (Kopp, 2015). Increases in efferent renal sympathetic nerve activity (ERSNA) 
increase afferent renal nerve activity (ARNA) to promote a subsequent decrease in 
ERSNA (Fig. 3). This activation of the renorenal reflexes to maintain low ERSNA 
minimizes sodium retention. Thus, high-sodium diet enhances the responsiveness of the 
renal sensory nerves, while low dietary sodium reduces the responsiveness to produce 
physiologically appropriate responses to maintain sodium balance in normotensive 
animals. Hypertension can be characterized by a pathophysiological hyporesponsiveness 
of the renal sensory nerves, allowing the excitatory reflexes of the efferent renal nerves to 
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prevail.  This suggests that impairment of this inhibitory renorenal reflex may act as a 
contributor to sodium retention and hypertension. Therefore, the afferent renal nerves 
arise as a potential candidate by which increases in total body fluid sodium are sensed to 
mediate appropriate central sympathetic outflow and physiological blood pressure 
control. 
 
Figure 3. Renorenal Reflex: The Negative Feedback Interaction Between ERSNA and 
ARNA 
Schematic representation of the renorenal reflex with (A) intact afferent renal sympathetic nerves 
and (B) selective denervation of afferent renal sympathetic nerves or pathological conditions 
characterized by ARNA hyporesponsiveness.  
 
Hypothalamic Signaling Mechanisms in Hypertension 
Over the last several years, the understanding of the signaling pathways acting 
within the hypothalamus to regulate blood pressure have dramatically increased. The 
PVN of the hypothalamus is a critical brain site acting to integrate central and peripheral 
inputs to ultimately impact blood pressure in multiple disease states that evoke 
hypertension (Coote, 1995; Coote et al., 1998; Coote, 2005; Guyenet, 2006; Fujita and 
Fujita, 2013). The hypothalamus acts as the interface between the endocrine and nervous 
systems (Guyenet, 2006), and a wide variety of functional changes in the hypothalamus 
characterize multiple forms of hypertension (Kenney et al., 2003; Parati and Esler, 2012). 
Increased understanding of hypothalamic activity in hypertension has the potential to 
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identify novel targets for future therapeutic interventions designed to treat hypertension. 
The PVN is an essential component of the neural network that regulates 
cardiovascular and fluid homeostasis and sympathetic outflow (Guyenet, 2006; Stocker et 
al., 2010) by serving to coordinate and integrate signal transduction in response a 
stimulus (Fig. 3). Neurons of the PVN have mono- and polysynaptic projections to the 
rostral ventrolateral medulla (RVLM), as well as directly to T1-T3 of the 
intermediolateral (IML) cell column of the spinal cord (Guyenet, 2006) by which 
sympathetic nerve discharge is modulated in a variety of physiological conditions. 
The PVN remains a predominant site within the hypothalamus at which signal 
transduction pathways in multiple hypertensive disease states evoke autonomic and 
endocrine imbalance to drive elevations in both sympathetic outflow and blood pressure 
(Coote, 1995; Coote et al., 1998). Recent work has focused on identifying the synaptic 
mechanisms driving increased PVN neuronal activity. In the Spontaneously Hypertensive 
Rat (SHR) model of neurogenic hypertension, patch-clamp electrophysiological studies 
conducted in brain slices have revealed that there is increased activity of spinally-
projecting PVN presympathetic neurons (Ye et al., 2012b; Ye et al., 2013; Li et al., 2014) 
and preautonomic PVN neurons that innervate the nucleus tractus solitarius (NTS) (Stern 
et al., 2012). Increased excitability of preautonomic PVN neurons is primarily mediated 
by an input-output function in response to depolarizing stimuli (Stern et al., 2012). PVN 
presympathetic neuron tone is regulated by excitatory and inhibitory GABAergic inputs. 
The polarities of the actions of γ-aminobutyric acid (GABA) on the GABAA receptor, a 
ligand-gated ion channel, are strongly influenced by intracellular chloride concentrations. 
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In the SHR, dysregulation of the intracellular chloride homeostasis of PVN 
presympathetic neurons is evoked by upregulation and glycosylation of the Na+-K+-
2Cl− cotransporter 1 (NKCC1) (Ye et al., 2012b), and this contributes to the impaired 
PVN GABAergic synaptic inhibition and increased sympathetic tone observed in the 
SHR. Additionally, impairment of PVN GABAergic inhibitory signaling has been 
observed in vivo in a mouse model of neurogenic hypertension (i.e., the Schlager mouse). 
This alteration of GABAergic signaling is postulated to contribute to Schlager mouse 
hypertension through reduced PVN inhibitory drive to presympathetic neurons (Hirooka 
et al., 2013). 
Highlighting the complexity of PVN glutamatergic pathways on the activity of 
spinally projecting PVN neurons are the opposing actions of group I and group II 
metabotropic glutamate receptors (mGluRs). The activity of group II mGluRs at PVN 
glutamatergic terminals, determined via patch-clamp studies in isolated brain slices, is 
enhanced in the SHR (Ye et al., 2013). This elevated activation of mGluRs attenuates 
increased glutamatergic input via a negative feedback pathway to reduce presympathetic 
PVN neuronal hyperactivity. In companion in vivo PVN microinjection studies, mGluR 
activation evoked reductions in sympathetic vasomotor tone and blood pressure in the 
SHR (Ye et al., 2013), suggesting that activation of PVN group II mGluRs attenuates 
elevated glutamatergic inputs and neuronal hyperactivity in the SHR. In contrast, 
determined in hypothalamic slices, increased endogenous expression of the group I 
mGluR5 in the PVN of the SHR drives increased basal firing of spinally projecting PVN 
neurons (Li et al., 2014). In vivo studies provide evidence that the mechanism underlying 
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mGluR5-driven hyperactivity of PVN presympathetic neurons in the SHR involves 
recruitment of N-methyl-d-aspartate (NMDA) receptors to the cell surface. This occurs 
via a protein kinase C (PKC) and synaptosomal-associated protein-mediated signal 
transduction pathway to increase NMDA receptor-mediated activity and subsequently 
sympathetic tone and blood pressure (Li et al., 2014). 
Increased presympathetic PVN neuron firing, as assessed in hypothalamic slices, 
is driven in part by an NMDA receptor-calpain-calcineurin signaling pathway that evokes 
glutamate receptor 2 (GluR2) internalization, increasing the activity of GluR2-lacking α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Li et al., 
2012). In addition to altering AMPA receptor activity, the NMDA receptor directly 
increases glutamatergic activity. Potentiated pre- and postsynaptic PVN NDMA receptor 
activity, determined via brain slice electrophysiological studies, is mediated by 
upregulation of synaptic GluR2A, an NMDA receptor subunit, that is dependent on 
protein kinase casein kinase 2 (PKCK2) activity (Ye et al., 2012a). PKCK2 also 
influences the activity of the small conductance calcium-activated K+ (SK) channel in the 
PVN. The SK channel impacts the intrinsic activity of presympathetic PVN neurons, and 
SK activity is reduced in the SHR via a CK2-mediated calmodulin phosphorylation 
mechanism (Pachuau et al., 2014). A critical issue facing the field, which remains to be 
fully addressed, is the potential difference in synaptic activity in vivo versus the 
measurements made in brain slices in which synaptic connections and synaptic drive are 
lost. Owing to considerable technical impediments, despite the significant insight 
provided via electrophysiological patch-clamp studies conducted in PVN neuron 
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containing brain slices (Stern et al., 2012; Ye et al., 2013; Li et al., 2014; Pachuau et al., 
2014), our understanding of PVN neuronal synaptic activity in vivo in hypertensive 
animals models remains limited. 
Selectivity of Central Gα-Proteins  
Key hypothalamic signaling mechanisms involved in driving sympathetic outflow 
are mediated by receptor systems utilizing intracellular signal transduction molecules 
known a guanosine nucleotide binding proteins (G-proteins). G-proteins are a family of 
heterotrimeric proteins composed of α, β, and γ subunits. Following ligand binding at a 
transmembrane G-protein coupled receptor (GPCR), signal transduction is initiated by α-
subunit mediated exchange of guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP) and the dissociation into activated α and βγ complexes that initiate downstream 
signal transduction to ultimately evoke a biological response (Fig. 4).  
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Figure 4. G-Protein Coupled Receptor Signal Transduction 
Schematic representation of the major Gα protein signal transduction pathways activated 
following ligand binding at a G-protein coupled receptor. 
 
 
There are four major subtypes of Gα proteins, Gαi/o, Gαs, Gαz, and Gαq, with a 
subsequent focus on Gαi2 proteins. The Gαi/o and Gαz classes of Gα proteins principally 
inhibit adenylate cyclase, thereby resulting in reduced cAMP levels. Additionally, via 
associated βγ subunits, Gαi/o proteins also activate potassium channels. In contrast, Gαs 
proteins stimulate the activity of adenylate cyclase to drive increased cAMP production. 
The final subtype, Gαq, does not impact cAMP levels, and instead activates 
phospholipase C (PLC), resulting in increased levels of intracellular inositol triphosphate 
(IP3) and modulation of calcium release. 
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It has been demonstrated in cell culture systems that selective recruitment and/or 
availability of Gα-subunit proteins plays a critical role in determining the intracellular 
signaling responses to GPCR activation following ligand binding (Nasman et al., 2001). 
The specific intracellular actions evoked by selective action of individual Gα proteins has 
been elegantly elucidated, in part, via studies conducted on the nociceptin/orphanin FQ 
receptor (NOP). Activation of the NOP GPCR results in signal transduction via Gαi1−3, 
Gαo, Gαz, and Gαq proteins to initiate multiple cellular responses, including activation of 
potassium channels and inhibition of calcium channels, adenylyl cyclase, and MAPK 
phosphorylation—all of which modulate neurotransmitter release and neuronal activity  
(Reinscheid et al., 1995; Hawes et al., 1998; Jeong and Ikeda, 1998; Yung et al., 1999). 
In vitro studies on the α2-adrenoceptor, an extensively studied key GPCR in 
cardiovascular regulation, have demonstrated signal transduction via Gαi1−3, Gαo, Gαs, 
Gαz, and Gαq subunit proteins which principally modulate adenylate cyclase activity 
(Remaury et al., 1993; Nasman et al., 2001; Hein, 2006).  
However, despite the elucidation of signal transduction pathways in vitro for the 
NOP and α2-adrenoceptor (among others), there are essentially no data at present 
correlating intracellular Gα protein pathways to the physiological responses elicited by 
central GPCR activation in vivo. Previous research from the laboratory provide new 
insight into the intracellular mechanism of action of brain α2-adrenoceptors in vivo and 
document that the physiological responses evoked by receptor activation are greatly 
influenced by the availability and/or brain protein expression levels of individual 
downstream Gα proteins (Wainford and Kapusta, 2012). Further, my thesis provides in 
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vivo support for the pharmacological paradigm of functional selectivity (Patel et al., 
2010) as predicted from in vitro studies and mathematical models (Nasman et al., 2001; 
Hein, 2006). 
Central G-Protein Coupled Receptor Systems in Hypertension  
It is well established in normotensive, salt-resistant subjects that neural (i.e., renal 
sympathetic) and humoral (i.e., angiotensin-aldosterone) sodium-retaining mechanisms 
are suppressed to counter the influence of dietary salt-intake on central sympathetic 
outflow and systemic cardiovascular hemodynamics (Lohmeier et al., 1999; Brooks et al., 
2005; Osborn et al., 2008). Maintenance of fluid and electrolyte homeostasis in response 
to acute increases in sodium intake occurs via complex integrated neural, humoral, and 
hemodynamic pathways to regulate the renal excretion of sodium. If these endogenous 
pathways are impaired, salt-sensitive hypertension can develop. GPCR-mediated output 
from PVN sympathetic neurons increases arterial pressure and dysfunction of these 
neurons has been associated with cardiovascular disease (CVD) (Patel, 2000). 
To counter the development of salt-sensitive hypertension, multiple brain G-
protein-coupled receptor (GPCR) systems are activated to facilitate sympathoinhibition, 
sodium homeostasis, and normotension. Currently, there is a paucity of knowledge 
regarding the role of downstream GPCR-activated Gα subunit proteins in these critically 
important physiological regulatory responses required for long-term blood pressure 
regulation. 
A key component of the renal handling of sodium and water, and thus blood 
pressure, in response to alterations in plasma sodium, is the regulation of sympathetic 
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outflow and renal sympathetic nerve traffic (Guyton, 1991; Lohmeier et al., 1999; 
DiBona, 2004, 2005; May et al., 2010), which is directly influenced by multiple brain 
GPCR systems (e.g., the α2-adrenoreceptor) (Ruffolo et al., 1991; Nasman et al., 2001). 
Therefore, endogenous GPCR mediated activation of brain Gαi2 protein-gated pathways 
represents a key mechanism by which sympathoinhibition and natriuresis occurs in 
vivo in response to acute challenges to sodium homeostasis. Collectively, this modulates 
the level of central sympathetic outflow, blood pressure, and natriuresis in response to 
acute pharmacological or physiological stimuli (Fig. 5). The central mechanisms 
regulating sympathetic outflow (global and renal specific) to facilitate natriuresis during 
elevations in plasma sodium continue to be investigated (DiBona, 2005; Kompanowska-
Jezierska et al., 2008; Bie, 2009).  
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Figure 5.  Cardiovascular, Sympathetic, and Renal/Humoral Responses to G-Protein 
Coupled Receptor Stimulation 
Schematic representation of the functional selectivity of G-protein coupled receptor activated Gα 
protein signal transduction pathways in mediating the physiological responses evoked by central 
exogenous administration of N/OFQ and guanabenz or the physiological stimuli of an IV volume 
expansion or sodium load.  
 
Neural Control of Blood Pressure by PVN Gαi2-Subunit Proteins 
Previous work in our laboratory has determined that brain Gαi2 proteins mediate 
natriuretic and sympathoinhibitory responses produced by acute pharmacological (α2-
adrenoceptor activation) and physiological challenges to sodium homeostasis (IV VE and 
1 M sodium load) in conscious SD rats. In our investigations of the role of central Gαi2 
proteins in the pathophysiology of salt-sensitive hypertension, we found that sodium-
stimulated changes in endogenous Gαi2 protein expression were restricted to the PVN 
and did not occur in other hypothalamic regions (e.g. supraoptic nucleus, posterior 
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hypothalamus) in the salt-resistant SD rat. Further, dietary sodium restriction or excess 
did not alter expression levels of Gαi1, Gαi3, or Gαio, proteins in any brain site examined. 
The observation of HS-evoked site- and subunit-specific changes in PVN Gαi2 protein 
expression is of considerable interest as this brain site plays a key role in responding to 
alterations in body fluid sodium concentrations and osmolality (Toney et al., 2003) and 
the central control of sympathetic outflow, sodium homeostasis, and blood pressure 
(Leenen et al., 2002; Kenney et al., 2003; Carmichael and Wainford, 2015). The PVN as 
a potential locus of Gαi2 protein-mediated regulation of sympathetic outflow is not 
unexpected, due to the critical role of the PVN in mediating sympathoinhibition (Akine et 
al., 2003; Coote, 2005), particularly in response to increased plasma and/or CSF sodium 
in salt-resistant subjects (Brooks et al., 2005; DiBona, 2005; He et al., 2005). 
Collectively, this demonstrates that brain, and likely PVN-specific, Gαi2 protein signal 
transduction represent a central molecular mechanism mediating sympathoinhibitory 
responses evoked to maintain sodium homeostasis and a salt-resistant phenotype. Further, 
impairment of this endogenous “anti-hypertensive” mechanism likely contributes to the 
pathophysiology of salt-sensitive hypertension. 
Clinical Significance 
A lower risk of cardiovascular disease outcome following treatment of 
hypertension has been demonstrated in clinical trials, with stroke reduction between 35-
40%, myocardial infarction between 15-25%, and heart failure up to 64% (Neal et al., 
2000; Chobanian et al., 2003; Psaty et al., 2003). This evidence critically supports the 
need for a further understanding of the pathophysiology of hypertension, as it is a key 
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driver of a multitude of disease outcomes. A lack of an appropriate target systolic blood 
pressure to significantly reduce cardiovascular morbidity and mortality is a large 
component of the problem clinicians face in adequate hypertension treatment. This can be 
attributed to the minimal understanding around the relative contribution of elevated blood 
pressure to cardiovascular risk. Observational studies identify a strong association 
between blood pressure and the risk of cardiovascular disease (Lewington et al., 2002), 
but with no evidence of a threshold for the relationship. Clinical studies have also 
demonstrated a reduced risk of CVD with antihypertensive drug therapy, but an optimal 
target for SBP lowering has remained uncertain (SHEP Cooperative Research Group, 
1991; Staessen et al., 1997; Verdecchia et al., 2009). Further, a major component of the 
controversy around defining a target systolic blood pressure has persisted due to 
inadequate data on the potential risks (not only benefits) of a goal SBP <140 mmHg 
(SHEP Cooperative Research Group, 1991; Staessen et al., 1997).  
A recent landmark NIH study—Systolic Blood Pressure Intervention Trial 
(SPRINT) (The SPRINT Research Group, 2015)—examined the effect of a more 
intensive high blood pressure treatment than is currently recommended. That is, 
hypertension patients were randomized into either the ‘Standard Treatment’ arm in which 
the goal was a systolic blood pressure (SBP)<140 mmHg (i.e., the currently 
recommended standard) or the ‘Intensive Treatment’ arm in which the goal was a 
SBP<120 mmHg. Despite being compared to the current standard of care, the authors 
hypothesized that patients with an even further reduction in SBP would show a lower 
cardiovascular disease composite rate—a quantifiable metric typically employed to 
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assess cardiovascular outcome. The primary composite outcome was defined as 
myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death 
from cardiovascular causes. It was determined that the incidence of primary outcome 
(composite of CVD events) was 25% lower in the intensive treatment group as compared 
to the standard treatment group, and all-cause mortality was reduced by 27%. The clinical 
trial was terminated early due to benefit after a median follow-up of 3.26 years, despite 
the trial being designed over the course of 6 years. These clinical data substantially add to 
the evidence of benefits of lowering systolic blood pressure with a defined target, and 
further, have provided adequate evidence in favor of the risk versus benefits of a lower 
than recommended target. 
 Another recent clinical study provides important support for the involvement of 
salt in the pathogenesis of hypertension. PATHWAY-2 (Williams et al., 2015) has 
suggested that the predominant underlying pathophysiological cause of resistant 
hypertension is sodium retention.  Because the optimal fourth line treatment for patients 
with resistant hypertension is undefined, the authors hypothesized that if resistant 
hypertension is most often caused by excessive sodium retention, then spironolactone as 
the fourth line therapy would therefore be superior to non-diuretic add-on drugs at 
lowering blood pressure. Indeed, spironolactone-treated patients exhibited a significantly 
greater drop in unadjusted home blood pressure as compared to doxazosin (α-1 
adrenergic receptor blocker), bisoprolol (β-1 adrenergic receptor blocker), and placebo 
treatment groups. These findings provide a solid clinical rationale for elevated salt and 
sodium retention as the predominant underlying pathophysiological cause of treatment-
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resistant hypertension. Further, this underscores the relevance and potential translational 
nature of the current work. 
Overall Significance 
Enhancing the understanding of the central mechanisms involved in both salt-
resistance and salt-sensitivity is of exceptional physiological and pathological 
significance, owing to the substantial health risks and financial costs associated with 
hypertension. My thesis research defines the differences between salt-sensitive and salt-
resistant individuals and will significantly extend our understanding of the CNS 
regulatory mechanisms influencing sodium homeostasis and the pathogenesis of 
hypertension. Notably, findings from my work possess exciting translational relevance, as 
single nucleotide polymorphisms (SNPs) in the human GNAI2 gene (the gene that 
encodes the Gαi2 protein) correlate with hypertension in multiple populations (Menzaghi 
et al., 2006; Kohara et al., 2008). In fact, our preliminary work suggests that GNAI2 
SNPs can potentially be utilized as a biomarker of both hypertension and the salt-
sensitivity of blood pressure in human subjects. These findings would directly address the 
need for standardized protocols to reliably and efficiently determine salt-sensitivity at an 
individual level. Our research strategy of establishing the mechanisms involved in 
preventing salt-sensitive hypertension is likely to result in the development of new 
clinical diagnostic biomarkers (i.e., GNAI2 SNPs) and therapeutic targets (e.g., afferent 
renal nerve activators) for the treatment of hypertension that have been overlooked in 
traditional pro-hypertensive orientated investigations 
This work is direct clinical evidence that highlights the translational implications 
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of the current work, and as such, our findings have significant potential to lead to the 
identification of new pre-clinical diagnostic and therapeutic targets for the treatment of 
hypertension. 
Overall Hypothesis and Specific Aims 
Overall Hypothesis 
PVN Gαi2 proteins mediate the central responses activated to counter the development of 
salt-sensitive hypertension. 
Specific Aims 
Specific Aim 1: To determine the role of brain Gαi2-subunit proteins in the chronic 
regulation of blood pressure in salt-resistant and salt-sensitive rat phenotypes. 
Specific Aim 2: To determine the influence of Gαi2-subunit proteins on the differential 
sodium evoked activity of PVN neuronal subpopulations during acute sodium challenge.  
Specific Aim 3: To determine whether PVN-specific Gαi2-subunit proteins mediate 
central sympathoinhibitory outflow to maintain sodium homeostasis and normotension 
during chronic sodium challenge. 
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CHAPTER TWO: Gαi2 Protein-Mediated Signal Transduction—Central Nervous 
System Molecular Mechanism Countering the Development of Sodium-Dependent 
Hypertension 
This chapter was previously published as: R. D. Wainford, C. Y. Carmichael, C. L. 
Pascale, & J. T. Kuwabara (2015). Gαi2-protein mediated signal transduction: A CNS 
molecular mechanism countering the development of sodium-dependent hypertension. 
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Abstract 
Excess dietary salt intake is an established cause of hypertension. At present, our 
understanding of the neuropathophysiology of salt-sensitive hypertension is limited by a 
lack of identification of the central nervous system mechanisms that modulate 
sympathetic outflow and blood pressure in response to dietary salt intake. We 
hypothesized that impairment of brain Gαi2 protein-gated signal transduction pathways 
would result in increased sympathetically mediated renal sodium retention, thus 
promoting the development of salt-sensitive hypertension. To test this hypothesis, naive 
or renal denervated Dahl salt-resistant and Dahl salt-sensitive (DSS) rats were assigned to 
receive a continuous intracerebroventricular control scrambled or a targeted Gαi2 
oligodeoxynucleotide infusion, and naive Brown Norway and 8-congenic DSS rats were 
fed a 21-day normal or high-salt diet. High salt intake did not alter blood pressure, 
suppressed plasma norepinephrine, and evoked a site-specific increase in hypothalamic 
paraventricular nucleus Gαi2 protein levels in naive Brown Norway, Dahl salt-resistant, 
and scrambled oligodeoxynucleotide-infused Dahl salt-resistant but not DSS rats. In Dahl 
salt-resistant rats, Gαi2 downregulation evoked rapid renal nerve-dependent hypertension, 
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sodium retention, and sympathoexcitation. In DSS rats, Gαi2 downregulation exacerbated 
salt-sensitive hypertension via a renal nerve-dependent mechanism. Congenic-8 DSS rats 
exhibited sodium-evoked paraventricular nucleus-specific Gαi2 protein upregulation and 
attenuated hypertension, sodium retention, and global sympathoexcitation compared with 
DSS rats. These data demonstrate that paraventricular nucleus Gαi2 protein-gated 
pathways represent a conserved central molecular pathway mediating sympathoinhibitory 
renal nerve-dependent responses evoked to maintain sodium homeostasis and a salt-
resistant phenotype. Impairment of this mechanism contributes to the development of 
salt-sensitive hypertension.  
Introduction 
Excess dietary salt intake is a well-established cause of human hypertension (Ji et 
al., 2008), and salt-sensitive patients with hypertension have a 3-fold increased risk of 
adverse cardiovascular events (Franco and Oparil, 2006). Despite the adverse impact of 
salt sensitivity, the mechanism(s) by which dietary salt evokes increased blood pressure 
remain to be fully elucidated (Stocker et al., 2013a). It has been hypothesized that among 
many proposed mechanisms, impaired sympathetic nervous system activity plays a 
critical role in the development of salt-sensitive hypertension (Brooks et al., 2005; 
Osborn et al., 2009; Fujita and Fujita, 2013), a theory supported by increased activation 
of the sympathetic nervous system in both animal models of salt-sensitive hypertension 
(Kandlikar and Fink, 2011b; Foss et al., 2013) and salt-sensitive humans (Yatabe et al., 
2010). In the setting of high salt intake, the regulation of central sympathetic outflow to 
the kidneys, via the renal sympathetic nerves, is of critical importance because of the 
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direct impact of the renal nerves on renal sodium reabsorption, blood volume, total 
peripheral resistance, and long term blood pressure (Guyton, 1991; Johns et al., 2011; 
Wadei and Textor, 2012). A key role for the renal sympathetic nerves in blood pressure 
regulation is highlighted by reports that renal nerve ablation attenuates Dahl salt-sensitive 
(DSS) hypertension (Foss et al., 2013) and hypertension in human subjects (Esler et al., 
2012; Krum et al., 2014). 
At present, the central nervous system (CNS) mechanisms that mediate reduced 
central sympathetic outflow to the kidney to facilitate sodium homeostasis and 
normotension require further investigation(Brooks et al., 2005; Ellison and Brooks, 2011; 
Fujita and Fujita, 2013; Stocker et al., 2013a). In response to increased sodium intake, 
sodium-sensitive receptors, present in the circumventricular organs and hypothalamic 
paraventricular nucleus (PVN) (Brooks et al., 2005; Stocker et al., 2013a), activate 
multiple brain G-protein coupled receptor (GPCR) systems (e.g., the α2 adrenoceptor) to 
inhibit renal sympathetic nerve activity to facilitate natriuresis, thus maintaining fluid and 
electrolyte homeostasis and normotension (Kenney et al., 2003; Johns et al., 2011). 
Despite our understanding of the role of multiple GPCRs in the regulation of renal 
sympathoinhibition and subsequent natriuresis, there remains a paucity of knowledge 
regarding potential common downstream signal transduction pathways that are activated 
by GPCRs to evoke these regulatory responses in vivo. Our laboratory has recently 
reported that brain Gαi2 subunit protein pathways, which mediate GPCR-stimulated 
signal transduction post-ligand binding, are required to mediate the natriuresis produced 
by central α2 adrenoceptor stimulation (Wainford and Kapusta, 2012), and acute isotonic 
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volume expansion (Kapusta et al., 2012), and acute isovolumetric sodium loading in 
conscious Sprague-Dawley (SD) rats (Wainford et al., 2013). In chronic studies, we 
demonstrated in the SD rat that (1) high salt intake evoked upregulation of hypothalamic 
PVN Gαi2 subunit proteins, and (2) downregulation of brain Gαi2 protein expression 
evoked the development of renal nerve-dependent salt-sensitive hypertension (Kapusta et 
al., 2013). Collectively, these findings suggest brain Gαi2 subunit protein signal 
transduction as a potential common pathway mediating GPCR-evoked natriuresis. 
Based on our prior findings, we hypothesized that high dietary sodium intake 
stimulates upregulation of PVN Gαi2 subunit proteins to suppress central sympathetic 
outflow, particularly to the kidneys, to maintain fluid and electrolyte balance and 
normotension in multiple salt-resistant phenotypes. Furthermore, we predict that failure 
to upregulate PVN Gαi2 subunit proteins in response to salt contributes to the 
pathophysiology of salt-sensitive hypertension. We investigated this hypothesis in the 
salt-resistant Brown Norway (BN) and Dahl salt-resistant (DSR) rat phenotypes and in 
the DSS rat model. After our observation of no increase in brain Gαi2 protein expression 
in response to salt intake in the DSS rat, additional studies were conducted in transgenic 
8-congenic DSS rats to assess the impact of upregulation of PVN Gαi2 protein levels on 
the development of DSS hypertension. 
Methods 
Animals  
Male Dahl salt-resistant (DSR) and Dahl salt-sensitive (DSS) rats were purchased 
from Harlan Laboratories Inc. (Indianapolis, IN; #2024), Brown Norway (BN) rats were 
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purchased from Charles River Laboratories (Kingston, NY; #K90) and 8-congenic Dahl 
salt-sensitive rats (8-congenic DSS) were purchased from the Medical College of 
Wisconsin (Milwaukee, WI). All experiments were conducted on male rats aged 10-14 
weeks. Animals were housed individually in a temperature (range (range 68-79°F) and 
humidity (range 30-70%) controlled facility under a 12-h light/dark cycle. Following 
completion of surgical procedures (see below), rats were randomly assigned to receive a 
standard rodent diet (Teklad Global Diet, Harlan Laboratories, WI, Teklad Global 18% 
Protein rodent diet #2918, 18% protein, 5% crude fat, 5% fiber, total NaCl content 0.4% 
[174 mEq Na+ /kg]) or high sodium diet (Test Diet, IN, Basal diet #5G01, 22% protein, 
5.5% crude fat, 5% fiber, modified to contain total NaCl content 8% [1,378 mEq Na+ 
/kg]) and water ad libitum for a 21-day experimental period. All procedures were 
approved by the Louisiana State University Health Sciences Center or Boston University 
School of Medicine Institutional Animal Care and Use Committee and are in accordance 
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.  
Surgical Procedures 
 Intracerebroventricular Oligodeoxynucleotide Infusion 
Chronic down-regulation of brain Gαi2 proteins was achieved by continuous 
intracerebroventricular (ICV) infusion of a phosphodiesterase oligodeoxynucleotide 
(ODN) probe that selectively and specifically targets Gαi2 proteins (5’-CTT GTC GAT 
CAT CTT AGA-3’) (Kapusta et al., 2012; Wainford and Kapusta, 2012; Kapusta et al., 
2013; Wainford et al., 2013). Control animals received an ICV infusion of a scrambled 
(SCR) ODN (5’-GGG CGA AGT AGG TCT TGG-3’) (Kapusta et al., 2012; Wainford 
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and Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 2013). In these studies, SCR 
and Gαi2 ODNs were dissolved in isotonic saline and infused ICV at 25µg/6µl/day, a 
technique previously reported by our laboratory to selectively downregulate Gαi2 subunit 
proteins throughout the brain of conscious Sprague-Dawley rats (Kapusta et al., 2013). 
To achieve ICV ODN infusion, animals were anesthetized (ketamine, 30 mg/kg 
intraperitoneally [IP] in combination with xylazine, 3 mg/kg IP) and stereotaxically 
implanted with a stainless steel cannula into the right lateral cerebral ventricle (Plastics 
One, VA) (Kapusta et al., 2012; Wainford and Kapusta, 2012; Kapusta et al., 2013; 
Wainford et al., 2013), which was connected via silastic tubing to a miniosmotic pump 
(model 2004; Durect Corporation, CA).4 A National Center for Biotechnology 
Information (NCBI) Basic Local Alignment Search Tool (BLAST) search of the Rattus 
norvegicus Reference Sequence (RefSeq) protein database was conducted to confirm 1) 
the specificity of the Gαi2 ODN for the Gαi2 rat protein sequence and, 2) the SCR ODN 
does not match any known rat protein sequence. In addition, our prior studies (Kapusta et 
al., 2012; Wainford and Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 2013), and 
the studies of other laboratories examining the effects of opioid analgesia and opioid 
induced feeding (Rossi et al., 1995; Standifer et al., 1996; Silva et al., 2000; Hadjimarkou 
et al., 2002), have demonstrated the selectivity and specificity of this Gαi2 ODN sequence 
in the downregulation of brain Gαi2 proteins in rats.  
Acute Femoral Vein, Artery and Bladder Cannulation 
In certain experimental groups, following 21-days normal (0.4% NaCl) or high 
(8% NaCl) salt intake, naïve rats (Fig. 6) or animals previously implanted with an ICV 
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cannula connected to a miniosmotic pump delivering a continuous central ODN infusion 
(Fig. 8, 9) were anaesthetized with sodium methohexital (20mg/kg IP, supplemented with 
10 mg/kg intravenously, [IV] as required). Once anesthetized, rats were instrumented 
with catheters in the left femoral artery, left femoral vein, and bladder for the 
measurement of arterial blood pressure, IV administration of saline and/or drugs, and 
renal function respectively (Kapusta et al., 2012; Wainford and Kapusta, 2012; Kapusta 
et al., 2013; Wainford et al., 2013). Rats were then placed in a plexiglass holder and an 
IV infusion of isotonic saline (20µl/min) was maintained for a 2h surgical recovery 
period prior to experimentation to enable the animal to regain full consciousness and 
cardiovascular/renal excretory function to stabilize. Mean arterial pressure (MAP) and 
heart rate (HR) were continuously recorded via the surgically implanted femoral artery 
cannula using computer-driven BIOPAC data acquisition software (MP150 and 
AcqKnowledge 3.8.2, CA) connected to an external pressure transducer (P23XL; Viggo 
Spectramed Inc., CA) (Kapusta et al., 2012; Wainford and Kapusta, 2012; Kapusta et al., 
2013; Wainford et al., 2013).  
Telemetry Probe Implantation 
A radiotelemetry device (PA-C40, DSI, MN) was implanted into the abdominal 
aorta via the left femoral artery under ketamine anesthesia (30 mg/kg IP ketamine; 3 
mg/kg IP xylazine). In all cases, radiotelemetry probes were implanted at least 5-7 days 
prior to ICV miniosmotic pump implantation. In animals in which no renal denervation 
surgery was conducted, blood pressure recording began 3 days post ICV miniosmotic 
pump implantation. Animals that received a sham or bilateral renal denervation (RDNX) 
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surgical procedure underwent ICV miniosmotic pump implantation followed 3 days later 
by RDNX. Blood pressure monitoring was initiated 24h post-RDNX. Radiotelemetry 
data were collected, stored, and analyzed using Dataquest A.R.T. 4.2 software (DSI, 
MN).  
Bilateral Renal Denervation 
Standard techniques were used to remove the influence of both the afferent and 
efferent renal sympathetic nerve fibers (Kapusta et al., 2013; Wainford et al., 2013). In 
brief, under pentobarbital anesthesia (30 mg/kg IP) each kidney was exposed by a dorsal 
flank incision. Using a dissecting microscope, the renal vein and artery were dissected 
out of the surrounding fascia and stripped of all visible renal nerve bundles. Following 
dissection, the renal artery was coated with a 10% phenol solution in ethanol to ensure 
the destruction of any remaining renal nerve fibers (Kapusta et al., 2013; Wainford et al., 
2013). The effectiveness of RDNX was confirmed at the end of the 21-day salt intake 
study via ELISA analysis of norepinephrine (NE) content in kidney tissue as per 
manufacturer’s instructions (ELISA IB89537, IBL America, MN). As shown, (Fig. 10) 
this surgical procedure resulted in at least 90% suppression of renal NE content at the end 
of the 21-day sodium intake protocol indicting in these animals there is still clear 
evidence of functional denervation as previously demonstrated by our group (Kapusta et 
al., 2013). These data are supported by recent evidence demonstrating significantly 
reduced efferent nerve innervation of the kidney at the 3-4 week time point following 
bilateral renal denervation (Mulder et al., 2013).   
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Acute Cardiovascular Studies 
Blood Pressure Measurement 
In certain studies (Figs. 6 and 8), after a 21-day normal or high salt intake, acute 
femoral vein, artery and bladder cannulation was performed. After a 2-h stabilization 
period in which rats were infused IV with isotonic saline (20 µl/min), baseline MAP was 
recorded continuously over a 30-min period in conscious rats (N=6/treatment group/diet) 
(Kapusta et al., 2013). 
ICV Guanabenz Administration 
In certain studies (Fig. 2), after measurement of baseline MAP, animals received 
an ICV injection of guanabenz (5µg/5µl delivered over a 60-second period) and peak 
changes in HR and MAP were recorded (N=6/treatment group/diet) to provide 
pharmacological verification of downregulation of brain Gαi2 proteins. As previously 
reported, we observed selective abolishment of the hypotensive but not bradycardiac 
responses to ICV guanabenz administration in animals receiving a central Gαi2, but not 
SCR, ODN (Fig. 10) (Wainford and Kapusta, 2012; Kapusta et al., 2013). 
Chronic BP Measurement and Autonomic Function Studies  
Baseline blood pressure was recorded by radiotelemetry for five consecutive days 
immediately following ICV miniosmotic pump implantation. Data was collected via 
scheduled sampling for 10-s every 10-min in DSR, DSS, BN and 8-congenic DSS 
cohorts which were either naive, receiving an ICV ODN infusion, or an ODN infusion 
plus prior RDNX/sham surgery. Rats were maintained on a normal salt diet (0.4% NaCl) 
for a 5-day baseline period and were then randomly assigned (N=6 per group) to either a 
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normal (0.4% total NaCl) or high (8% total NaCl) salt diet and blood pressure was 
recorded for a further 21-days. Autonomic function was assessed before high salt-intake 
(day 3 of baseline blood pressure measurement period) and on day-21 of high salt-intake 
by IP injection of chlorisondamine (5 mg/kg). At the end of the protocol, whole brains 
and plasma were collected and stored at -80°C.  
Metabolic Balance Studies  
Metabolic balance studies were conducted in certain treatment groups (Figs. 6 & 
17) on a normal salt diet and again on day-21 of the dietary sodium intake period. In 
certain studies (Figs. 14-16), metabolic balance studies were conducted prior to, and on 
days 1, 2, 3, 5, 7, 14 and 21 of high salt-intake. For these studies, rats were housed in 
individual metabolic cages (model 18cv, Fenco, MA) with external food containers and 
water bottles. Metabolic cages were equipped with a double-fine mesh screen that 
allowed separation of food and feces contamination from urine that was collected in vials 
that contained a layer of mineral oil to prevent urine evaporation. Rats were randomly 
assigned to receive a normal or high sodium intake diet. All rats were provided free 
access to rodent chow and tap water via external trays and bottles, respectively. On the 
day of study measurements were then made for body weight, food and water intake, and 
urine output during a 24-h period enabling calculation of daily sodium and water balance 
(Kapusta et al., 2012; Kapusta et al., 2013). 
Measurement of Brain Gα Subunit Protein Levels  
Following completion of experimental protocols, whole brains were removed and 
frozen at -80°C. Frontal brain cortex (BC), hypothalamic paraventricular nucleus (PVN) 
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and ventrolateral medulla (VLM) samples were extracted from frozen brains cut on a 
cryostat using a brain punch tool (Stoelting, IL) as previously described (Kapusta et al., 
2012; Wainford and Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 2013). Tissue 
lysates were prepared from brain punch samples and protein levels were quantified using 
the BCA assay as per manufacturers’ instruction (Thermo Scientific, IL). Lysates were 
resolved on a 10% SDS-PAGE gel and transferred to nitrocellulose membrane (GE 
Healthcare, NJ). Gαi1-3 and Gαo levels were determined as previously published by our 
laboratory using commercially available antibodies purchased from Santa Cruz 
Biotechnologies (Santa Cruz, CA), directed against Gαi1 (1:100, sc- 391), Gαi2 (1:200, 
sc-13534), Gαi3 (1:1000, sc-262) and Gαo (1:200, sc-382); protein levels were 
normalized to GAPDH (anti-GAPDH 1:1000, ab-9483, Abcam, MA) (Kapusta et al., 
2012; Wainford and Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 2013). 
Chemiluminescent immunoreactive bands were detected by a horseradish peroxidase-
conjugated secondary antibody; data was imaged and semi-quantified using Bio-Rad 
Quantity One image analysis software. Probing with each antibody was performed 
sequentially following stripping of the membrane with a commercially available stripping 
reagent as per manufacturers’ instruction (Bio-Rad Laboratories, CA).  
Plasma Renin Activity and Norepinephrine Assays  
Plasma renin activity (PRA) and plasma NE levels were determined as previously 
described (Kapusta et al., 2013; Wainford et al., 2013). In brief, following plasma 
extraction samples were frozen at -80°C until later analysis. For the PRA assay samples 
were analyzed using a GammaCoat® Plasma Renin Activity 125I RIA Kit (DiaSorin, 
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MN) for the quantitative determination of PRA by the radioimmunoassay of generated 
angiotensin I as per manufacturers’ instructions. Plasma NE levels were quantified using 
an ELISA kit (Immuno-Biological Laboratories, Inc., MN) as per manufacturers’ 
instructions (Kapusta et al., 2012; Kapusta et al., 2013).  
Analytical Techniques  
Urine volume was determined gravimetrically assuming 1g = 1 ml. Urinary and 
plasma sodium concentrations were measured by flame photometry (model 943, 
Instrumentation Laboratories, MA) (Kapusta et al., 2012; Wainford and Kapusta, 2012; 
Kapusta et al., 2013; Wainford et al., 2013). Plasma osmolality was determined using a 
VAPRO® vapor pressure osmometer (model 5600, Wescor, UT) (Kapusta et al., 2013; 
Wainford et al., 2013). Plasma hematocrit (Hct) was determined using a micro-hematocrit 
centrifuge (Adams Readacrit, Clay Adams, NJ) (Kapusta et al., 2013). Hct was used to 
calculate estimated plasma volume (EPV) and estimated blood volume (EBV) using the 
following equations; EPV = (0.065 x body weight (kg)) x (100 – Hct), EBV = (EPV x 
100)/(100-Hct) (Lee and Blaufox, 1985; Wainford et al., 2013).  
Statistical Analysis  
Data are expressed as mean ± SEM. Differences occurring between treatment 
groups (e.g., SCR vs. Gαi2 ODN) were assessed by a two-way repeated-measures 
ANOVA, with treatment group being one fixed effect and time the other, with the 
interaction included. The time (min) was then the repeated factor. Post hoc analysis was 
performed by a Newman-Keuls test, to compare variations among the groups. Statistical 
analysis was carried out using Prism 5 (GraphPad Software, CA). Statistical significance 
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was defined as probability (P)<0.05.  
Results 
Elevated Dietary Sodium Intake Differentially Impacts CNS Gα Subunit Expression 
in Naïve DSR and DSS Rats 
DSR rats exhibited a classical normotensive phenotype, featuring suppression of 
neural (plasma norepinephrine) and humoral (PRA) sodium retaining mechanisms (Fig. 
6) after high salt intake. 
 
Figure 6. Brain Gα Protein Expression in Dahl Salt-Resistant versus Dahl Salt-Sensitive 
Animals Receiving a Gαi2 or SCR ODN Infusion Maintained on a Normal or High Salt Diet 
Gα-subunit protein expression in the brain cortex, PVN and VLM of male DSR and DSS rats 
receiving an ICV infusion of a SCR or Gαi2 ODN (25µg/6µl/day) maintained for 21-days on a 
normal or high salt-intake for which physiological data is presented in Fig. 8A and 8B (values are 
means ± SEM, N=6/group).  
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In these normotensive DSR rats, high salt intake produced a site-specific increase in PVN 
Gαi2 protein expression (Figs. 7A and 7B). In contrast, DSS rats exhibited hypertension, 
sodium and water retention, and a failure to suppress neurally mediated sodium 
reabsorption (Fig. 6) that was accompanied by no change in PVN Gαi2 protein expression 
levels (Figs. 7A and 7C) when maintained on a high salt intake. 
 
 
Figure 7. Endogenous Brain Gα Protein Expression in Dahl Salt-Resistant versus Dahl Salt-
Sensitive Animals Maintained on a Normal or High Salt Diet 
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(A) Gα-subunit protein expression in the brain cortex, paraventricular nucleus (PVN), and 
ventrolateral medulla (VLM) of naïve male Dahl salt-resistant (DSR) and Dahl salt-sensitive 
(DSS) rats maintained for 21-days on a normal or high salt intake (mean±SEM, N=6/group). 
*P<0.05 vs. respective normal salt intake group value. τP<0.05 vs. DSR high salt intake group 
value. (B) and (C) Representative immunoblots illustrating brain Gα-subunit protein levels in 
DSR and DSS rats. 
 
Central Gαi2 Subunit Protein-Gated Pathways Counter the Development of Salt-
Sensitive Hypertension 
 The salt-resistant and salt-sensitive phenotypes exhibited by Dahl rats were not 
altered by the central infusion of a control scrambled oligodeoxynucleotide during high 
salt intake (Figs. 8A and 8B).  
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Figure 8. Blood Pressure, Plasma Norepinephrine, Plasma Renin Activity, and Index of 
Salt-Sensitivity in Dahl Salt-Resistant versus Dahl Salt-Sensitive Animals 
(A) Mean arterial pressure (MAP) (mmHg), plasma norepinephrine (NE; nmol/L) and plasma 
renin activity (ng/mL/hr) and  (B) index of salt sensitivity of male Dahl salt-resistant (DSR) and 
Dahl salt-sensitive (DSS) rats receiving an intracerebroventricular (ICV) infusion of a scrambled 
(SCR) or Gαi2 oligodeoxynucleotide (ODN; 25 µg/6 µl/day) maintained for 21 days on a normal 
or high salt intake (mean±SEM, N=6/group). *P<0.05 vs. respective normal salt intake group 
value. τP<0.05 vs. DSR high salt intake group value. 
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High salt treatment produced significant upregulation of hypothalamic PVN Gαi2 proteins 
in SCR ODN infused DSR, but not DSS rats (Figs. 9A and 9B), without altering brain 
Gαi1, Gαi3, or Gαio protein levels (Fig. 6).  
  
 
Figure 9. Brain Gαi2 Protein Expression in Dahl Salt-Resistant versus Dahl Salt-Sensitive 
Animals Receiving an ICV SCR or Gαi2 ODN Infusion Maintained on a Normal or High 
Salt Diet 
(A) Gαi2 subunit protein expression in the brain cortex, paraventricular nucleus (PVN), and 
ventrolateral medulla (VLM) of male Dahl salt-resistant (DSR) and Dahl salt-sensitive (DSS) rats 
receiving an intracerebroventricular (ICV) infusion of a scrambled (SCR) or Gαi2 
oligodeoxynucleotide (ODN; 25 µg/6 µl/day) maintained for 21 days on a normal or high salt 
intake (mean±SEM, N=6/group). *P<0.05 vs. respective normal salt intake group value. τP<0.05 
vs. DSR high salt intake group value. (B) Representative immunoblots illustrating ODN-mediated 
downregulation of brain Gαi2 subunit protein levels in DSR and DSS rats. 
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In Dahl rats fed a high, but not a normal sodium content diet, central Gαi2 ODN infusion 
resulted in the development of salt-sensitive hypertension in the DSR phenotype and 
exacerbated the magnitude of hypertension in the DSS rat (Fig. 8A). In both Dahl 
phenotypes maintained on a high salt diet and receiving a SCR or Gαi2 ODN infusion, 
PRA was suppressed, as seen in naïve rats (Fig. 8A). In contrast to the suppression of 
plasma NE in SCR ODN infused DSR rats, plasma NE levels were significantly elevated 
in Gαi2 ODN infused DSR rats challenged with a high salt diet (Fig. 8A). In response to 
increased dietary salt intake, DSS rats receiving a Gαi2 ODN infusion exhibited 
significantly increased levels of plasma NE versus animals receiving a control SCR ODN 
treatment. In both Dahl rat phenotypes, we observed no difference in plasma sodium 
concentration or osmolality between experimental treatment groups (Tables 1 and 2).  
Table 1. Plasma Sodium and Osmolality in Dahl Salt-Resistant Animals Receiving an ICV 
SCR or Gαi2 ODN Infusion Maintained on a Normal or High Salt Diet 
 
 Dietary Sodium Intake Group 
 0.4% NaCl 8% NaCl 
ICV  ODN Infusion SCR Gαi2 SCR Gαi2 
pNa [mEqL-1] 139.6±2.1 140.3±1.8 139.3±1.6 140.4±1.4 
pOsm [mOsm/kg] 299.6±4.5 302.4±4.2 301.6±3.8 301.3±4.4 
 
Plasma sodium (pNa [mEqL-1]) and plasma osmolality (pOsm [mOsm/kg]) in Dahl salt-resistant 
rats receiving an ICV infusion of a SCR or Gαi2 ODN (25µg/6µl/day) measured on day-21 of a 
normal or high sodium diet. Values are mean±SEM (N=6/group). 
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Table 2. Plasma Sodium and Osmolality in Dahl Salt-Sensitive Animals Receiving an ICV 
SCR or Gαi2 ODN Infusion Maintained on a Normal or High Salt Diet 
 
 Dietary Sodium Intake Group 
 0.4% NaCl 8% NaCl 
ICV ODN Infusion SCR Gαi2 SCR Gαi2 
pNa [mEqL-1] 140.6±2.4 140.2±2.1 139.6±1.9 140.7±2.2 
pOsm [mOsm/kg] 300.3±4.7 301.8±3.8 301.6±3.9 301.3±4.3 
 
Plasma sodium (pNa [mEqL-1]) and plasma osmolality (pOsm [mOsm/kg]) in Dahl salt-sensitive 
rats receiving an ICV infusion of a SCR or Gαi2 ODN (25µg/6µl/day) measured on day-21 of a 
normal or high sodium diet. Values are mean±SEM (N=6/group). 
 
Illustrated as an index of the salt sensitivity of blood pressure, SCR ODN infused DSR 
rats exhibited a classical salt resistant phenotype. Gαi2 ODN infusion caused a significant 
reduction in the slope of the pressure-natriuresis relationship in DSR rats (Fig. 8B), 
reflecting increased salt sensitivity of blood pressure. In the DSS phenotype, as in the 
DSR rat, ICV Gαi2 ODN infusion produced selective and efficacious downregulation of 
global CNS Gαi2 proteins (Figs. 9A and Table 2), as we have previously reported in the 
SD rat. In these animals, central Gαi2 ODN infusion selectively blocked the hypotensive, 
but not bradycardiac, response to acute ICV injection of the α2 agonist guanabenz (Fig. 
10)—a finding consistent with our prior observations after acute and chronic central Gαi2 
protein downregulation. 
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Figure 10. Peak Change in Heart Rate and Blood Pressure in Dahl Salt-Resistant and Dahl-
Salt Sensitive Animals Receiving an ICV SCR or Gαi2 ODN Infusion Maintained on a 
Normal or High Salt Diet 
Peak change in heart rate (HR; bpm) and mean arterial blood pressure (MAP; mmHg) in male 
Dahl salt-resistant and Dahl salt-sensitive rats receiving an ICV infusion of a scrambled (SCR) or 
Gαi2 oligodeoxynucleotide (ODN;  25µg/6µl/day) maintained for 21 days on a normal or high salt 
intake for which physiological data is presented in Fig. 8A and 8B (mean±SEM, N=6/group).  
 
Development of Salt Sensitive Hypertension in Central Gαi2 Oligodeoxynucleotide 
Infused Rats is Renal Nerve Dependent 
 Bilateral RDNX abolished the development of rapid-onset dietary salt-induced 
hypertension produced by continuous central Gαi2 ODN infusion in DSR rats (Figs. 11A-
C). As observed in in intact DSR Gαi2 ODN infused rats, we observed a significant 
decrease in the slope of the pressure-natriuresis relationship in sham RDNX rats—a 
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change abolished by RDNX (Fig. 11).  
 
Figure 11. Blood Pressure, Sodium Balance, and Index of Salt Sensitivity in Dahl Salt-
Resistant Animals Receiving an ICV SCR or Gαi2 ODN Infusion Maintained on a Normal 
or High Salt Diet Following Sham or Bilateral Renal Denervation 
Effect of elevated dietary sodium intake on (A) daily mean arterial pressure (MAP) (mmHg), (B) 
24-hr sodium balance (mEq), and (C) index of salt sensitivity in male Dahl salt-resistant (DSR) 
rats receiving an intracerebroventricular (ICV) infusion of a scrambled (SCR) or Gαi2 
oligodeoxynucleotide (ODN; 25µg/6µl/day) maintained for 21days on a normal or high salt 
intake post sham or bilateral renal denervation (RDNX) surgery (mean±SEM, N=6/group). 
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Mechanistically, in response to 21-day high salt intake, Gαi2 ODN infused bilateral 
RDNX DRS rats did not exhibit elevated global sympathetic activity or an increased 
depressor response to ganglionic blockade as was observed in hypertensive sham-
operated animals (Figs. 12A and 12C). Furthermore, in sham operated Gαi2 ODN infused 
DSR rats, we observed a significant elevation in both estimated plasma volume and 
estimated blood volume after high salt intake—a change that was abolished in RDNX 
rats (Figs. 12B and 12D). 
 
Figure 12. Plasma Norepinephrine, Change in Blood Pressure, and Estimated Blood and 
Plasma Volume in Dahl Salt-Resistant Animals Receiving an ICV SCR or Gαi2 ODN 
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Infusion Maintained on a Normal or High Salt Diet Following Sham or Bilateral Renal 
Denervation 
Effect of elevated dietary sodium intake on (A) plasma norepinephrine (NE; nmol/L), (B) 
estimated plasma volume (EPV) (mL), (C) peak ΔMAP (mmHg) after intraperitoneal 
chlorisondamine (5 mg/kg), and (D) estimated blood volume (EBV) (mL) in male Dahl salt-
resistant (DSR) rats receiving an intracerebroventricular (ICV) infusion of a scrambled (SCR) or 
Gαi2 oligodeoxynucleotide (ODN; 25µg/6µl/day) maintained for 21days on a normal or high salt 
intake post sham or bilateral renal denervation (RDNX) surgery (mean±SEM, N=6/group). 
 
 In sham RDNX central Gαi2 ODN infused DSS rats, we observed an increase in 
speed and magnitude of salt-induced hypertension compared with control SCR ODN 
infused rats—an effect prevented by bilateral RDNX (Fig. 13A). DSS rats that underwent 
a sham RDNX procedure exhibited a significant elevation in 24-hour sodium balance 
during the first five days of high salt intake compared with bilateral RDNX animals (Fig. 
13B). As in intact DSS Gαi2 ODN infused rats, we observed a decrease in the slope of the 
pressure-natriuresis relationship in sham RDNX rats that was accompanied by a small 
(~8 mmHg) parallel shift in the pressure-natriuresis relationship—a change abolished by 
RDNX (Fig. 13C).  
	 
48 
 
Figure 13. Blood Pressure, Sodium Balance, and Index of Salt Sensitivity in Male Dahl Salt-
Sensitive Animals Receiving an ICV SCR or Gαi2 ODN Infusion Maintained on a Normal or 
High Salt Diet Following Sham or Bilateral Renal Denervation. 
Effect of elevated dietary sodium intake on (A) daily mean arterial pressure (MAP) (mmHg), (B) 
24-hr sodium balance (mEq), and (C) index of salt sensitivity in male Dahl salt-sensitive (DSS) 
rats receiving an intracerebroventricular (ICV) infusion of a scrambled (SCR) or Gαi2 
oligodeoxynucleotide (ODN; 25µg/6µl/day) maintained for 21-days on a normal or high salt 
intake post sham or bilateral renal denervation (RDNX) surgery (mean±SEM, N=6/group). 
	 
49 
Sham RDNX DSS rats also exhibited enhanced increases in plasma NE content (Fig. 
14A) and an increased peak depressor response to chlorisondamine-mediated ganglionic 
blockade (Fig. 14C) compared with high salt intake RDNX or intact animals. In sham 
RDNX DSS Gαi2 ODN infused rats, we observed significant elevations in estimated 
plasma volume and estimated blood volume after 21 days of high salt intake, the 
magnitude of which was attenuated in RDNX rats (Figs. 14B and 14D) 
Figure 14. Plasma Norepinephrine, Change in Blood Pressure, and Estimated Blood and 
Plasma Volume in Dahl Salt-Sensitive Animals Receiving an ICV SCR or Gαi2 ODN 
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Infusion Maintained on a Normal or High Salt Diet Following Sham or Bilateral Renal 
Denervation. 
Effect of elevated dietary sodium intake on (A) plasma norepinephrine (NE; nmol/L), (B) 
estimated plasma volume (EPV) (mL), (C) peak ΔMAP (mmHg) after intraperitoneal 
chlorisondamine (5 mg/kg), and (D) estimated blood volume (EBV) (mL) in male Dahl salt-
sensitive (DSS) rats receiving an intracerebroventricular (ICV) infusion of a scrambled (SCR) or 
Gαi2 oligodeoxynucleotide (ODN; 25µg/6µl/day) maintained for 21-days on a normal or high salt 
intake post sham or bilateral renal denervation (RDNX) surgery (mean±SEM, N=6/group). 
 
There were no differences in plasma sodium or plasma osmolality between DSR and DSS 
Gαi2 ODN infused experimental treatment groups in sham or RDNX animals (Tables 3 
and 4). RDNX was verified by observation of a significant reduction in kidney NE 
content in denervated versus sham-operated animals (Fig. 15). 
 
Table 3. Plasma Sodium and Osmolality in Dahl Salt-Resistant Animals Maintained on a 
Normal or High Salt Diet 
 Dietary Sodium Intake Group 
 0.4% NaCl 8% NaCl 
ICV ODN 
Infusion Gαi2 Gαi2 Gαi2 Gαi2 
Surgical 
Procedure Sham RDNX RDNX Sham RDNX RDNX 
pNa [mEqL-1] 140.8±1.6 139.6±1.4 139.8±0.7 140.7±0.9 
pOsm 
[mOsm/kg] 298.6±3.8 300.6±2.8 298.7±3.2 300.9±3.7 
 
Plasma sodium (pNa [mEqL-1]) and plasma osmolality (pOsm [mOsm/kg]) in male Dahl Salt-
Resistant rats receiving an ICV infusion of a Gαi2 ODN (25µg/6µl/day) measured on day 21 of a 
normal or high sodium diet post sham or bilateral RDNX surgery (means±SEM; N=6/group). 
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Table 4. Plasma Sodium and Osmolality in Dahl Salt-Sensitive Animals Maintained on a 
Normal or High Salt Diet 
 Dietary Sodium Intake Group 
 0.4% NaCl 8% NaCl 
ICV ODN 
Infusion Gαi2 Gαi2 Gαi2 Gαi2 
Surgical 
Procedure Sham RDNX RDNX Sham RDNX RDNX 
pNa [mEqL-1] 140.3±1.3 141.1±1.8 138.9±1.2 140.4±1.1 
pOsm [mOsm/kg] 301.4±4.2 301.8±3.6 299.4±3.8 301.2±3.2 
 
Plasma sodium (pNa [mEqL-1]) and plasma osmolality (pOsm [mOsm/kg]) in male Dahl Salt-
Sensitive rats receiving an ICV infusion of a Gαi2 ODN (25µg/6µl/day) measured on day 21 of a 
normal or high sodium diet post sham or bilateral RDNX surgery. The values are mean±SEM 
(N=6/group). 
 
 
 
Figure 15.  Kidney Norepinephrine Content in Sham or Renal Denervated Dahl Salt-
Resistant and Dahl Salt-Sensitive Animals 
Kidney norepinephrine (NE content) (pg/mg) in male Dahl salt-resistant and salt-sensitive rats 
receiving an ICV infusion of a Gαi2 ODN (25µg/6µl/day) measured on day 21 of a high sodium 
diet post sham or bilateral RDNX surgery. Values are mean±SEM (N=6/group). *P<0.05 vs. 
respective sham RDNX group. 
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Chromosome 8 Substitution Restores Sodium-Evoked CNS Gαi2 Subunit Protein 
Upregulation and Attenuates the Development of DSS Hypertension 
 A high salt challenge increased PVN Gαi2 protein expression in the BN (Fig. 16A 
and 16B) and 8-congenic DSS rat (a DSS strain containing chromosome 8 from the BN 
phenotype; Figs. 16A and 16C).  
 
Figure 16. Paraventricular Nucleus Gαi2 Protein Expression in Brown Norway, Dahl Salt-
Sensitive, and 8-Congenic Dahl Salt-Sensitive Animals Maintained on a Normal or High 
Salt Diet 
(A) Gαi2 subunit protein expression in the paraventricular nucleus (PVN) of naïve Brown 
Norway, Dahl salt-sensitive (DSS), and 8-congenic DSS rats maintained for 21 days on a normal 
or high salt intake. Values are mean±SEM (N=6/group). *P<0.05 vs. respective normal salt 
intake group value. τP<0.05 vs DSS high salt intake group value, and representative immunoblots 
illustrating PVN Gαi2 subunit protein levels in (B) Brown Norway and (C) 8-congenic DSS rats 
(DSS data reproduced from Figure 7). 
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During high salt intake, BN rats exhibited stable blood pressure (Fig. 17A), sodium 
homeostasis (Fig. 17B), suppression of plasma NE content (Fig. 17C), and no change in 
blood or plasma volume (Figs. 17E and 17F). Compared with naïve DSS rats, 8-congenic 
DSS rats display a slower initial rise in mean arterial pressure over the first several days 
of high salt intake and a significant reduction in development of sympathetically 
mediated salt-sensitive hypertension (Fig. 17A-E). 
 
Figure 17. Blood Pressure, Sodium Balance, Plasma Norepinephrine, Change in Blood 
Pressure, and Estimated Blood and Plasma Volume in Brown Norway, Dahl Salt-Sensitive, 
and 8-Congenic Dahl Salt-Sensitive Animals Maintained on a Normal or High Salt Diet 
Effect of elevated dietary sodium intake on (A) daily mean arterial pressure (MAP; mmHg), (B) 
24-hr sodium balance (mEq), (C) plasma norepinephrine (NE; nmol/L), (D) peak ΔMAP (mmHg) 
after intraperitoneal chlorisondamine (5 mg/kg), (E) estimated plasma volume (EPV; mL), and 
(F) estimated blood volume (EBV; mL) in naïve male Brown Norway, Dahl salt-sensitive (DSS), 
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and 8-congenic DSS rats maintained for 21-days on a normal or high sodium diet. Values are 
mean±SEM (N=6/group). *P<0.05 vs. respective normal salt intake group value. τP<0.05 vs DSS 
high salt intake group value. 
 
Discussion 
 High dietary sodium intake evoked a site-specific upregulation of PVN Gαi2 
protein levels in DSR rats. These findings significantly extend our prior report that PVN 
Gαi2 proteins are upregulated in SD rats in response to increased salt intake (Kapusta et 
al., 2013) and demonstrate that this endogenous mechanism is conserved across salt-
resistant rat phenotypes. After high salt intake in the DSS rat, which developed salt-
sensitive hypertension, we detected no change in the expression of PVN Gαi2 proteins. 
The lack of PVN Gαi2 protein upregulation in response to increased salt intake, in 
contrast to that observed in SD (Kapusta et al., 2013) and DSR rats, suggests that this 
reflects an underlying central mechanism driving, in part, the development of salt-
sensitive hypertension in the DSS phenotype. To determine the significance of a sodium-
evoked increase in PVN Gαi2 proteins in DSR rats, and the potential role(s) of CNS Gαi2 
proteins in the DSS rat, we examined the impact of chronic downregulation of brain Gαi2 
protein levels. Downregulation of brain Gαi2 proteins was achieved via ICV infusion of 
Gαi2-targeted ODN sequence that we have demonstrated produces significant and 
specific downregulation of the target protein in vivo (Kapusta et al., 2012; Wainford and 
Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 2013). In these studies, after ODN 
infusion, we observed significant downregulation of Gαi2 proteins in all brain areas 
studied in DSR and DSS rats that was of comparable magnitude during both normal and 
high salt intake.  
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 In Dahl rat phenotypes fed a normal salt diet, downregulation of brain Gαi2 
proteins did not alter any physiological parameter studied. These data indicate that under 
baseline sodium intake, downregulation of Gαi2 proteins does not evoke hypertension and 
that the remaining minimal expression of CNS Gαi2 proteins (10%-15% of control) is 
sufficient to maintain sodium homeostasis. During high salt intake, central Gαi2 protein 
expression evoked sympathetically mediated salt-sensitive hypertension in the DSR rat 
and exacerbated the magnitude of salt-sensitive hypertension observed in the DSS 
phenotype. These data indicate that despite a failure to upregulate PVN Gαi2 proteins 
during high salt intake, endogenous brain Gαi2 protein-gated signal transduction 
pathways, likely located within the PVN, are acting to attenuate the magnitude of DSS 
hypertension. This is evidenced by the fact that removal of the influence of the 
endogenous expression of brain Gαi2 proteins exacerbated salt sensitivity in the DSS 
phenotype. In naïve DSR and DSS rats, we observed the suppression of PRA after high 
salt intake, as has been previously reported (Wilson et al., 1986; Zhu et al., 2009). After 
downregulation of CNS Gαi2 proteins and either development (DSR) or exacerbation 
(DSS) of salt-sensitive hypertension, we again observed suppression of PRA. The 
mechanism driving the suppression of PRA in this setting, in which enhanced 
sympathetic outflow would be assumed to stimulate renin release, remains to be 
established. However, our prior studies in which downregulation of CNS Gαi2 proteins 
did not prevent sodium-stimulated suppression of renin secretion (Kapusta et al., 2013; 
Wainford et al., 2013) support the present findings and suggest that PRA is regulated by a 
mechanism that does not involve brain Gαi2 proteins. 
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 Radiotelemetry data revealed that downregulation of CNS Gαi2 proteins evoked 
an immediate elevation in blood pressure in the DSR rat on high salt challenge, followed 
by a slower gradual increase in blood pressure over time. In the DSS rat, an enhanced 
pressor response to salt intake was also observed after CNS Gαi2 protein downregulation, 
after which the rate of development of hypertension was comparable between SCR and 
Gαi2 treated animals. In both Dahl phenotypes, CNS Gαi2 protein downregulation evoked 
a rapid ~20 mmHg increase in mean arterial pressure within two to three days, indicating 
the dramatic impact of this pathway on blood pressure regulation in response to salt 
across phenotypes. We hypothesize that the overall blood pressure in the DSS phenotype 
remained significantly higher than that observed in the DSR rat, despite Gαi2 
downregulation to the existing complex multifactorial nature of DSS. Our data strongly 
support the hypothesis of distinct phases of salt sensitivity (Van Vliet et al., 2006) and 
suggest that endogenous CNS Gαi2 protein pathways are activated and likely undergo 
upregulation immediately on increased sodium intake to facilitate sodium homeostasis. 
 Chronic removal of the influence of both the afferent and efferent renal 
sympathetic nerves, via bilateral RDNX, prevented central Gαi2 ODN induced 
sympathetically mediated salt sensitive hypertension in DSR rats and attenuated the 
development of salt sensitive hypertension in DSS rats. Recent studies have reported that 
renal efferent nerve reinnervation has begun four weeks after RDNX, as assessed via 
immunohistochemistry (Mulder et al., 2013). Therefore, we think, owing to dramatically 
suppressed renal NE content at the end of our 21-day sodium challenge, there was 
negligible functional impact of efferent renal nerve innervation during our studies. 
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Confirming our findings in intact Dahl rats, sham RDNX DSR and DSS animals 
receiving an ICV Gαi2 ODN infusion exhibited a rapid hypertensive response to elevated 
salt intake with blood pressure remaining elevated during high salt intake. There is a clear 
association between renal nerve activity and the regulation of renal sodium excretion 
(Lohmeier et al., 1999), and recent studies have suggested that increased renal nerve 
release of NE initiates renal sodium transporter dysregulation to drive the 
pathophysiology of salt sensitive hypertension (Mu et al., 2011). Our current studies 
provide clear evidence of a direct role of renal sympathetic innervation of the kidney in 
the development of salt sensitive hypertension. Based on our prior studies demonstrating 
a failure to suppress renal sympathetic nerve traffic and sympathetic outflow in response 
to pharmacological and physiological stimuli after Gαi2 protein downregulation (Kapusta 
et al., 2012; Wainford and Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 2013), 
we speculate in these studies that there was a failure to suppress sympathetic outflow to 
the kidneys. This failure to suppress nerve traffic to the kidney would enhance renal NE 
release and increase NE-mediated sodium reabsorption to evoke the observed sodium 
retention. In these studies, bilateral RDNX abolished the development of salt sensitivity. 
We speculate that this reflects the removal of excess efferent stimulation of the kidney 
and subsequent NE-mediated renal sodium reabsorption. Owing to the use of RDNX, we 
are unable to delineate the individual impact of the afferent versus efferent nerves, which 
interact structurally and functionally (Kopp et al., 2007), on the observed responses. 
Supporting our finding of a critical role of the renal sympathetic nerves in countering the 
development of salt sensitivity is the fact that the removal of the influence of the afferent 
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renal nerves, which inhibit efferent nerve traffic during high salt intake, via dorsal 
rhizotomy evoked the development of salt sensitive hypertension in the SD rat (Kopp et 
al., 2003). Collectively, these studies highlight the critical, yet minimally explored, 
importance of the interactions between the afferent and efferent renal nerves in the 
regulation of blood pressure during high salt intake. 
 The rapid development of persistent hypertension in both sham-denervated Dahl 
phenotypes correlated with dramatically enhanced sodium retention over the first several 
days of high salt intake. In these animals, sodium balance returned to levels observed in 
RDNX animals within seven days while blood pressure remained elevated throughout the 
21-day protocol. We think that the observed rapid elevation in blood pressure, after Gαi2 
protein downregulation, is a result of a reduction in the slope of the blood pressure-
sodium excretion relationship, indicative of increased short-term salt sensitivity of blood 
pressure. This has the effect of resetting the pressure-natriuresis set-point to a higher 
level—a level reached within several days, as hypothesize din current models of the 
development of salt sensitive hypertension (Van Vliet et al., 2006; McLoone et al., 2009; 
Fujita and Fujita, 2013). These data demonstrate that CNS Gαi2 protein downregulation 
decreases the slope of the pressure-natriuresis relationship to drive early onset phase 1 
hypertension to maintain sodium homeostasis. During prolonged exposure to a high salt 
intake (i.e., >21 days), it is probable that we would see a significant rightward parallel 
shift in the pressure-natriuresis relationship, reflecting the irreversible resetting of blood 
pressure to a higher level after renal damage, as has been documented in the DSS rat 
(Van Vliet et al., 2006). Furthermore, in these sham operated animals, we observed 
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increased plasma and blood volume in both DSR and DSS rats after Gαi2 protein 
downregulation. Despite the controversial role of an expansion in blood volume in the 
pathophysiology of DSS (Simchon et al., 1989; Greene et al., 1990), our studies provide 
evidence for blood and plasma volume expansion, without changes in plasma sodium or 
osmolality, in the development of salt sensitive hypertension evoked by central Gαi2 
protein downregulation. 
 To strengthen our hypothesis that upregulation of PVN Gαi2 subunit proteins 
represents a conserved central mechanism required for salt resistance, we conducted 
studies that demonstrated the BN rat exhibits PVN Gαi2 subunit protein upregulation, 
normotension, and sympathoinhibition during high salt intake. Using the 8-congenic DSS 
rat, a congenic DSS rat that contains chromosome 8, which encodes the guanine 
nucleotide binding protein [G protein] alpha inhibiting activity polypeptide 2 (GNAI2) 
gene from the BN rat (Mattson et al., 2008), we investigated the impact of restoring the 
upregulation of PVN Gαi2 proteins on the development of salt sensitivity in the DSS rat. 
When challenged with a high salt intake, the 8-congenic DSS rat exhibited upregulation 
of PVN Gαi2 proteins, attenuation of sodium-evoked hypertension, sodium retention, 
sympathoexcitation, and stable plasma and blood volume. Owing to the multiple 
mechanisms underlying the pathophysiology of DSS, the fact that restoration of the PVN 
Gαi2 protein upregulation attenuated, not abolished, the magnitude of DSS is expected. In 
the 8-congenic rat, we observed a significantly slower increase in blood pressure during 
the first several days of salt intake versus DSS rats, further supporting a role of Gαi2 
proteins in preventing the initiation/development of salt sensitivity. 
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 A key question that remains unanswered, and is beyond the current studies, is the 
mechanism driving the increased expression of Gαi2 proteins in response to altered 
sodium intake. Despite no detectable change in either plasma sodium or osmolality in the 
current studies, we speculate minute changes in plasma sodium/osmolality after sodium 
ingestion sensed by osmo/sodium-sensitive receptors located in the hypothalamic PVN, 
the CVOs (Brooks et al., 2005; Stocker et al., 2013a), or the afferent renal nerve 
terminals (DiBona and Kopp, 1997), trigger the observed alterations in protein 
expression. Human studies have reported the presence of a single nucleotide 
polymorphism in the human GNAI2 gene is associated with increased hypertension risk 
by the Millennium Genome Project for Hypertension in Japan (Kohara et al., 2008) and 
in white Italians (Menzaghi et al., 2006). Menzaghi et al. identified a C>G single 
nucleotide polymorphism in the promoter region of the GNAI2 gene which prevents 
binding of the specificity protein 1 transcription factor. The DSS rat phenotype contains 
several C>G single nucleotide polymorphisms in the GNAI2 gene compared with both 
the BN and DSR phenotypes, one of which is located in the specificity protein 1-binding 
domain. We hypothesize that in response to sodium intake, PVN Gαi2 protein 
upregulation is driven by sodium-evoked stimulation of specificity protein 1 binding that 
is likely impaired in the DSS rat, resulting in deficient specificity protein 1-mediated 
gene transcription after high salt intake and the observed failure to upregulation PVN 
Gαi2 proteins. 
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Perspectives 
 At present, the central mechanisms acting to facilitate sodium homeostasis and 
normotension remain to be fully established (Fujita and Fujita, 2013; Stocker et al., 
2013a). The observed genetically conserved endogenous increase in PVN Gαi2 protein 
expression in multiple salt resistant phenotypes, and a failure of this response in the DSS 
rat, is of high physiological significance because of the pivotal role that the PVN plays in 
the neural network that influences sympathetic outflow and blood pressure regulation 
(Kenney et al., 2003). Our studies (1) implicate sympathetic innervation of the kidney as 
a critical component in the pathogenesis of salt sensitive hypertension, and (2) suggest 
the underlying pathogenesis of salt sensitive hypertension involves integration of both the 
CNS and the kidneys with communication being regulated by the renal sympathetic 
nerves via CNS Gαi2 protein gated signal transduction pathway. Brain Gαi2 protein 
pathways, therefore, represent a central molecular pathway that acts to regulate central 
sympathetic outflow to the kidneys in response to alterations in salt intake. Significantly, 
our data support the theoretical dynamic modeling of DSS hypertension, which proposes 
several phases over the pathophysiology of salt sensitivity of varying duration (Van Vliet 
et al., 2006; McLoone et al., 2009). Collectively, these findings demonstrate a critical 
role for Gαi2 protein gated signal transduction in the early response to high salt intake, at 
which point there are dramatic increases in the set-point of the pressure natriuresis 
relationship to maintain sodium homeostasis if the endogenous sympathoinhibitory 
responses to sodium intake (which we demonstrate require brain Gαi2 proteins) are 
impaired.
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CHAPTER THREE: Impaired Sodium-Evoked Paraventricular Nucleus Neuronal 
Activation and Blood Pressure Regulation in Conscious Sprague-Dawley Rats 
Lacking Central Gαi2 Proteins 
 
This chapter was previously published as: C. Y. Carmichael, A. C. T. Carmichael, J. T. 
Kuwabara, J. T. Cunningham, & R. D. Wainford (2016). Impaired sodium-evoked PVN 
neuronal activation underlies prolonged elevated blood pressure in conscious Sprague-
Dawley rats lacking central Gαi2 proteins. Acta Physiologica 216 (3): 314-329. PMID: 
26412230. 
 
Abstract 
We determined the role of brain Gαi2 proteins in mediating the neural and 
humoral responses of conscious male Sprague-Dawley rats to acute peripheral sodium 
challenge. Rats pretreated (24-hours) intracerebroventricularly with targeted 
oligodeoxynucleotide (25µg/5µl) to downregulate brain Gαi2 protein expression or a 
scrambled control oligodeoxynucleotide were challenged with an acute sodium load 
(intravenous bolus 3M NaCl; 0.14ml/100g) and cardiovascular parameters were 
monitored for 120-minutes. In additional groups, hypothalamic paraventricular nucleus 
Fos immunoreactivity was examined at baseline, 40-minutes, and 100-minutes post-
sodium challenge. In response to intravenous hypertonic saline, no difference was 
observed in peak change in mean arterial pressure between groups. In scrambled 
oligodeoxynucleotide pretreated rats, arterial pressure returned to baseline by 100-
minutes while it remained elevated in Gαi2 oligodeoxynucleotide pretreated rats 
(P<0.05). No difference between groups was observed in sodium-evoked increases in 
Fos-positive magnocellular neurons or vasopressin release. V1a receptor antagonism 
failed to block the prolonged elevation of arterial pressure in Gαi2 oligodeoxynucleotide 
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pretreated rats. A significantly greater number of Fos-positive ventrolateral parvocellular, 
lateral parvocellular, and medial parvocellular neurons were observed in scrambled vs. 
Gαi2 oligodeoxynucleotide pretreated rats at 40- and 100-minutes post-hypertonic saline 
challenge (P<0.05). In scrambled, but not Gαi2 oligodeoxynucleotide pretreated rats, 
hypertonic saline evoked suppression of plasma norepinephrine (P<0.05). This highlights 
Gαi2 protein signal transduction as a novel central mechanism acting to differentially 
influence paraventricular nucleus parvocellular neuronal activation, sympathetic outflow, 
and arterial pressure in response to acute hypertonic saline, independently of actions on 
magnocellular neurons and vasopressin release.  
Introduction 
The hypothalamic paraventricular nucleus (PVN) acts as a critical site of 
integration of homeostatic autonomic and neuroendocrine activity to influence central 
sympathetic outflow in response to osmotic stimuli (Pyner, 2009; Nunn et al., 2011). 
Further, there is growing support for a role of dietary salt intake in altering the 
excitability of the sympathetic nervous system to produce elevated arterial pressure and 
hypertension (Fujita and Fujita, 2013; Stocker et al., 2013a). Despite the progressive 
understanding of these mechanisms, the neural circuitry and neurochemical/receptor 
substrates within the PVN governing the immediate central nervous system (CNS) 
responses to acute increases in plasma sodium and osmolality in response to salt remain 
unclear.  
The acute actions of plasma sodium on the CNS likely involve the coordinated 
activity of multiple brain sites, including the PVN, whose activity is driven by afferent 
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projections from osmosensitive forebrain structures (subfornical organ [SFO], organum 
vasculosum laminae terminalis [OVLT], median preoptic nucleus [MnPO]), with 
descending projections to brainstem (rostral ventrolateral medulla [RVLM]) and spinal 
cord structures (intermediolateral cell column T1-T3 [IML]). The ability of the PVN to 
coordinate the hormonal and neural responses to alterations in osmolality (Antunes-
Rodrigues et al., 2004; Antunes et al., 2006) is mediated by two distinct cell types within 
this region—magnocellular and parvocellular nuclei, respectively. Within the 
magnocellular division are oxytocin- and vasopressin (AVP)-containing neurons—the 
latter a neurohypophyseal hormone classically involved in body fluid homeostasis 
through the regulation of water retention (Swanson and Sawchenko, 1980; Antunes-
Rodrigues et al., 2004). The parvocellular division of the PVN includes sympathetic-
regulatory neurons that project to the RVLM and/or the IML of the spinal cord (Swanson 
and Sawchenko, 1980; Stocker et al., 2004b; Ferguson et al., 2008) and neuroendocrine 
neurons that project to the median eminence that are involved in the release of hormones 
into the hypophyseal portal system (Swanson and Kuypers, 1980; Swanson and 
Sawchenko, 1980; Ferguson et al., 2008). Both acute hypertonic saline (HS) (Kantzides 
and Badoer, 2003; Antunes et al., 2006) and water deprivation (Stocker et al., 2004b)—
two stimuli that increase plasma sodium and osmolality—have been previously reported 
to increase PVN neuronal activation as assessed by Fos immunoreactivity. 
The principal neurotransmitters of the CNS (e.g., GABA and glutamate) have 
been localized within the PVN and the complex inhibitory and excitatory actions evoked 
by these neurotransmitters serve to produce an appropriate differential sympathetic output 
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in the normotensive state (Pyner, 2009; Nunn et al., 2011). Electrophysiological studies 
have shown inhibition of both inhibitory and excitatory actions on PVN neurons by 
presynaptic G-protein coupled (GPCR) GABAB receptors (Chen and Pan, 2006). Cell 
culture studies have demonstrated that Gα-subunit protein availability can play a critical 
role in determining the intracellular signaling response to GPCR activation following 
ligand binding (Nasman et al., 2001). Our laboratory has demonstrated that brain 
Gαi2 proteins, inhibitory intracellular signaling proteins coupled to GPCRs (e.g., 
GABAB) post ligand binding, possess a functionally selective and facilitory role in 
central cardiovascular regulation. Specifically, Gαi2 proteins mediate the hypotensive 
response to direct central α2-adrenoceptor activation, the renal sympathoinhibitory 
response to an acute volume expansion, and the global sympathoinhibitory response to a 
non-pressor sodium challenge in the normotensive, Sprague-Dawley rat—a strain which 
is salt-resistant (Kapusta et al., 2012; Wainford and Kapusta, 2012; Wainford et al., 
2013). Based on these findings, we propose that Gαi2 protein signal transduction 
contributes to a sympathoinhibitory GPCR-activated neuronal mechanism within the 
PVN. These PVN mechanisms functionally normalize sympathetic outflow and arterial 
pressure following an acute pressor sodium challenge in a salt-resistant rat phenotype. 
In the present study, we hypothesized that salt-resistant rats with compromised 
Gαi2 protein expression would exhibit prolonged elevated blood pressure in response to 
an acute HS challenge. Also, this sustained pressor response would involve altered PVN 
neuronal activation and impaired regulation of the release of norepinephrine (NE) and/or 
AVP. To address this hypothesis we: 1) used an oligodeoxynucleotide (ODN) 
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knockdown approach to test the role of central Gαi2 proteins in mediating the blood 
pressure response to an acute HS challenge, 2) examined the impact of removing central 
Gαi2 proteins on the sodium-evoked activation of PVN subnuclei, and 3) examined the 
impact of removing central Gαi2 proteins on sodium-evoked alterations in plasma NE and 
AVP. 
Methods 
Animals 
Male Sprague-Dawley (SD) rats (Harlan Laboratories Inc., IN) weighing 275-
300g were individually housed in a temperature- (range: 20-26°C) and humidity-
controlled (range: 30-70%) environment under a 12-h light/dark cycle and were randomly 
assigned to experimental treatment groups. Rats were allowed tap water and standard 
rodent diet (Test Diet, St. Louis, MO, USA) ad libitum.  All experimental protocols were 
approved by the Institutional Animal Care and Use Committee in accordance with the 
guidelines of Boston University School of Medicine and the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. 
Surgical Procedures 
Intracerebroventricular cannulae implantation  
Animals were anesthetized (ketamine, 30 mg/kg intraperitoneally [IP] in 
combination with xylazine, 3 mg/kg IP) and stereotaxically implanted with a stainless 
steel cannula into the right lateral cerebral ventricle 5-7 days prior to experimentation, as 
previously described (Wainford and Kapusta, 2012). 
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Acute femoral vein, artery, and bladder cannulation 
On the day of the study, intracerebroventricular (ICV) control scrambled (SCR) or 
Gαi2 ODN pretreated rats were anesthetized with sodium methohexital (20 mg/kg IP, 
supplemented with 10 mg/kg intravenously [IV] as required) and instrumented with 
catheters in the left femoral vein, left femoral artery, and bladder for administration of an 
isotonic saline infusion, bolus HS load, or V1a receptor antagonist, measurement of heart 
rate (HR) and arterial blood pressure (MAP), and renal function, respectively (Kapusta et 
al., 2012; Wainford and Kapusta, 2012; Wainford et al., 2013).  
Experimental Protocols 
Acute intracerebroventricular oligodeoxynucleotide administration 
Twenty-four hours prior to the day of the study, downregulation of brain Gαi2 
protein expression levels in rats was achieved by ICV injection (25 µg/5 µl delivered over 
60-sec) of a phosphodiesterase ODN probe dissolved in isotonic saline that selectively 
targets Gαi2 proteins (5’-CTT GTC GAT CAT CTT AGA-3’) (Kapusta et al., 2012; 
Wainford and Kapusta, 2012; Wainford et al., 2013). Control studies involved ICV 
injection of a SCR ODN (5’-GGG CGA AGT AGG TCT TGG-3’) (The Midland 
Certified Reagent Company Inc., Midland, TX, USA). An NCBI Basic Local Alignment 
Search Tool search of the Rattus norvegicus RefSeq protein database was conducted to 
confirm the specificity of the Gαi2 ODN for the rat Gαi2 protein sequence and that the 
SCR ODN does not match any known rat protein sequence. Multiple publications from 
our laboratory have confirmed effective (~85%) ODN-mediated downregulation of Gαi2 
protein expression in the acute setting as assessed by Western blotting (Kapusta et al., 
	 
68 
2012). This was not carried out in the current study due to the different methods of tissue 
processing required for immunohistochemical analysis (PFA mediated fixation) vs. 
Western blotting (snap frozen) that do not allow for both methods to be performed in a 
single animal. 
Acute sodium challenge  
Following femoral vein, artery, and bladder cannulation (as outlined above), rats 
were placed in a Plexiglas holder and an IV infusion of isotonic saline (20 µl/min) was 
maintained for a 2-h surgical recovery period prior to experimentation to enable the 
animal to regain full consciousness and for cardiovascular and renal excretory functions 
to stabilize. HR and MAP were continuously recorded via the surgically implanted 
femoral artery cannula using computer-driven BIOPAC data acquisition software 
(MP150 and AcqKnowledge 3.8.2, Goleta, CA, USA) connected to an external pressure 
transducer (P23XL; Viggo Spectramed Inc., San Francisco, CA, USA) (Wainford and 
Kapusta, 2012; Wainford et al., 2013). Following the 2-h recovery period, HR and MAP 
were recorded continuously over a 20-min baseline period in conscious rats. After 
measurement of baseline parameters, animals received a peripheral HS challenge: IV 
bolus dose of 3M NaCl (0.14 ml/100 g delivered over 30-sec) (Antunes et al., 2006; 
Veitenheimer and Osborn, 2011) and changes in HR and MAP were continuously 
recorded for 120-min and urine was collected in 10-min increments for the duration of 
the experiment (N=6/treatment group/time point).  
Separate groups of animals underwent an identical HS challenge protocol, but 
were sacrificed at baseline, 40-min, and 100-min post HS administration by either 
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intracardiac perfusion for CNS IHC (N=8/treatment group/time point) [outlined below in 
Central Nervous System Tissue Collection section] or at baseline, 10-min, 40-min, and 
100-min by conscious decapitation for trunk blood collection (N=5/treatment group/time 
point) [outlined below in Acute sodium challenge blood sample collection section]. 
Respective time points at which PVN Fos expression was evaluated were determined 
based on the expression profile of Fos protein post-stimulus. An initial early time point at 
which sodium-evoked alterations in Fos would be detectable is represented by 40-min 
(Herrera and Robertson, 1996) and a time point at which there was a divergence in the 
MAP response between groups (Fig. 18) and at which there would be robust Fos 
expression is represented by 100-min.   
Acute sodium challenge during V1a receptor antagonism 
An additional group of rats underwent an identical ODN pretreatment and HS 
challenge protocol [outlined above in Acute ICV ODN administration and Acute sodium 
challenge sections, respectively], but HS was injected five minutes following 
pretreatment with [β-mercapto-β, β -cyclopentamethylene-propionyl1,O-me-Tyr2,-Arg8]-
vasopressin (a V1a receptor antagonist, 10 µg/kg/mL, IV bolus) (Veitenheimer and 
Osborn, 2011) (Sigma-Aldrich, St. Louis, MO, USA). 
Acute sodium challenge + autonomic function 
An additional group of rats underwent an identical ODN pretreatment and HS 
challenge protocol [outlined above in Acute ICV ODN administration and Acute sodium 
challenge sections, respectively], but the ganglionic blocker hexamethonium (IV 30 
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mg/kg) (Kapusta et al., 2013) was administered 110-min post HS and peak change in 
MAP was recorded (N=5/group) 
Acute sodium challenge blood sample collection 
Conscious decapitation was performed at either baseline, 10-min, 40-min, or 100-
min time points post HS administration and trunk blood was collected in a heparinized 
tube. Following plasma extraction, samples were frozen at -80°C until later analysis of 
sodium, osmolality, NE, and AVP. 
Cardiac baroreflex curve  
Baroreflex regulation of HR was assessed in a separate group of 24-h ICV SCR or 
Gαi2 ODN pretreated conscious rats instrumented with femoral vein and artery cannulae, 
as outlined above (N=6/treatment group). Doses of phenylephrine and sodium 
nitroprusside (10 µg in 0.2 ml saline for each) were infused (IV; 0.05 ml every 10-sec) 
over 40-sec to increase and decrease blood pressure by 50-60 mmHg, respectively, to 
generate a dynamic baroreflex gain curve for HR. Changes in HR and MAP were 
continuously recorded via the surgically implanted femoral artery cannula using 
computer-driven BIOPAC data acquisition software connected to an external pressure 
transducer. A four-parameter logistic equation was used to generate a baroreflex gain 
curve in which average values of HR were calculated for each 5 mmHg change in MAP 
using the 1-sec values stored on the hard drive. This allowed for calculation of the range 
over which the curve operated (A1), the sensitivity or curvature coefficient of the 
relationship (A2), the mid-point mean blood pressure of the curve (A3), and the lowest 
point to which the HR could be driven (A4) (Huang et al., 2006). 
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Central Nervous System Tissue Collection 
Following completion of the HS challenge protocol, rats were deeply anesthetized 
with sodium methohexital (10 mg/kg IV) and immediately perfused transcardially with 
0.2-0.3 L of 0.1M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde 
(PFA) in 0.1M PBS (4°C, 0.3-0.5 L). The brains were removed and placed in a vial 
containing 4% PFA in PBS overnight and then switched to a 30% w/v sucrose solution 
for two days (Randolph et al., 1998). The PVN was sectioned into three separate sets of 
serial 40-µm coronal sections that were collected into a cryoprotectant [30% sucrose + 
30% ethylene glycol + 1% polyvinyl-pyrrolidone in 0.1M PBS] and stored at -20°C until 
they were processed for immunohistochemistry.  
Fos Immunoreactivity and Histological Analysis 
Free-floating sections from each brain were processed for Fos 
immunohistochemistry using a rabbit polyclonal anti-Fos antibody (Calbiochem, San 
Diego, CA, USA) as previously described (Randolph et al., 1998). Briefly, sections were 
brought to room temperature and rinsed twice for 30-min in 0.1M PBS to remove 
cryoprotectant. Sections were incubated in 0.3% hydrogen peroxide in distilled water for 
30-min at room temperature then rinsed for 30-min in 0.1M PBS. Sections were then 
incubated for 2-h at room temperature in PBS diluent [3% normal horse serum in 0.1M 
PBS containing 0.25% Triton-100 (Sigma-Aldrich, St. Louis, MO, USA)]. The rabbit 
polyclonal anti-Fos antibody was diluted to 1:30,000 in PBS diluent and the sections 
were incubated in the primary antibody for 48-h at 4°C. After two 30-min rinses in 0.1M 
PBS, sections were incubated in a biotinylated horse anti-rabbit IgG (Vector 
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Laboratories, Burlingame, CA, USA) diluted to 1:200 in PBS diluent for 2-h at room 
temperature. The tissue was reacted with an avidin-peroxidase conjugate (ABC-
Vectastain kit; Vector Laboratories, Burlingame, CA, USA) and PBS containing 0.04% 
3,3’-diaminobenzidene hydrochloride and 0.04% nickel ammonium sulfate (Sigma-
Aldrich, St. Louis, MO, USA). Sections were mounted on gel-coated slides, processed 
through a series of dehydrating alcohols followed by xylenes, and placed under a 
coverslip with Permount mounting medium. 
Tissue sections were analyzed using an Olympus microscope (BX41) equipped 
for epifluorescence and an Olympus DP70 digital camera with DP manager software (v 
2.2.1). The PVN was identified using the stereotaxic atlas of Paxinos and Watson 
(Paxinos and Watson, 1998) and sampled at three rostral-caudal levels, as previously 
described (Stocker et al., 2004b). Care was taken to ensure that the sections used were 
from the same rostral-caudal plane in each brain. Analysis was performed on two sets of 
tissue for each animal. The number of Fos-positive cells were visually quantified by 
participants blind to the experimental conditions using National Institutes of Health 
ImageJ software and the counts for each PVN subnucleus was averaged for each animal. 
Analytical Techniques 
Analysis of Urine 
Urine volume was determined gravimetrically assuming 1g = 1ml. Urinary 
osmolality was measured using a Vapor Pressure osmometer (model 5600; Wescor Inc., 
South Logan, UT, USA). Free water clearance (CH2O) was calculated as a difference 
between the rate of urine volume (µl/min) and the osmolar clearance (Kapusta et al., 
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2013). 
Analysis of Plasma Samples 
Plasma sodium was determined by flame photometry (model 943; Instrumentation 
Laboratory, Bedford, MA, USA) and plasma osmolality was measured using a Vapor 
Pressure Osmometer (model 5600; Wescor Inc, South Logan, UT, USA) (Kapusta et al., 
2013; Wainford et al., 2013; Wainford et al., 2015b). Plasma NE content was determined 
using a NE ELISA kit as per manufacturers’ instruction (Immuno-Biological 
Laboratories, Inc, Minneapolis, MN, USA). For AVP analysis, equal volumes of 0.1% 
(v/v) trifluoroacetic acid (TFA) and distilled water were added to plasma samples that 
were centrifuged for 15 min (17,000 G at 4°C). Sep-Pak C18 columns (EMD Millipore, 
Billerica, MA, USA) were preconditioned with 1 ml acetonitrile followed by 10-25 ml 
0.1% TFA and the supernatant was added. The columns were washed with 10-25 ml of 
0.1% TFA and the peptides were eluted by 3 ml of 60:40 acetonitrile and 0.1% TFA and 
1 ml fractions were collected. All samples were evaporated to dryness on a Savant Speed 
Vac and reconstituted in 250 µl of assay buffer. Following extraction, plasma AVP 
concentration was determined using an AVP ELISA kit as per manufacturers’ instruction 
(Enzo Life Sciences, Farmingdale, NY, USA) (Wainford and Kapusta, 2010). 
Statistical Analysis 
Results are expressed as mean ± SEM. The magnitude of change in 
cardiovascular and free water clearance parameters at different time points after HS or 
V1a receptor antagonism + HS were compared with respective group control values by a 
one-way repeated-measures (RM) ANOVA with a subsequent Dunnett’s multiple 
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comparisons test (GraphPad Prism v. 6.00 for Mac OS X; GraphPad Software, San 
Diego, CA, USA). Differences occurring between treatment groups were assessed by a 
two-way RM (mixed model) ANOVA (treatment x time) with a subsequent Sidak’s 
multiple comparisons test. Baroreflex gain curves were generated using a non-linear least 
squares fit approach and analyzed by a two-way RM ANOVA with a subsequent Sidak’s 
multiple comparisons test. Baroreflex parameters (A1-A4) were analyzed by independent 
t-tests. Plasma sodium, osmolality, NE content, and AVP content were compared with 
respective group control values by a one-way ANOVA with a subsequent Sidak’s 
multiple comparisons test. Differences occurring between treatment groups were assessed 
by a two-way ANOVA with a subsequent Sidak’s multiple comparisons test. The number 
of Fos-positive cells in each subregion of interest was compared with respective group 
control values by a one-way ANOVA and between groups by a two-way ANOVA with a 
subsequent Dunnett’s and Sidak’s multiple comparisons test, respectively. In each case, 
statistical significance was defined as P<0.05. 
Results 
Effect of HS on cardiovascular and renal excretory parameters  
Table 5 presents HR and MAP values in all conscious SD rats pretreated ICV 
with a SCR or Gαi2 ODN used through the course of these experiments to illustrate there 
was no difference in baseline hemodynamic parameters prior to HS (3M, IV) stimulus 
(i.e., no ODN-specific effect).  
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Table 5. Cardiovascular Parameters in All Conscious Sprague-Dawley Animals 
 
 
Baseline(N=57/group) 
 
SCR ODN Gαi2 ODN 
HR (bpm) 427 ± 8 436 ± 9 
MAP (mmHg) 126 ± 2 128 ± 2 
 
HR (bpm) and MAP (mmHg) in all conscious Sprague-Dawley rats pretreated ICV with a control 
SCR or experimental Gαi2 ODN (25 µg/5 µL) to illustrate no difference in baseline 
hemodynamic parameters prior to HS stimulus. Data are mean±SEM (N=6/group). HR, heart 
rate; MAP, mean arterial pressure; ICV, intracerebroventricular; ODN, oligodeoxynucleotide; 
SCR, scrambled; HS, hypertonic saline. 
 
 
Following HS in male SD rats pretreated (24-h) with a control SCR or Gαi2 ODN, 
peak bradycardia was significantly greater in SCR as compared to Gαi2 ODN pretreated 
groups (HS ΔHR [bpm]; SCR ODN: -79±15 vs. Gαi2 ODN: -59±12, P<0.05). No 
difference was observed in the peak change in MAP between ODN pretreatment groups 
(HS ΔMAP [mmHg] SCR ODN: +17±4 mmHg vs. Gαi2 ODN: +13±3, P>0.05). In SCR 
ODN pretreated rats, MAP returned to baseline by 100-min whereas in Gαi2 ODN 
pretreated rats, MAP remained significantly elevated (MAP 100-min [mmHg] SCR 
ODN: 134±2 vs. Gαi2 ODN: 146±3, P <0.05). No differences in free water clearance 
were observed between ODN pretreatment groups at any time point (Fig. 18). 
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Figure 18. Acute Cardiovascular and Free Water Clearance Parameters in Sprague-Dawley 
Animals  
Systemic cardiovascular and free water clearance responses produced by HS challenge (3M, 0.14 
mL 100g-1, IV) in conscious male Sprague-Dawley rats pretreated ICV with a control SCR or 
experimental Gαi2 ODN (25 µg 5 µL-1) expressed as raw values (A-C) or percent change from 
baseline (D, E). Data are mean±SEM (N=8/group). *P<0.05, sig. diff. vs. respective group 
baseline value, τP<0.05, sig. diff. vs. respective SCR ODN group value. 
 
 
Effect of central Gαi2 protein downregulation on the cardiac baroreflex  
The impact of central Gαi2 protein downregulation on the ability of the arterial 
baroreceptors to reflexively regulate heart rate was investigated in separate groups of 
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ODN pretreated animals (Fig. 19). Table 6 presents the four parameters of the baroreflex 
gain curves for HR in animals pretreated centrally with a SCR or Gαi2 ODN. No 
differences were observed between ODN pretreatment groups in the range of the curves 
(A1), the sensitivity or curvature coefficient of the relationship (A2), or the mid-point 
mean blood pressure (A3). Central Gαi2 protein downregulation significantly altered the 
lowest point to which HR could be driven (A4) in an acute setting (lowest HR [bpm] SCR 
ODN: 258.8±9.9 vs. Gαi2 ODN: 288.2±13.7, P<0.05). Separate analysis of the high-
pressure baroreflex revealed a significant difference between pretreatment groups in 
baroreflex sensitivity (A2) ([bpm mmHg-1] SCR ODN: 0.044±0.004 vs. Gαi2 ODN: 
0.083±0.004, P<0.05). 
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Figure 19. Cardiac Baroreflex Curve in SCR versus Gαi2 ODN Pretreated Sprague-Dawley 
Animals 
Cardiac baroreflex relationship produced by IV infusion of phenylephrine and sodium 
nitroprusside in conscious male Sprague-Dawley rats pretreated ICV with a control SCR or 
experimental Gαi2 ODN (25 µg/5 µL). Midpoint MAP (mmHg) indicated by dashed line. Data are 
mean ± SEM (N=6/group). τP<0.05, sig. diff. vs. respective SCR ODN group value. 
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Table 6. Baroreflex Parameters for Heart Rate in Sprague-Dawley Animals Pretreated ICV 
with a SCR or Gαi2 ODN 
 A1 (bpm) A2 (bpm mmHg
-1) A3(mmHg) A4 (bpm) 
SCR ODN 235.1 ± 14.7 -0.034 ± 0.005 129.9 ± 2.0 258.8 ± 9.9 
Gαi2 ODN 213.0 ± 18.4 -0.033 ± 0.006 135.8 ± 2.7 288.2 ± 13.7 τ 
 
Baroreflex parameters for heart rate obtained in conscious Sprague-Dawley rats pretreated ICV 
with a control SCR or experimental Gαi2 ODN (25 µg/5 µL). Data are mean ± SEM (N=6/group). 
ICV, intracerebroventricular; ODN, oligodeoxynucleotide; SCR, scrambled. A1, range of the 
curve; A2, sensitivity of the curve; A3, mid-point mean of the blood pressure; A4, lowest point to 
which HR could be driven. τP<0.05, sig. diff. vs. respective SCR ODN group value. 
 
Effect of HS on Fos immunoreactivity in PVN parvocellular neurons 
PVN Fos immunoreactivity was analyzed by subnuclei whose cytoarchitechtonic 
boundaries were determined based on the rostral-caudal level of each section (Stocker et 
al., 2004b). Table 7 presents the mean HR and MAP group values in response to an IV 
3M NaCl bolus from ODN pretreated animals in which cFos IHC was conducted at 
baseline, 40-min, and 100-min. These data demonstrate that the cardiovascular responses 
were no different as those observed in animals from which the initial physiological data 
was derived (Fig. 18), confirming the reproducibility of our experimental paradigm.  
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Table 7. Cardiovascular and Free Water Clearance Parameters in Sprague-Dawley 
Animals for cFos Immunohistochemistry 
 
Baseline 
(N=24/group)  10-min (N=24/group)  40-min (N=16/group)  100-min (N=8/group) 
 SCR ODN Gαi2 ODN  SCR ODN Gαi2 ODN  SCR ODN Gαi2 ODN  SCR ODN Gαi2 ODN 
HR (bpm) 437±7 435±6  388±9* 399±11*
τ  343±11* 385±13*
τ  417±14 442±10
τ 
MAP 
(mmHg) 123±2 127±2  136±3* 138±6*  131±2* 139±4*  127±3 138±3*
τ 
CH2O 
(ml/min) 
-526±61 -592±55  -463±51 -480±42  -826±50 -702±37  -1003±65 -873±35 
 
HR (bpm), MAP (mmHg), and CH2O (ml/min) during baseline, 10-min, 40-min, and 100-min 
post-sodium challenge in conscious Sprague-Dawley rats pretreated ICV with a SCR or Gαi2 
ODN (25 µg/5 µL) and sacrificed at baseline, 40-min, or 100-min for cFos 
immunohistochemistry. Data are mean ± SEM. *P<0.05, sig. diff. vs. respective baseline group 
value, τP<0.05, sig. diff. vs. respective SCR ODN group value. 
 
PVN parvocellular neurons were analyzed as dorsal (DP), medial (MP), 
ventrolateral (VLP), and lateral (LP) subregions based on the respective rostral-caudal 
level of the PVN. No differences between the ODN pretreatment groups in the number of 
Fos-positive nuclei were observed in any parvocellular subregion prior to HS. At 40-min, 
HS significantly increased Fos immunoreactivity in the MP region in the SCR ODN 
pretreatment group ([MP Fos+ cells] SCR ODN baseline: 8±1 vs. 40-min: 29±4, P<0.05), 
while no differences in any region were observed in the Gαi2 ODN group as compared to 
respective baseline levels. At 100-min, SCR ODN pretreated rats exhibited significant 
increases in DP, MP, VLP, and LP regions as compared to baseline. As compared to SCR 
ODN pretreated rats, Gαi2 ODN pretreated rats exhibited significantly less Fos-positive 
cells in MP, VLP, and LP regions at the 100-min post HS challenge time point. No 
significant differences were observed between ODN pretreatment groups in the DP 
region at any time point (Fig. 20, 21).  
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Figure 20. Representative Images of cFos Immunoreactivity at Level Three of the 
Paraventricular Nucleus 
Representative images of total PVN Fos-positive nuclei at level three in male Sprague-Dawley 
rats pretreated ICV with a control SCR or experimental Gαi2 ODN (25 µg/5 µL) at baseline, 40-
min, and 100-min post HS challenge. Counts are summarized in Figs. 22, 23. 
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Figure 21. Mean Number of Parvocellular Nuclei in SCR versus Gαi2 ODN Pretreated 
Sprague-Dawley Animals 
Mean number (per section) of Fos-positive parvocellular nuclei averaged across all rostral-caudal 
levels in male Sprague-Dawley rats pretreated ICV with a control SCR or experimental Gαi2 
ODN (25 µg/5 µL) at baseline, 40-min, and 100-min post HS challenge. Data are mean ± SEM 
(N=8/group/time point). *P<0.05, sig. diff. vs. respective group baseline value, τP<0.05, sig. diff. 
vs. respective SCR ODN group value. 
 
Effect of HS on Fos immunoreactivity in PVN magnocellular neurons 
The total number of Fos-positive magnocellular neurons (i.e., posterior magnocellular 
[PM]) was significantly greater at 100-min as compared to baseline in both SCR and Gαi2 
ODN pretreatment groups ([PM Fos+ cells] SCR ODN baseline: 3±1 vs. 100-min: 31±5; 
Gαi2 ODN baseline: 2±0 vs. 100-min: 26±4, P<0.05). There were no significant 
differences in Fos-positive magnocellular neurons between SCR and Gαi2 ODN 
pretreatment groups at any time point (Fig. 4, 6).  
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Figure 22. Representative Images of cFos Immunoreactivity at Level Two of the 
Paraventricular Nucleus 
Representative images of total PVN Fos-positive nuclei at level two in male Sprague-Dawley rats 
pretreated ICV with a control SCR or experimental Gαi2 ODN (25 µg/5 µL) at baseline, 40-min, 
and 100-min post HS challenge. Counts are summarized in Figs. 21, 23. 
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Figure 23. Mean Number of Magnocellular Nuclei in SCR versus Gαi2 ODN Pretreated 
Sprague-Dawley Animals 
Mean number (per section) of magnocellular Fos-positive nuclei averaged across all rostral-
caudal levels in male Sprague-Dawley rats pretreated ICV with a control SCR or experimental 
Gαi2 ODN (25 µg/5 µL) at baseline, 40-min, and 100-min post HS challenge. Data are mean ± 
SEM (N=8/group/time point). *P<0.05, sig. diff. vs. respective group baseline value. 
 
Analysis of free water clearance revealed a decrease in free water clearance in 
both ODN pretreatment groups, but there were no significant differences in this 
parameter between the groups at any time point (Table 8). 
Effect of HS on plasma sodium, osmolality, and circulating NE and AVP 
An IV HS challenge produced a significant increase in plasma sodium at 10-min 
in both SCR (plasma Na+ [µeq] baseline: 138.5±1.7 vs. 10-min: 150.1±0.9, P<0.05) and 
Gαi2 (plasma Na+ [µeq] baseline: 138.7±1.5 vs. 10-min: 149.2±0.9, P<0.05) ODN 
pretreatment groups (Table 9). IV HS challenge also produced a significant increase in 
plasma osmolality at 10-min in both SCR (plasma osmolality [mmol/kg] baseline: 298±2 
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vs. 10-min: 319±1, P<0.05) and Gαi2 (plasma osmolality [mmol/kg] baseline: 296±3 vs. 
10-min: 317±1, P<0.05) ODN pretreatment groups. Control values and the resultant 
changes in plasma sodium and osmolality were similar between ODN pretreatment 
groups at all time points (P>0.05) and returned to baseline levels at 40-min (Table 8).  
Table 8. Plasma Sodium and Osmolality in Sprague-Dawley Animals 
 
Baseline 
(N=5/group)  
10-min 
(N=5/group)  40-min (N=5/group)  
100-min 
(N=5/group) 
 
SCR 
ODN 
Gαi2 
ODN  
SCR 
ODN 
Gαi2 
ODN  
SCR 
ODN 
Gαi2 
ODN  
SCR 
ODN 
Gαi2 
ODN 
Plasma Na
+ 
(µeq) 
138.5 ± 
1.7 
138.7 ± 
1.5  
150.1 ± 
0.9* 
149.2 ± 
0.9*  
139.0 ± 
1.5 
139.9 ± 
1.2  
137.2 ± 
3.1 
139.2 ± 
2.5 
Plasma Osm 
(mmol/kg) 298 ± 2 296 ± 3  319 ± 1* 317 ± 1*  303 ± 2 304 ± 2  299 ± 1 300 ± 2 
 
Plasma sodium (µEq) and osmolality (mmol/kg) during baseline, 10-min, 40-min, and 100-min 
post HS challenge in conscious Sprague-Dawley rats pretreated ICV with a SCR or Gαi2 ODN 
(25 µg/5 µL). Data are mean ± SEM (N=5/group). *P<0.05, sig. diff. vs. respective baseline 
group value. 
 
 
No differences in plasma NE or AVP content were observed between ODN 
pretreatment groups at baseline time points prior to HS (P>0.05) (Fig. 24). Following HS 
challenge, plasma NE content significantly decreased at 10-min in SCR ODN pretreated 
rats as compared to baseline (plasma NE [nmol/L] baseline: 44.1±4.9 vs. 10-min: 
17.4±3.9, P<0.05) while no change was observed in Gαi2 ODN pretreated rats (P>0.05). 
No differences in plasma NE content were observed at 40- and 100-min compared to 
baseline or between ODN pretreatment groups (Fig. 24A). Significant increases in 
plasma AVP content were observed in both ODN pretreatment groups at 10-min (plasma 
AVP [pg mL-1] SCR ODN baseline:  12.2±1.6 vs. 10-min: 62.8±6.9, Gαi2 ODN baseline: 
12.1±1.5 vs. 10-min: 67.7±7.7 P<0.05) (Fig. 24B). At 40- and 100-min, plasma AVP 
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content was not significantly different than baseline in either ODN pretreatment group 
(P>0.05).  
 
Figure 24. Plasma Norepinephrine and Vasopressin in SCR versus Gαi2 ODN Pretreated 
Sprague-Dawley Animals 
(A) Plasma norepinephrine (NE) and (B) plasma vasopressin (AVP) content in male Sprague-
Dawley rats pretreated ICV with a control SCR or experimental Gαi2 ODN (25 µg/5 µL) at 
baseline, 10-min, 40-min, and 100-min post HS challenge. Data are mean ± SEM 
(N=5/group/time point). *P<0.05, sig. diff. vs. respective group baseline value, τP<0.05, sig. diff. 
vs. respective SCR ODN group value. 
 
Table 9 presents the mean HR and MAP group values in response to an IV 3M 
NaCl bolus from ODN pretreated animals in which plasma sodium, osmolality, NE, and 
AVP was conducted at baseline, 10-min, 40-min, and 100-min. These data demonstrate 
that the cardiovascular responses were the same as those observed in animals from which 
the initial physiological data was derived (Fig. 18). 
	 
86 
Table 9. Cardiovascular Parameters in Sprague-Dawley Animals for Plasma Analysis 
 Baseline (N=20/group)  10-min (N=15/group)  40-min (N=10/group)  100-min (N=5/group) 
 SCR ODN Gαi2 ODN  SCR ODN Gαi2 ODN  SCR ODN Gαi2 ODN  SCR ODN Gαi2 ODN 
HR (bpm) 435±5 438±6  363±8* 397±12*
τ  348±9* 374±7*
τ  399±13 440±6
τ 
MAP 
(mmHg) 122±2 121±3  135±3* 139±3*  134±4* 140±3*  122±3 130±1*
τ 
 
HR (bpm) and MAP (mmHg) during baseline, 10-min, 40-min, and 100-min post-sodium 
challenge in conscious Sprague-Dawley rats pretreated ICV with a SCR or Gαi2 ODN (25 µg/5 
µL) and sacrificed for plasma sodium, osmolality, norepinephrine, and vasopressin measurement. 
Data are mean ± SEM. *P<0.05, sig. diff. vs. respective baseline group value, τP<0.05, sig. diff. 
vs. respective SCR ODN group value. 
 
 
Effect of ganglionic blockade on blood pressure following acute sodium challenge 
Hexamethonium-mediated ganglionic blockade at 110-min post HS challenge 
resulted in a significantly greater reduction in MAP in hypertensive Gαi2 ODN pretreated 
rats compared with SCR ODN pretreated rats (ΔMAP [mmHg] SCR ODN: 26±3 vs. Gαi2 
ODN: 38±2, P <0.05). Ganglionic blockade reduced baseline blood pressure to a similar 
level in both pretreatment groups (Table 10). 
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Table 10. Cardiovascular Parameters in Sprague-Dawley Animals Given a Ganglionic 
Blocker  
 SCR ODN Gαi2 ODN 
Baseline MAP (mmHg) 136 ± 2 137 ± 3 
110-min MAP (mmHg) 135 ± 4 146 ± 3*τ 
Δ MAP (mmHg) post-hex 26 ± 3 38 ± 3τ 
Endpoint MAP (mmHg) 109 ± 5* 108 ± 5* 
 
MAP (mmHg) during baseline, 110-min post HS challenge, the change in MAP following IV 
hexamethonium, and 120-min (endpoint) MAP in conscious Sprague-Dawley rats pretreated ICV 
with a SCR or Gαi2 ODN (25 µg/5 µL) and given a ganglionic blocker at 110-min. Data are mean 
± SEM. *P<0.05, sig. diff. vs. respective baseline group value, τP<0.05, sig. diff. vs. respective 
SCR ODN group value. 
 
Effect of acute sodium challenge during V1a receptor antagonism on cardiovascular 
and renal excretory parameters 
Pretreatment with a peripheral V1a receptor antagonist abolished the rapid (within 
10-minutes) elevation in MAP and the bradycardiac response to HS observed in both 
SCR and Gαi2 ODN pretreatment groups. V1a receptor blockade also prevented any 
significant HS-evoked increases in MAP in SCR ODN pretreated rats.  In contrast, Gαi2 
ODN pretreated rats showed a delayed peak MAP but remained significantly elevated 
(MAP 100-min [mmHg] SCR ODN: 125±2 vs. Gαi2 ODN: 135±0, P <0.05) (Fig. 25). 
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Figure 25. Cardiovascular Parameters in Sprague-Dawley Animals Following V1a Receptor 
Antagonism 
Systemic cardiovascular responses produced by V1a receptor antagonism (10 µg/kg/mL, IV) 
followed by HS challenge (3M, 0.14 mL/100g, IV) in conscious male Sprague-Dawley rats 
pretreated ICV with a SCR or Gαi2 ODN (25 µg/5 µL). Antagonist pretreatment occurred 5 min 
prior to HS, indicated by the dashed line. Data are mean ± SEM (N=6/group). *P<0.05, sig. diff. 
vs. respective group baseline value, τP<0.05, sig. diff. vs. respective SCR ODN group value. 
 
Discussion 
The current studies were designed to determine whether central Gαi2 subunit 
proteins are critical to physiological blood pressure regulation following an acute HS 
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challenge. Both control SCR and experimental Gαi2 ODN pretreatment groups exhibited 
characteristic rapid increases in plasma sodium, osmolality, and MAP in response to IV 
HS, as has been previously reported in conscious rats (Garcia-Estan et al., 1989; Bealer, 
2000; Antunes et al., 2006). MAP returned to baseline by 100-min in control SCR ODN 
pretreated rats, while Gαi2 ODN pretreated rats exhibited a significant persistent 
elevation in MAP during the course of the 120-min experimental protocol. Reflexive 
bradycardia was observed in both groups following IV HS administration, but peak 
changes in HR were significantly greater in control SCR ODN pretreated rats. 
Downregulation of brain Gαi2 proteins was not directly measured in these studies due to 
the different methods of tissue processing for IHC vs. Western blotting. Nonetheless, 
based on our extensive prior studies, we are confident that ICV Gαi2 ODN administration 
resulted in significant and widespread downregulation of brain and PVN Gαi2 proteins 
(Kapusta et al., 2012; Kapusta et al., 2013; Wainford et al., 2013; Wainford et al., 2015b). 
Collectively, these data demonstrate that central Gαi2 proteins contribute to the 
normalization of MAP in response to an acute hyperosmotic stimulus, while the absence 
of these inhibitory proteins produces a prolonged increase in MAP that did not return to 
baseline during the 120-min protocol. Thus impaired Gαi2 function resulted in blood 
pressure dysregulation following an acute HS challenge.  
Because the bradycardia observed following acute HS administration was 
significantly less in animals lacking Gαi2 proteins at all time points in our experiment, we 
examined potential impairments in the cardiac baroreflex in a separate group of animals 
as a possible mechanism contributing to the observed pathophysiological hypertensive 
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pressor response. Cardiac baroreflex sensitivity is known to be reduced in hypertensive 
animals and altered baroreflex responses are often implicated as a mechanism whereby 
blood pressure remains elevated in the experimental setting (Gordon et al., 1981; Bunag 
and Miyajima, 1984). In our cardiac baroreflex studies, Gαi2 ODN pretreated rats showed 
a significant increase in the lowest point to which HR could be driven (A4) (i.e., these rats 
did not lower their HR to the same level as rats with intact Gαi2 proteins at higher blood 
pressures). Further, a decrease in baroreflex sensitivity was evident in Gαi2 ODN 
pretreated rats when the high-pressure baroreflex was analyzed independent of the low-
pressure baroreflex curve. Alterations in PVN projections to parasympathetic cardiac 
vagal neurons (CVN) in the dorsal motor nucleus of the vagus may also contribute to 
dysregulation of central autonomic function and baroreflex control of heart rate 
(Dergacheva et al., 2014). Dergacheva et al. (Dergacheva et al., 2014) have demonstrated 
that impaired glutamatergic PVN pathways to brain stem CVNs attenuate cardiac 
parasympathetic activity that may underlie blunted baroreflex control associated with 
cardiovascular diseases. Although not directly tested in the current studies, we speculate 
that our data demonstrating altered PVN neuronal activation in rats lacking brain Gαi2 
proteins during HS challenge may be affecting the PVN projections to CVNs mediating 
the observed impairment in the high pressure baroreflex activity during HS challenge and 
acute pharmacological baroreflex activation. On the basis of our prior studies in which 
chronic downregulation of central Gαi2 proteins resulted in the development of salt-
sensitive hypertension in multiple salt-resistant rat phenotypes (Kapusta et al., 2013; 
Wainford et al., 2015b), we speculate that brain Gαi2 protein-mediated attenuation of the 
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high pressure baroreflex is a factor contributing to the development of sodium-dependent 
hypertension.  
The PVN is a critical brain region involved in CNS responses to osmotic stimuli 
(Scrogin et al., 1999) that functions in concert with peripheral osmoreceptors to regulate 
the sympathetic responses to sodium challenge (Morita et al., 1997). Our laboratory has 
previously reported that endogenous upregulation of PVN Gαi2 proteins is required to 
maintain physiological blood pressure regulation following chronic dietary sodium 
challenge in salt resistant rat phenotypes (Kapusta et al., 2012; Kapusta et al., 2013; 
Wainford et al., 2015b). However, the effect of downregulation of central Gαi2 proteins 
on PVN neuronal activation in response to an acute HS challenge is not known. Increased 
expression of the protein product Fos results from a substance binding to cell surface 
receptors to induce the immediate early gene c-fos (Dragunow and Faull, 1989; Morgan 
and Curran, 1991; Herrera and Robertson, 1996)—therefore, the presence of Fos (i.e., 
activation of that cell) does not necessarily imply neuronal excitation but merely that an 
extrinsic signal (e.g. neurotransmitter) modified the cell’s function via receptor binding 
(Herrera and Robertson, 1996). The current study analyzed Fos protein expression in 
PVN neurons as a surrogate marker of neuronal activation to determine whether impaired 
activation in this critical site of autonomic integration underlies the pathophysiological 
prolonged elevation in arterial pressure observed in the acute HS paradigm following 
downregulation of brain Gαi2 proteins. No differences in the number of Fos-positive 
nuclei were observed between the ODN pretreatment groups (i.e., control SCR vs. 
experimental Gαi2) in any PVN subregions under baseline conditions 24h post ODN 
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administration. These data suggest that during basal conditions in which plasma 
sodium/osmolality is stable, loss of brain Gαi2 protein expression does not impact tonic 
activation of neurons within the PVN. This is in line with electrophysiological data 
showing that pharmacological blockade of inhibitory-mediated receptor systems has little 
effect on firing activity of PVN neurons in the normotensive state (Li and Pan, 2006).  
In our studies, acute HS-evoked increases in total PVN Fos-positive nuclei were 
observed in SCR ODN pretreated rats at both 40- and 100-min post HS challenge—a 
finding in agreement with the notion that elevations in plasma osmolality induce 
increases in Fos immunoreactivity (Randolph et al., 1998; Kantzides and Badoer, 2003; 
Stocker et al., 2004b). Varied evidence exists for the roles of PVN magnocellular 
neurosecretory, parvocellular neuroendocrine, and parvocellular sympathetic neurons 
with regard to alterations in body fluid homeostasis that influence the sympathetic 
nervous system to regulate blood pressure (Randolph et al., 1998; Kantzides and Badoer, 
2003; Stocker et al., 2004b; Antunes et al., 2006). The PVN was analyzed by subnuclei 
dependent on respective rostral-caudal level to account for the heterogeneous structure 
and accompanying function of the PVN.  
Multiple studies have established that alterations in sympathetic nerve discharge 
are elicited by a hyperosmotic challenge, with PVN parvocellular neurons acting as a key 
mediator of sympathetic outflow in this setting (Swanson and Kuypers, 1980; Kannan et 
al., 1989; Badoer, 1996; Toney et al., 2003). Gαi2 ODN pretreatment significantly 
attenuated HS-induced Fos staining in the MP, VLP, and LP subnuclei of PVN 
demonstrating an impairment in parvocellular neuronal activation following central Gαi2 
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protein downregulation. SCR ODN pretreated rats significantly suppressed circulating 
levels of plasma NE at 10-min post HS. There was no HS-evoked reduction in plasma NE 
content in Gαi2 ODN pretreated rats. The levels of plasma NE are similar to previous 
findings from our laboratory and these data support our prior report that central 
Gαi2 proteins are required to suppress the release of NE during an acute sodium challenge 
(Kapusta et al., 2013). Taken together with our Fos data, these results are consistent with 
the hypothesis that HS-evoked PVN parvocellular neuronal activation represents, in part, 
activation of sympathoinhibitory pathways in control SCR ODN pretreated rats that may 
involve the MP, VLP and LP portions of PVN.  Our hypothesis of an inhibitory role of 
the PVN on sympathetic outflow to reduce blood pressure post acute HS challenge is 
supported by prior reports of inhibitory-mediated PVN modulation of renal sympathetic 
nerve activity to attenuate elevations in arterial pressure (Akine et al., 2003; Stocker et 
al., 2004a). Directly relevant to our finding of sympathoinhibition in response to acute 
HS challenge are data generated in conscious sheep demonstrating the existence of 
central, likely PVN-centric, sodium sensitive pathways that selectively suppress renal 
sympathetic nerve activity in response to elevated sodium content, independently of the 
high pressure baroreflex (May and McAllen, 1997; Frithiof et al., 2009; Frithiof et al., 
2014). Further, studies utilizing selective destruction of PVN parvocellular neurons—
while leaving magnocellular neurons intact—have previously demonstrated that 
parvocellular neurons are a critical synaptic relay site in the activated reflex arc to reduce 
renal nerve discharge during an osmotic challenge (Haselton et al., 1994). 
HS-evoked increases in Fos-positive magnocellular nuclei were observed at 100-
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min in both SCR and Gαi2 ODN pretreated rats. No differences were observed between 
the two ODN pretreatment groups at any time point, suggesting that downregulation of 
brain Gαi2 proteins does not impair the activity of PVN magnocellular neurons in 
response to acute HS.  Consistent with these results, we observed that Gαi2 ODN 
pretreatment had no effect on the observed reduction in free water clearance by the 
kidneys seen after acute HS challenge in the same animals used for Fos staining. To 
address the direct impact of Gαi2 proteins on AVP release to an acute HS challenge, 
circulating plasma AVP was directly measured in separate groups of ODN pretreated 
animals because the volume of blood required for the assay was not compatible with 
repeated sampling. A significant increase in AVP levels was detected 10-min post HS 
challenge in both ODN pretreatment groups, while no differences were observed between 
the groups at any time point, and these levels are similar to prior data from our laboratory 
(Wainford and Kapusta, 2010). The similar levels of AVP release in both SCR and Gαi2 
ODN pretreated groups are concurrent with the observed pattern of increased Fos-
positive nuclei in magnocellular neurons and suggest that brain Gαi2 proteins are not 
involved in the neural regulation of AVP release following acute HS challenge. Previous 
work has established that a rise in plasma sodium concentration promotes 
neurohypophyseal release of AVP (Bourque, 2008) and elevated circulating levels of 
vasopressin following peripheral administration of HS (Russ et al., 1992; Antunes et al., 
2006), a process largely determined by the activity of magnocellular neurons (Badoer, 
2010). Collectively, these data indicate that both neuroendocrine and sympathetic-
regulatory parvocellular neurons are activated in response to acute HS and brain 
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Gαi2 signal transduction is required to mediate sodium-evoked parvocellular autonomic, 
but not magnocellular vasopressinergic, responses to maintain physiologically 
appropriate blood pressure regulation. 
We postulate that the differences in PVN Fos staining following HS between the 
SCR and Gαi2 pretreated rats could reflect, in part, activation of neuronal pathways 
mediating sympathoinhibition necessary for physiological blood pressure control. 
Evidence exists for a PVN-mediated inhibition of renal sympathetic nerve activity 
associated with increases in arterial pressure (Akine et al., 2003; Stocker et al., 2004a). 
As such, we speculate that some PVN neurons activated by HS in SCR ODN pretreated 
rats promote inhibitory mediated signaling required to reduce sympathetic nerve 
discharge and return MAP to basal levels. In contrast, in Gαi2 ODN pretreated rats, 
failure to activate PVN sympathoinhibitory neurons represents a potential mechanism by 
which impairment of Gαi2 signal-transduction may contribute to the prolonged elevation 
in MAP.  
Alterations of inhibitory mechanisms within the PVN, namely mediated by 
GABA and NO, underlie the neural component of cardiovascular reflexes by influencing 
renal sympathetic nerve discharge (Li and Patel, 2003). The presence of GABA neurons 
and NOS immunoreactive neurons in the PVN has been well characterized (Decavel and 
Van den Pol, 1990) and pharmacological blockade of these inhibitory systems elicit 
significant increases in efferent renal sympathetic nerve traffic and MAP (Li and Patel, 
2003). This supports the present findings that implicate activation of PVN parvocellular 
neurons as a critical component in the central neural circuitry contributing to 
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physiological blood pressure regulation. In congruence with this, GABAergic inhibition 
in the modulation of sympathetic outflow may be impaired in hypertension as a 
consequence of a functional change in pre- and post-synaptic GABA receptor activity, 
specifically in the firing activity of PVN-RVLM projecting neurons (Chen and Pan, 
2006; Li and Pan, 2006, 2007). It has been previously reported that GABAB receptors 
play a significant role in tonic GABAergic inhibition of the excitability of the PVN 
output neurons in hypertension. This increased excitability of PVN-RVLM neurons is 
due to inadequate GABAergic inhibition (disinhibition) and may play a role in the 
heightened sympathetic vasomotor tone in adult hypertensive rats (Li and Pan, 2006). 
Owing to the fact that GABAB receptors are coupled to intracellular Gαi2 proteins, we 
speculate that the observed impact of Gαi2 downregulation on cardiovascular 
hemodynamics is reflective of altered GABAergic signaling.    
Several studies utilizing a similar hyperosmotic challenge have reported variable 
effects of acute HS on the neuronal circuits mediating elevations in MAP. Antunes et al. 
postulated a V1a receptor-sensitive mechanism to be solely mediating prolonged 
elevations of MAP (Antunes et al., 2006) while Veitenheimer and Osborn found that 
spinal V1a receptors are not required for elevations of MAP in conscious rats under acute 
or chronic osmotic stress conditions (Veitenheimer and Osborn, 2011).  In the current 
study, it is acknowledged that AVP contributes to initial HS-evoked increases in MAP—
as the rapid peak pressor response was abolished in both ODN pretreatment groups 
during V1a receptor antagonism. However, pharmacological antagonism of V1a receptors 
did not attenuate the prolonged elevation in MAP in Gαi2 ODN pretreated rats following 
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HS challenge. This suggests that V1a receptors are not solely responsible for regulating 
MAP in conditions of acute hyperosmolality. Further, it demonstrates that a significant 
component of blood pressure control in this setting is regulated by the sympathetic 
nervous system—as supported by our observation of attenuated activation of PVN 
parvocellular neurons and a failure to suppress circulating levels of NE in Gαi2 ODN 
pretreated rats.  
Despite the observed differential levels of Fos-positive PVN parvocellular 
neurons between control SCR and Gαi2 ODN pretreatment groups—which we 
hypothesize underlie the observed prolonged elevation in MAP—Fos immunoreactivity 
possesses limitations (Dragunow and Faull, 1989; Morgan and Curran, 1991). It cannot 
be assumed that an increase in Fos expression results in changes in neuronal firing, and 
thus it is difficult to conclude altered intracellular signal transduction as a consequence of 
brain Gαi2 protein downregulation. Further, inhibitory neurons also express Fos (i.e., 
activation does not equate to excitation). Therefore, this technique does not allow one to 
directly understand the precise downstream activity of synaptically coupled neurons (i.e., 
whether this resulted in excitatory or inhibitory post-synaptic potentials). Though not 
feasible in the current study, whole cell patch-clamp recordings performed on 
retrogradely labeled PVN neurons projecting to the RVLM in brain slices have revealed 
reduced frequency and amplitude of GABAergic inhibitory post synaptic currents in the 
SHR (Li and Pan, 2006). Taken together, modulation of PVN parvocellular neurons by 
inhibitory neurotransmitter-receptor systems is critical in the regulation of sympathetic 
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outflow and we speculate decreased activation of these inhibitory neurons contributes to 
the observed HS-evoked elevations in arterial pressure in rats lacking brain Gαi2 proteins. 
Multiple lines of evidence support increased PVN Fos immunoreactivity following 
osmotic challenge [i.e., hypertonic sodium injection (Antunes et al., 2006), water 
deprivation (Stocker et al., 2004b), and sodium infusion (Kantzides and Badoer, 2003)], 
though the subset of activated PVN neurons vary with stimuli. Although the projections 
of activated neurons were not investigated in the current study, studies by Stocker et al. 
(Stocker et al., 2004b) reported that water deprivation increased Fos immunoreactivity in 
RVLM- and spinally-projecting PVN neurons, demonstrating a role for elevated plasma 
osmolality in increased activation of PVN autonomic neurons. Kantzides and Badoer 
(Kantzides and Badoer, 2003) observed an increase in total PVN Fos production in 
response to HS infusion in conscious SD rats, but this increase was not localized to PVN 
neurons with projections to the RVLM and IML. Observed differences between the 
subpopulations of activated PVN nuclei could exist due to the change in MAP produced 
by a bolus sodium challenge in the current study that was not seen in response to HS 
infusion. This is plausible as parvocellular neurons regulate cardiovascular function 
through their afferent projections to medullary and spinal autonomic control centers 
(Ferguson et al., 2008), thus showing increased levels of activation in settings of elevated 
MAP.  
The current data highlight Gαi2 protein signal transduction as a novel CNS 
mechanism acting to influence PVN neuronal activation in response to an acute HS 
challenge in a salt-resistant phenotype. Increased understanding of the acute CNS 
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responses to elevations in plasma osmolality has valuable implications for 
pathophysiological changes that may contribute to the development of hypertension, and 
particularly salt sensitive hypertension. These data extend our understanding of the CNS 
regulatory mechanisms influencing blood pressure regulation and contributes novel 
insight to the ongoing pursuit to define the central neural circuitry that is activated in 
response to increased plasma sodium and osmolality. We speculate that the acute 
activation of PVN neurons in response to elevated plasma sodium/osmolality reflects a 
mechanism mediating sympathoinhibition to facilitate the maintenance of a normotensive 
state. Under conditions in which CNS Gαi2 protein signal transduction is impaired (e.g., 
the Dahl salt-sensitive rat phenotype) (Wainford et al., 2015b), alterations in PVN 
neuronal activity may play a role in driving sympathetically-mediated sodium retention 
and the pathophysiology of salt-sensitive hypertension. Following the discovery of a 
correlation between single nucleotide polymorphisms in the human GNAI2 gene and 
increased hypertension risk (Menzaghi et al., 2006), potential translational implications 
of our findings exist with regard to the pathogenesis of human hypertension and for the 
development of novel anti-hypertensive therapeutics designed to target Gαi2 protein-
gated signal transduction pathways. 
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CHAPTER FOUR: Identification of Hypothalamic Paraventricular Nucleus-
Specific Gαi2 Protein Signal Transduction as a Long-Term Regulator of Blood 
Pressure and Sodium Homeostasis  
Abstract 
Excess dietary salt is an established cause of hypertension and results from the 
complex pathophysiological interaction of multiple homeostatic/regulatory systems. 
Critically, there is no clear understanding of the sodium-sensitive mechanisms that 
operate between the brain and the kidney to facilitate sodium homeostasis and 
normotension in salt-resistant phenotypes. Additionally, derangements in these pathways 
in salt-sensitive subjects represent novel therapeutic antihypertensive targets. The 
purpose of the current study was several-fold. First, we sought to determine whether 
whether hypothalamic PVN-specific Gαi2 protein downregulation impacts the long-term 
regulation of blood pressure during increased dietary salt intake. Lastly, the role of the 
renal nerves in mediating this response was assessed through bilateral renal denervation.  
It was hypothesized that PVN-specific Gαi2 protein downregulation results in 
sympathetically driven, renal nerve-dependent hypertension evoked by a high sodium 
diet. Naïve or bilateral renal denervated Sprague-Dawley rats received either a 
continuous hypothalamic PVN control scrambled or targeted Gαi2 oligodeoxynucleotide 
(ODN) infusion and were fed a normal or high salt diet. PVN-specific infusion of a Gαi2 
ODN evoked salt-sensitive hypertension, elevated plasma and renal norepinephrine 
content, and increased renal NCC activity.  Bilateral renal denervation abolished salt-
sensitive hypertension, restored suppression of plasma and renal norepinephrine, and 
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decreased NCC-mediated sodium reabsorption. These findings implicate PVN Gαi2 
protein-mediated signal transduction as a novel antihypertensive mechanism that prevents 
the development of salt-sensitive hypertension. Further, these data highlight the 
interaction between the central nervous system and kidney, as well as the role of the 
sympathetic nervous system, in the long-term regulation of MAP. 
Introduction 
The effect of elevated salt intake on central sympathoexcitation is deeply involved 
in the pathogenesis of salt-sensitive hypertension, yet there remains broad agreement that 
the specific mechanisms of salt to increase blood pressure are poorly understood. 
Previous studies have shown that increases in dietary sodium intake enhance the activity 
of the sympathetic nervous system and blood pressure responses in normotensive, salt-
resistant rats. Central to the regulation of sympathetic nerve activity and blood pressure 
control is the central nervous system. Evidence from animal models suggest that dietary 
salt intake modulates the responsiveness of forebrain hypothalamic autonomic pathways 
to alter the regulation of SNA and MAP (Simmonds et al., 2014). 
The hypothalamic PVN is a key component of the neural network that modulates 
cardiovascular and fluid homeostasis and sympathetic activity in both the physiological 
state as well as a variety of pathological conditions (Coote, 2005; Guyenet, 2006; Fujita 
and Fujita, 2013). Mono- and polysynaptic projections to the medulla and spinal cord 
from the PVN regulate SNA (Guyenet, 2006). Sodium/osmo-sensitive neural pathways 
exert a major influence on the activity of PVN parvocellular neurons, which are tightly 
coupled to excitatory glutamatergic and inhibitory GABAergic synaptic inputs (Tasker 
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and Dudek, 1993; Haselton and Vari, 1998; Zhong et al., 2008; Wang et al., 2009), and 
therefore central sympathetic outflow (Takeda et al., 1991; Kenney et al., 2003; Gabor 
and Leenen, 2009). Activation of sodium responsive pathways evokes PVN-mediated 
renal sympathoinhibition to facilitate urinary natriuresis and normotension in salt-
resistant subjects (Akine et al., 2003; Frithiof et al., 2014). In contrast, the PVN mediates 
elevated sympathetic outflow, sodium retention, and increased MAP in salt-induced 
hypertension (Gabor and Leenen, 2009; Simmonds et al., 2014; Holbein and Toney, 
2015). A central role of the PVN in salt-sensitive hypertension is further highlighted by 
evidence of PVN-evoked sympathetic hyperactivity (Huang et al., 2001; Gabor and 
Leenen, 2009) and impaired GABAergic sympathoinhibitory (Li and Pan, 2006, 2007; Li 
et al., 2008)responses in multiple salt-sensitive animal models, and is supported by 
studies in which PVN lesions attenuate hypertension (Goto et al., 1981; Nakata et al., 
1989; Takeda et al., 1991). 
The effect of physiological PVN-mediated sympathoinhibition has been suggested 
to be initiated by increased sodium concentration (Frithiof et al., 2014), though the 
specific neural circuitry by which salt is sensed remains unclear.  Alterations in 
sympathetic outflow to the kidneys the affect long-term regulation of blood pressure 
through the dynamic modulation of sodium balance (Lohmeier et al., 1999; Brooks et al., 
2005; Grassi, 2009; Coffman, 2014). The central role of the renal sympathetic nerves in 
the control of blood pressure is supported by data, including that from our laboratory, in 
which removal of the renal sympathetic nerves reduces MAP in hypertensive animals and 
human subjects (Esler et al., 2012; DiBona, 2013; Kapusta et al., 2013; Wainford et al., 
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2015a). 
Critically, there is no clear understanding of the sodium-sensitive mechanisms 
that operate between the brain (Fujita and Fujita, 2013; Stocker et al., 2013a; Fujita and 
Fujita, 2016) and the kidney (DiBona and Kopp, 1997; Bie, 2009; Coffman, 2014) to 
facilitate sodium homeostasis and normotension in salt-resistant phenotypes. 
Additionally, derangements in these pathways in salt-sensitive subjects represent new 
therapeutic antihypertensive targets. 
 Our laboratory has recently demonstrated brain Gαi2 protein-mediated 
transduction as a candidate molecular mechanism involved in countering the 
development of salt-sensitive hypertension. Therefore, it was hypothesized that PVN-
specific Gαi2 protein downregulation results in sympathetically driven, renal nerve-
dependent hypertension evoked by a high sodium diet. To address this hypothesis, we: 1) 
used an oligodeoxynucleotide (ODN) knockdown approach to test the role of PVN-
specific Gαi2 proteins in mediating the blood pressure response to a chronic dietary 
sodium challenge, 2) examined the impact of removing the influence of the renal nerves 
on sodium-evoked changes to cardiovascular parameters and sodium homeostasis, 3) 
assessed the impact of central Gαi2 proteins on the sodium-evoked activation of PVN 
subnuclei in both salt-resistant and salt-sensitive rat phenotypes, and 4) determined the 
differential effects of PVN GABAergic and glutamatergic antagonism during PVN Gαi2 
protein downregulation and high salt intake. 
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Methods 
Animals 
Male Sprague-Dawley (SD) rats (Harlan Laboratories Inc., IN) weighing 275-
300g were individually housed in a temperature- (range: 20-26°C) and humidity-
controlled (range: 30-70%) environment under a 12-h light/dark cycle and were randomly 
assigned to experimental treatment groups. Rats were allowed tap water and standard 
rodent diet (Test Diet, St. Louis, MO, USA) ad libitum.  Following completion of 
surgical procedures (see below), rats were randomly assigned to continue receiving a 
standard rodent diet (Teklad Global Diet, Harlan Laboratories, WI, Teklad Global 18% 
Protein rodent diet #2918, 18% protein, 5% crude fat, 5% fiber, total NaCl content 0.4% 
[174 mEq Na+/kg]) or high sodium diet (Test Diet, IN, Basal diet #5G01, 22% protein, 
5.5% crude fat, 5% fiber, modified to contain total NaCl content 8% [1,378 mEq 
Na+/kg]) and water ad libitum for a 7-day experimental period. All experimental 
protocols were approved by the Institutional Animal Care and Use Committee in 
accordance with the guidelines of Boston University School of Medicine and the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. 
Surgical Procedures 
Chronic ODN administration Bilateral Osmotic Mini-Pump Infusion 
 Animals were anesthetized (ketamine, 30 mg/kg intraperitoneally [IP] in 
combination with xylazine, 3 mg/kg IP) and stereotaxically implanted with a bilateral 
stainless steel cannula (Plastics One, VA) connected via silastic tubing to an osmotic 
mini-pump (model 2006; Durect Corporation, CA) (Kapusta et al., 2013) into the PVN 
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(AP -1.8 mm from bregma, ML ±0.5 mm from bregma, DV -8.0 mm from the skull 
surface) (Paxinos and Watson, 1998) 5-7 days prior to experimentation, as previously 
described (Wainford and Kapusta, 2012).(Kapusta et al., 2013). An NCBI Basic Local 
Alignment Search Tool search of the Rattus norvegicus RefSeq protein database was 
conducted to confirm the specificity of the Gαi2 ODN for the rat Gαi2 protein sequence 
and that the SCR ODN does not match any known rat protein sequence.  
Chronic downregulation of PVN Gαi2 proteins was achieved by continuous 
bilateral PVN infusion of a phosphodiesterase oligodeoxynucleotide (ODN) probe that 
selectively and specifically targets Gαi2 proteins (5’-CTT GTC GAT CAT CTT AGA-3’) 
(Kapusta et al., 2012; Wainford and Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 
2013). Control animals received a bilateral PVN infusion of a scrambled (SCR) ODN (5’-
GGG CGA AGT AGG TCT TGG-3’). All ODNs were dissolved in isotonic saline (300 
ng/side; 3.6 µl/day). Two separate negative control groups were carried out following the 
identical method outlined above: (1) intracerebroventricular cannulation + Gαi2 ODN 
(600 ng in the right lateral ventricle; 3.6 µl/day) and (2) bilateral posterior hypothalamus 
cannulation + Gαi2 ODN (300 ng/side; 3.6 µl/day). 
The ICV dose of 600 ng of ODN was not sufficient to downregulate brain Gαi2 
proteins, but was utilized to address the potential confound by which the PVN dose could 
disperse and affect protein expression in unintended brain regions; based on our data, this 
dose did not have off-target effects. The posterior hypothalamus injected group was 
performed to confirm effects were specific to the PVN and not hypothalamus in general.  
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Bilateral Renal Denervation (RDNX) 
In a separate group of animals receiving a PVN Gαi2 ODN infusion, bilateral renal 
denervation (RDNX) or sham denervation was performed prior to PVN cannulation. In 
these animals, a 5-7 day surgical recovery period was observed following RDNX surgery 
prior to the subsequent implantation of a PVN cannula and osmotic mini-pump, and a 
further 5-7 day recovery period elapsed following PVN cannulation before ODN infusion 
(as described above).  
Standard techniques were used to remove the influence of both the afferent and 
efferent renal sympathetic nerve fibers (Kapusta et al., 2013; Wainford et al., 2013). In 
brief, under pentobarbital anesthesia (30 mg/kg IP), each kidney was exposed by a dorsal 
flank incision. Using a dissecting microscope, the renal vein and artery were dissected 
out of the surrounding fascia and stripped of all visible renal nerve bundles. Following 
dissection, the renal artery was coated with a 10% phenol solution in ethanol to ensure 
the destruction of any remaining renal nerve fibers. The effectiveness of RDNX was 
confirmed at the end of the 7-day salt intake study via ELISA analysis of norepinephrine 
(NE) content in kidney tissue. These data are supported by recent evidence demonstrating 
at the 3-4 week time point following bilateral renal denervation there is significantly 
reduced evidence of efferent nerve innervation of the kidney (Mulder et al., 2013). 
Acute Femoral Vein, Artery and Bladder Cannulation 
In certain experimental groups, following acute ODN injection or chronic ODN 
infusion and 7 days of normal (0.4% NaCl) or high (8% NaCl) intake, animals were 
anaesthetized with sodium methohexital (20mg/kg IP, supplemented with 10 mg/kg 
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intravenously, [IV] as required). Once anesthetized, rats were instrumented with catheters 
in the left femoral artery, left femoral vein, and bladder for the measurement of arterial 
blood pressure, IV administration of saline and/or drugs, and renal function, respectively 
(Kapusta et al., 2012; Wainford and Kapusta, 2012; Kapusta et al., 2013; Wainford et al., 
2013). Rats were then placed in a plexiglass holder and an IV infusion of isotonic saline 
(20µl/min) was maintained for a 2-h surgical recovery period to enable the animal to 
regain full consciousness and cardiovascular/renal excretory function to stabilize prior to 
experimentation. Mean arterial pressure (MAP) and heart rate (HR) were continuously 
recorded via the surgically implanted femoral artery cannula using computer-driven 
BIOPAC data acquisition software (MP150 and AcqKnowledge 3.8.2, CA) connected to 
an external pressure transducer (P23XL; Viggo Spectramed Inc., CA). 
Experimental Protocols 
Acute Volume Expansion Studies 
 These studies were conducted in animals receiving a chronic ODN injection 
following seven days NS intake. After surgical cannulation and a 2-h stabilization period 
in which rats were infused IV with isotonic saline (20 µl/min), cardiovascular and renal 
excretory parameters were measured, and urine was collected during a 20-min control 
period. The infusate was then increased so that rats received an isotonic saline load 
equivalent to 5% of body weight (BW) over a 30-min period. Continuous 10-min urine 
samples were collected during the VE period. The isotonic saline infusate was then 
returned to a rate of 20 µL/min, after which urine samples were collected during a 90-min 
recovery period (Wainford and Kapusta, 2010). 
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Chronic Dietary Sodium Challenge 
 Following RDNX/sham surgery and/or osmotic mini-pump and cannula 
implantation, all animals were assigned to receive either seven days of high salt or 
normal salt food, ad libitum. Metabolic balance studies (outlined below) were conducted 
on day seven, and then animals were sacrificed for collection of plasma or underwent an 
acute cardiovascular study. At the end of either protocol, whole brains and both kidneys 
were collected and stored at -80°C for confirmation of PVN Gαi2 protein downregulation 
and RDNX, respectively, as well as assessment of PVN and renal NE content. 
Acute Cardiovascular Studies 
In certain studies, animals underwent an autonomic function or 
hydrochlorothiazide challenge. After seven days of NS or HS intake, acute femoral vein, 
artery and bladder cannulation was performed. After a 2-h stabilization period in which 
rats were infused IV with isotonic saline (20 µl/min), baseline mean arterial blood 
pressure was recorded continuously over a 30-min period in conscious rats 
(N=6/treatment group/diet) (Kapusta et al., 2013). (a) Autonomic Function Challenge: 
Following baseline MAP recording, IV bolus hexamethonium (30 mg/kg) (Wainford et 
al., 2015a) was administered, and peak changes in MAP were recorded (n=6/treatment 
group/diet). (b) Hydrochlorothiazide (HCTZ) Challenge: Following baseline MAP 
recording, animals received an IV bolus of HCTZ (2 mg/kg) (Ashek et al., 2012). HR and 
MAP were continually monitored for 90-min, and urine was collected in 10-min intervals 
to assess peak natriuresis to IV HCTZ (n=6/group). The peak natriuretic response 
(UNaV; µEq/min) was determined by subtracting the baseline UNaV value from the 
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maximum natriuretic value observed.  
Glutamate Microinjection 
To physiologically confirm accurate placement of the bilateral PVN cannula, 
animals received a microinjection of L-glutamic acid (Sigma-Aldrich, St. Louis, MO) 
dissolved in isotonic saline (15 nmol; 60 nL) following completion of the acute 
cardiovascular experiment. A 0.5 µL syringe (7001KH; Hamilton, Reno, NV) connected 
to a 33G injection needle (Small Parts, Miami Lakes, FL) by a segment of PE-10 tubing 
was used to microinject glutamate into the PVN. The injection needles were 1.0 mm 
longer than the guide cannulas. Subsequent changes in MAP were measured via the 
previously implanted femoral artery cannula. Animals implanted with a posterior 
hypothalamus cannula were given an identical glutamate microinjection as a negative 
control.  
Following protocol completion, rats were decapitated while conscious, and the 
brain and both kidneys were collected and immediately frozen at -80°C for measurement 
of Gα-proteins and renal NE content, respectively. 
Blood Sample Collection 
Conscious decapitation was performed in certain treatment groups (i.e. groups 
which did not undergo the acute cardiovascular study) on day seven of the assigned 
sodium diet and trunk blood was collected in a heparinized tube. Following plasma 
extraction, samples were frozen at -80°C until later analysis of renin activity and 
norepinephrine content. 
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Metabolic Balance Studies 
Metabolic balance studies were conducted in certain treatment groups on day 7 of 
the dietary sodium intake period. Rats were housed in individual metabolic cages (model 
18cv, Fenco, MA) with external food containers and water bottles. Metabolic cages were 
equipped with a double-fine mesh screen that allowed separation of food and feces 
contamination from urine that was collected in vials containing a layer of mineral oil to 
prevent urine evaporation. Rats were randomly assigned to receive a normal or high 
sodium intake diet and provided access to their respective rodent chow and allowed tap 
water ad libitum via external trays and bottles, respectively. On the day of study, 
measurements were made for body weight, food and water intake, and urine output 
during a 24 h period enabling calculation of daily sodium and water balance (Kapusta et 
al., 2012; Kapusta et al., 2013). Daily water balance was determined by calculating the 
difference between water intake and urine output. Daily sodium balance was determined 
by calculating the difference between sodium intake (dietary sodium intake) and sodium 
output (urinary sodium excretion). 
Measurement of Brain Gα-Subunit Protein Levels  
Following completion of experimental protocols, whole brains were removed and 
frozen at -80°C.  Hypothalamic paraventricular nucleus (PVN) samples were extracted 
from frozen brains cut on a cryostat using a brain punch tool (Stoelting, Wood Dale, IL) 
as previously described (Wainford and Kapusta, 2010; Kapusta et al., 2012; Wainford 
and Kapusta, 2012; Kapusta et al., 2013). Tissue lysates were prepared from brain punch 
samples and protein levels were quantified using the BCA assay as per manufacturers’ 
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instruction (Thermo Fisher Scientific, Waltham, MA). Lysates were resolved on a 10% 
SDS-PAGE gel and transferred to nitrocellulose membrane (GE Healthcare, Pittsburgh, 
PA). Gαi1-3 levels were determined as previously published by our laboratory using 
commercially available antibodies purchased from Santa Cruz Biotechnologies (Santa 
Cruz, CA), directed against Gαi1 (1:100, sc-391), Gαi2 (1:200, sc-13534), Gαi3 (1:1000, 
sc-262); protein levels were normalized to GAPDH (anti-GAPDH 1:1000, ab-9483, 
Abcam, Cambridge, MA). Chemiluminescent immunoreactive bands were detected by a 
horseradish peroxidase-conjugated secondary antibody; data were imaged and semi-
quantified using Bio-Rad Quantity One image analysis software. Probing with each 
antibody was performed sequentially following stripping of the membrane with a 
commercially available stripping reagent as per manufacturers’ instruction (Bio-Rad 
Laboratories, Hercules, CA). 
Analytical Techniques 
Analysis of Urine 
Urine volume was determined gravimetrically assuming 1g = 1ml. Urinary 
osmolality was measured using a Vapor Pressure osmometer (model 5600; Wescor Inc., 
South Logan, UT). Urine angiotensinogen was determined using an ELISA kit (Immuno-
Biological Laboratories, Inc., Minneapolis, MN; cat#IB27414) as per manufacturers’ 
instructions 
Analysis of Plasma  
Plasma renin activity (PRA) and plasma norepinephrine levels were determined as 
previously described (Kapusta et al., 2013; Wainford et al., 2013). In brief, following 
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plasma extraction samples were frozen at -80°C until later analysis. For the PRA assay, 
samples were analyzed using a GammaCoat® Plasma Renin Activity 125I RIA Kit 
(DiaSorin, MN) for the quantitative determination of PRA by the radioimmunoassay of 
generated angiotensin I as per manufacturers’ instructions. Plasma NE levels were 
quantified using an ELISA kit (Immuno-Biological Laboratories, Inc., Minneapolis, MN; 
cat#IB89552) as per manufacturers’ instructions (Kapusta et al., 2012; Kapusta et al., 
2013; Wainford et al., 2013). Plasma hematocrit (Hct) was determined using a micro-
hematocrit centrifuge (Adams Readacrit, Clay Adams, NJ) (Kapusta et al., 2013). Hct 
was used to calculate estimated plasma volume (EPV) and estimated blood volume 
(EBV) using the following equations; EPV = (0.065 x body weight (kg)) x (100 – Hct), 
EBV =  (EPV x 100)/(100-Hct) (Lee and Blaufox, 1985; Wainford et al., 2013). 
Analysis of PVN and Renal Norepinephrine Content  
Brains and kidneys were harvested from animals following completion of the 
acute cardiovascular protocol and stored at −80°C. NE content was determined via 
ELISA (Immuno-Biological Laboratories, Inc., Minneapolis, MN; cat#IB89537) as per 
manufacturers’ instructions.  
Analysis of Brain and Renal Norepinephrine Turnover 
 Norepinephrine turnover was calculated based on measurement of the 
disappearance rate of NE after inhibition of tyrosine hydroxylase with α-methyl-p-
tyrosine (Patel et al., 1997). All rats were kept in their home cages during the NE 
turnover study. Following seven days of NS or HS diet, Sprague-Dawley animals infused 
with a PVN-specific SCR or Gαi2 ODN were randomly assigned to one of four 
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subgroups. The first subgroup (n = 6) did not receive the tyrosine hydroxylase inhibitor 
and were used to obtain time ‘zero’ values (endogenous NE turnover). The second, third, 
and fourth subgroups received tyrosine hydroxylase inhibitor, α-methyl-p-tyrosine 
(AMPT-the methyl ester of HCl salt, 300 mg/kg IP; Sigma-Aldrich), at time ‘zero’ and 
animals were sacrificed 3- h, 6-h, or 9-h later, respectively. The brains and kidneys were 
quickly removed, weighed, and then homogenized in cold perchloric acid (0.4 M) 
containing EDTA (0.5 g/l) and sodium metabisulfite (1 g/l), then centrifuged at 4°C for 
15 min at 15 000 x g. The supernatants were stored at - 70°C until they were assayed for 
catecholamines. NE turnover was determined using alumina extraction followed by 
separation and analysis with high performance liquid chromatography (HPLC) and 
electrochemical detection (Bioanalytical Systems).  
Statistical Analysis 
Results are expressed as mean ± SEM. In acute studies, the magnitude of change 
in cardiovascular and renal excretory parameters at different time points after volume 
expansion were compared with respective group control values by a one-way repeated-
measures (RM) ANOVA with a subsequent Dunnett’s multiple comparisons test. 
Differences occurring between treatment groups were assessed by a two-way RM (mixed 
model) ANOVA (treatment x time) with a subsequent Sidak’s multiple comparisons test. 
In chronic studies, differences occurring between treatment groups (e.g., SCR/Gαi2 ODN 
treatment versus NS/HS diet) were assessed by a two-way ANOVA, followed by a 
Newman-Keuls post hoc test, to compare variations among the groups. Where 
appropriate, an unpaired Student’s t-test was also used to compare means between the 
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two groups. Statistical analysis was carried out using a software program (GraphPad 
Prism v. 6.00 for Mac OS X; GraphPad Software, San Diego, CA, USA). In each case, 
statistical significance was defined as P<0.05. 
Results 
PVN-specific Gαi2 protein downregulation attenuates the diuretic and natriuretic 
response to volume expansion 
 Following seven days of NS diet, the physiological stimulus of an acute IV 
isotonic saline volume expansion had no effect on HR and MAP in any ODN-infused 
treatment groups (P>0.05). Volume expansion evoked a significant diuretic and 
natriuretic response in PVN SCR ODN, ICV Gαi2 ODN, and PH Gαi2 ODN treatment 
groups. PVN-specific Gαi2 protein downregulation significantly attenuated the diuretic 
[urine flow rate; V] (30-min peak V [µL/min] PVN Gαi2: 185.0±21.8 vs. PVN SCR: 
320.0±35.0, P<0.05) and natriuretic [sodium excretion; UNaV] (30 min peak UNaV 
[µeq/min] PVN Gαi2: 15.7±4.1 vs. PVN SCR: 27.9±4.1, P<0.05) response to IV volume 
expansion (Fig. 26A). The attenuation of these renal excretory responses resulted in 
significantly reduced cumulative diuretic (−22.1±8.4%) and natriuretic (−32.9±1.4%), 
responses during the 30-min VE period in SCR (Fig. 26B, C; blue bars) vs. Gαi2 (Fig. 
26B, C; red bars) ODN pretreatment groups. 
	 
115 
 
Figure 26. Cardiovascular and Renal Excretory Parameters in Volume Infused Animals 
(A) Systemic cardiovascular and renal excretory responses, (B) cumulative urine output 
(µL/min), and (C) cumulative urinary sodium excretion (µEq/min) produced by IV volume 
expansion (5% body weight) in conscious male Sprague-Dawley rats pretreated (24-h) with a 
control SCR or experimental Gαi2 ODN (300 ng/side) and maintained on a NS diet for 7 days. 
Data are mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group baseline value, 
τP<0.05, sig. diff. vs. respective SCR ODN group value. 
 
 
PVN-specific Gαi2 protein downregulation produces salt-sensitive hypertension  
 The salt-resistant phenotype exhibited by Sprague-Dawley rats was not altered by 
continuous PVN-specific infusion of a control SCR ODN during HS intake. Animals 
receiving a central or posterior hypothalamus infusion of a Gαi2 ODN (as negative 
controls) also remained normotensive following HS intake. Conversely, animals in which 
PVN Gαi2 proteins were downregulated exhibited hypertension following seven days of 
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high sodium intake (MAP [mmHg] PVN Gαi2 + NS: 127±3 vs. PVN Gαi2 + HS: 147±3, 
P<0.05) (Fig. 27A). Further, these animals displayed significantly greater sodium 
retention during high salt intake (24-h sodium balance [mEq] PVN SCR + HS: 0.4±0.2 
vs. PVN Gαi2 + HS: 1.9±0.4, P<0.05) (Fig. 27B). 
 
 
Figure 27. Blood Pressure and Sodium Balance in Sprague-Dawley Animals Maintained on 
a Normal or High Salt Diet 
(A) Basal MAP (mmHg) and (B) 24-h sodium balance in conscious male Sprague-Dawley rats 
infused with a PVN-specific control SCR or experimental Gαi2 ODN (300 ng/side), PH-specific 
Gαi2 ODN (300 ng/side), or ICV Gαi2 ODN (600 ng) and maintained on a NS or HS diet for 7 
days. Data are mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group baseline value, 
τP<0.05, sig. diff. vs. respective SCR ODN group value. 
 
 
	 
117 
Salt-sensitive hypertension resulting from PVN-specific Gαi2 protein 
downregulation is sympathetically driven 
Chronic HS intake evoked a significant suppression in circulating NE in animals 
with intact PVN Gαi2 proteins (i.e. animals receiving either a PVN SCR ODN infusion or 
posterior hypothalamus Gαi2 ODN infusion) (plasma NE [nmol/L] PVN SCR + NS: 
72.0±5.0 vs. PVN SCR + HS: 43.0±4.0; ICV Gαi2 + NS: 72.2±5.0 vs. ICV Gαi2 + HS: 
43.0±4.7; PH Gαi2 + NS: 69.0±4.5 vs. PH Gαi2 + HS: 38.0±4.7, P<0.05). In direct 
opposition to this, HS intake produced a significant increase in circulating plasma NE in 
animals receiving a PVN-specific Gαi2 ODN infusion, as compared to animals fed a NS 
diet (plasma NE [nmol/L] PVN Gαi2 + NS: 67.0±6.2 vs. PVN Gαi2 + HS: 107.7±8.1, 
P<0.05) (Fig. 28A). No differences were observed between treatment groups in HS diet-
evoked suppression of plasma renin activity (Fig. 28B) or HS diet-evoked suppression of 
urinary angiotensinogen (P>0.05) (Fig. 28C). 
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Figure 28. Plasma Norepinephrine, Plasma Renin Activity, and Urinary Angiotensinogen in 
Sprague-Dawley Animals Maintained on a Normal or High Salt Diet 
(A) Circulating plasma norepinephrine (nmol/L), (B) plasma renin activity (Ang I generation 
ng/mL/h), and (C) urinary angiotensinogen (ng/mL) in conscious male Sprague-Dawley rats 
infused with a PVN-specific control SCR or experimental Gαi2 ODN (300 ng/side), PH-specific 
Gαi2 ODN (300 ng/side), or ICV Gαi2 ODN (600 ng) and maintained on a NS or HS diet for 7 
days. Data are mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group baseline value, 
τP<0.05, sig. diff. vs. respective SCR ODN group value. 
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Hypothalamic PVN ODN infusion prevents sodium-evoked suppression of NCC 
activity and results in increased blood and plasma volume  
Animals with intact PVN Gαi2 proteins exhibited a HS-evoked increase in 
fractional sodium excretion (FENa [%] SCR + NS: 0.62±0.07 vs. SCR + HS: 0.87±0.06, 
P<0.05) and a significantly lower peak change in urinary sodium excretion to IV 
hydrochlorothiazide (Peak UNaV [µEq/µL] SCR + NS: 10.4±0.6 vs. SCR + HS: 
07.4±0.6, P<0.05). PVN-specific Gαi2 protein downregulation significantly decreased the 
fractional sodium excretion during HS intake (FENa [%] Gαi2 + NS: 0.57±0.06 vs. Gαi2 
+ HS: 0.18±0.08, P<0.05) and resulted in a significantly greater peak change in urinary 
sodium excretion (Peak UNaV [µEq/µL] Gαi2 + NS: 10.8±0.5 vs. Gαi2 + HS: 14.7±0.9, 
P<0.05) (Fig. 29A, B). These animals also displayed HS-evoked elevations in estimated 
blood volume and estimated plasma volume (Fig. 29C). 
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Figure 29. Fractional Excretion of Sodium, Peak Sodium Excretion, and Estimated Blood 
and Plasma Volume in Sprague-Dawley Animals Receiving a PVN SCR or Gαi2 ODN 
Infusion Maintained on a Normal or High Salt Diet 
(A) Fractional excretion of sodium (FENa; %), (B) peak sodium excretion (UNaV) to IV 
hydrochlorothiazide (µEq/µL), (C) estimated blood volume (mL), and (D) estimated plasma 
voume (mL) in conscious male Sprague-Dawley rats infused with a PVN-specific control SCR or 
experimental Gαi2 ODN (300 ng/side) and maintained on a NS or HS diet for 7 days. Data are 
mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group baseline value. 
 
Hypothalamic PVN ODN infusion increases renal norepinephrine content and 
turnover  
PVN-specific Gαi2 protein downregulation had no effect on PVN NE content or 
sodium-evoked suppression of PVN NE turnover (P>0.05). PVN-specific Gαi2 protein 
downregulation significantly increased renal NE content and renal NE during HS intake 
as compared to an observed suppression in PVN SCR ODN-infused animals (Fig. 30). 
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Figure 30. Norepinephrine Content and Turnover in Sprague-Dawley Animals Receiving a 
PVN SCR or Gαi2 ODN Infusion Maintained on a Normal or High Salt Diet 
(A) PVN NE content (pg/mg), (B) PVN NE turnover (pg/mg/h), (C) renal NE content (pg/mg), 
and (D) renal NE turnover (pg/mg/h) in conscious male Sprague-Dawley rats infused with a 
PVN-specific control SCR or experimental Gαi2 ODN (300 ng/side) and maintained on a NS or 
HS diet for 7 days. Data are mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group 
baseline value. 
 
Hypothalamic PVN ODN infusion selectively targets Gαi2-subunit protein 
expression 
Immunoblotting studies were performed to confirm the in vivo selectivity of Gα-
subunit targeted ODN sequences (Fig. 31). Brain tissue samples from all ODN-infused 
groups, for which physiological data are presented in Figure 26 and 27, were examined 
for the expression of targeted and non-targeted Gα-subunit proteins under investigation 
(i.e. Gαi1, Gαi2, and Gαi3 expression in both SCR and Gαi2 ODN groups). PVN-specific 
infusion of male SD rats with a Gαi2-subunit ODN sequence resulted in highly significant 
and selective target protein downregulation as compared to the SCR ODN infused group 
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(P<0.05). There was no effect of downregulation of related isoforms (i.e., Gαi1 and Gαi3) 
in either ODN-infused group. 
 
Figure 31. Confirmation of Isoform- and Site-Specific ODN Mediated Downregulation of 
Gαi2 Proteins 
(A) Selectivity of central Gαi2 targeted ODN infusion on Gα1-3-subunit protein expression levels 
normalized to GAPDH and (B) representative immunoblots in the VMH, PH, RTN, and PVN of 
Sprague-Dawley rats chronically infused with a control SCR or experimental Gαi2 ODN and 
maintained on a NS diet for 7 days. Data are mean±SEM (N=6/group). *P<0.05, sig. diff. vs. 
respective group baseline value.  
 
Glutamate microinjection into the PVN evokes a pressor response 
To confirm accurate placement of the PVN cannula, animals with a PVN or PH 
cannula were given an acute microinjection of glutamate at the end of the acute 
cardiovascular protocol. It has been shown that microinjection of L-glutamate into the 
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PVN evokes a tachycardiac and pressor response in unanesthetized rats (Busnardo et al., 
2009). Microinjection of L-glutamate evoked a transient pressor response in rats with a 
PVN cannula while no effect was observed in rats with a posterior hypothalamus cannula 
(peak ΔMAP [mmHg] PVN: 16±3 vs. PH: 2±3, P<0.05) (Fig. 32). 
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Figure 32. Pressor Response to L-Glutamate in Sprague-Dawley Animals  
(A) Peak ΔMAP (mmHg) in response to PVN or PH microinjected L-glutamate in Sprague-
Dawley rats chronically infused with an experimental Gαi2 ODN and maintained on a NS diet for 
7 days. Data are mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group baseline value.  
 
 
Salt-sensitive hypertension resulting from PVN-specific Gαi2 protein 
downregulation is renal nerve dependent 
The salt-resistant phenotype exhibited by SD rats was not altered by PVN-specific 
infusion of a control SCR ODN during high salt intake. In a separate group of animals 
with intact renal nerves, PVN Gαi2 ODN infusion produced hypertension following 
chronic HS intake. Bilateral RDNX abolished sodium-evoked hypertension produced by 
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continuous PVN-specific infusion of a Gαi2 ODN (MAP [mmHg] Intact PVN Gαi2 + HS: 
147±3 vs. RDNX + PVN Gαi2 + HS: 132±4, P<0.05) (Fig. 33A). It also resulted in a 
profound reduction of sodium retention (24-h sodium balance [mEq] Intact + PVN Gαi2 
+ HS: 1.9±0.4 vs. RDNX + PVN Gαi2 + HS: 0.4±0.2, P<0.05) (Fig. 33B). Sham 
denervated animals exhibited salt-sensitive hypertension (MAP [mmHg] RDNX + PVN 
Gαi2 + HS: 132±4 vs. Sham + PVN Gαi2 + HS: 148±1, P<0.05)—a response similar to 
animals with intact renal nerves (Fig. 33A). These animals also displayed significantly 
greater sodium retention during high salt intake (24-h sodium balance [mEq] RDNX + 
PVN Gαi2 + HS: 0.4±0.2 vs. Sham + PVN Gαi2 + HS: 1.6±0.3 P<0.05) (Fig. 33B).  
Illustrated as an index of the salt-sensitivity of blood pressure, both ICV and PH Gαi2 
ODN-infused animals (i.e. intact PVN proteins) exhibit a classical salt-resistant 
phenotype. PVN-specific Gαi2 protein downregulation caused a significant reduction in 
the slope of the pressure-natriuresis relationship in sham RDNX animals, reflecting the 
increased salt-sensitivity of blood pressure. This rightward shift was abolished by RDNX 
(Fig. 33C).  
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Figure 33. Blood Pressure, Sodium Balance, and Index of Salt-Sensitivity in Renal 
Denervated Sprague-Dawley Animals Maintained on a Normal or High Salt Diet 
(A) Basal MAP (mmHg), (B) 24-h sodium balance, and (C) index of salt-sensitivity in intact, 
renal denervated, or sham denervated conscious male Sprague-Dawley rats infused with a PVN-
specific control SCR or experimental Gαi2 ODN (300 ng/side), PH-specific Gαi2 ODN (300 
ng/side), or ICV Gαi2 ODN (600 ng) and maintained on a NS or HS diet for 7 days. Data are 
mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group baseline value, τP<0.05, sig. 
diff. vs. respective SCR ODN group value. φP<0.05, sig. diff. vs. SCR + HS group value.  
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PVN-specific Gαi2 protein downregulation evokes renal nerve dependent increased 
renal norepinephrine content and renal sodium chloride co-transporter activity 
Hexamethonium-mediated ganglionic blockade resulted in a significantly greater 
reduction in MAP in PVN-specific Gαi2 ODN infused animals with intact renal nerves 
and sham denervation compared with SCR ODN-infused rats (peak ΔMAP [mmHg] 
Intact + PVN SCR + HS: -48±7 vs. Intact + PVN Gαi2 + HS: -73±7; Sham  + PVN 
Gαi2 + HS: -70±5; P<0.05). Renal denervation resulted in significantly lower reduction in 
MAP (peak ΔMAP [mmHg] Sham  + PVN Gαi2 + HS: -70±5 vs. RDNX + PVN Gαi2 + 
HS: -52±6; P<0.05) (Fig. 34A).   
Furthermore, bilateral RDNX restored sodium-induced suppression of circulating 
plasma NE (plasma NE [nmol/L] Intact + PVN Gαi2 + HS: 108±11 vs. RDNX + PVN 
Gαi2 + HS: 80±4; P<0.05), while sham denervated animals showed a significant increase 
in plasma NE (plasma NE [nmol/L] Intact + PVN Gαi2 + HS: 108±11 vs. Sham + PVN 
Gαi2 + HS: 103±7; P<0.05) (Fig. 34B).  
Animals with intact renal nerves receiving a PVN SCR ODN infusion exhibit a 
HS diet-induced suppression in renal NE content (Fig. 34C) and NCC activity (peak 
UNaV [µeq/µL] Intact + PVN SCR + NS: 10.4±0.6 vs. Intact + PVN SCR + HS: 7.4±0.6; 
P<0.05) (Fig. 34D). Conversely, animals with intact renal nerves or a sham denervation 
exhibit a significant sodium-evoked elevation in renal NE content and NCC activity 
(peak UNaV [µeq/µL] Intact + PVN Gαi2 + NS: 10.8±0.5 vs. Intact + PVN Gαi2 + HS: 
14.7±0.9; Sham + PVN Gαi2 + HS: 14.8±1.2; P<0.05) produced by a PVN Gαi2 ODN 
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infusion. Bilateral RDNX restored sodium-induced suppression of renal NE content and 
NCC activity (peak UNaV [µeq/µL] Sham + PVN Gαi2 + HS: 14.8±1.2 vs. RDNX + 
PVN Gαi2 + HS: 8.46±0.7; P<0.05) in animals receiving a PVN Gαi2 ODN infusion and 
challenged by a HS diet. 
	 
128 
 
Figure 34. Change in Blood Pressure to Ganglionic Blockade, Plasma Norepinephrine 
Content, Renal Norepinephrine Content, and NCC Activity in Renal Denervated Sprague-
Dawley Animals Maintained on a Normal or High Salt Diet 
(A) Peak ΔMAP (mmHg) after IV hexamethonium (30 mg/kg), (B) circulating plasma 
norepinephrine (nmol/L), (C) renal norepinehprine content (pg/mg), and (D) NCC activity 
(µEq/µL) in conscious intact, RDNX, or sham RDNX male Sprague-Dawley rats infused with a 
PVN-specific control SCR or experimental Gαi2 ODN (300 ng/side) and maintained on a NS or 
HS diet for 7 days. Data are mean±SEM (N=6/group). *P<0.05, sig. diff. vs. respective group 
baseline value, τP<0.05, sig. diff. vs. respective SCR ODN group value, φP<0.05, sig. diff. vs. 
SCR + HS group value. 
	 
129 
Discussion 
The key finding of the current study is that the PVN is the critical brain region 
through which intracellular Gαi2 signal transduction proteins mediate physiological 
sympathoinhibitory responses to chronic elevated dietary sodium. This conclusion is 
based on several novel observations in the Sprague-Dawley rat—an animal which 
typically exhibits a salt-resistant phenotype: (1) exogenous PVN-specific downregulation 
of Gαi2 proteins attenuates the natriuretic and diuretic response to IV volume expansion, 
(2) PVN-specific downregulation of Gαi2 results in sodium evoked hypertension, (3) 
development of salt-sensitive hypertension in this model requires the actions of the renal 
nerves, and (4) elevated plasma and renal norepinephrine suggest this effect is 
sympathetically driven. These findings significantly extend our prior report that ODN-
mediated downregulation of brain Gαi2 proteins in Dahl salt-resistant rats leads to 
sympathetically driven salt-sensitive hypertension and impaired sodium balance. The 
current work went beyond this to identify the PVN of the hypothalamus as the brain 
region at which Gαi2 proteins mediate sympathetic outflow to influence blood pressure 
control and sodium homeostasis.  
Acute volume expansion had no effect on basal HR or MAP in any ODN-infused 
treatment groups, confirming no inherent activity of the SCR or Gαi2 ODN alone. As we 
have previously published (Kapusta et al., 2012; Kapusta et al., 2013), acute isotonic 
volume expansion elicited a profound diuretic and natriuretic response in animals with 
intact PVN Gαi2 proteins. PVN-specific infusion of a Gαi2 ODN significantly attenuated 
the diuretic and natriuretic response to IV volume expansion, suggesting the influence of 
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PVN Gαi2 proteins on downstream sodium homeostasis. Indeed, other groups have 
published a significant role for PVN neurons in challenges to whole body fluid volume  
by decreasing renal SNA (Coote, 2005) to aid in maximal urinary excretion of sodium 
(Ramchandra et al., 2013; Frithiof et al., 2014). Additionally, the sympathetic response to 
volume expansion has been characterized by a reduction in the discharge of spinally-
projecting PVN neurons (Lovick and Coote, 1988). These findings in an acute volume 
expansion model prompted the investigation of the role of PVN Gαi2 proteins in the 
chronic setting. 
Chronic downregulation of PVN Gαi2 proteins resulted in sodium-evoked 
hypertension, while animals with intact PVN Gαi2 proteins consuming the same HS diet 
remained normotensive. Evidence supporting this is marked sodium retention, a 
significant elevation in systemic arterial blood pressure, and a profound rightward shift of 
the pressure-natriuresis curve. Mechanistically, the development of salt-sensitive 
hypertension produced by sustained PVN-specific Gαi2 protein downregulation in this 
model likely involves global sympathoexcitation, as evidenced by increased plasma NE 
levels and renal NE content in these animals. Excess NE drives enhanced renal tubular 
sodium reabsorption and contributes to an increase in systemic arterial pressure over time 
(Lohmeier et al., 1999; Johns et al., 2011) and is concurrent with our observation of an 
increase in 24-h sodium balance. Impairment of PVN Gαi2 signal transduction during HS 
intake also results in dysregulation of renal NE content and turnover, but interestingly, 
has no effect on PVN NE content or HS-induced suppression of PVN NE turnover. We 
believe that impairments in Gαi2 protein-mediated signal transduction localized to the 
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PVN affects the downstream alterations in sympathetic outflow to the kidney, thus 
revealing elevations in renal NE content and turnover. This imbalance likely drives 
sodium and fluid retention to stimulate the development of hypertension.  
Further, an enhanced depressor response to ganglionic blockade (hexamethonium) 
points to an impairment of SNA. These findings suggest that elevated plasma levels of 
NE also contribute to the elevation in MAP in Gαi2 ODN-treated rats on high-salt intake 
by increasing vascular resistance to peripheral organ beds (e.g., potentially splanchnic or 
renal vasculature). All ODN infusion groups exhibited a suppression of PRA and urinary 
angiotensinogen upon HS intake. These data suggest that suppression of PRA, and 
presumably aldosterone secretion, occur independently of central Gαi2 protein signal 
transduction pathways. Nonetheless, these data point to a key role for humoral 
mechanisms (i.e., renin-angiotensin system) in maintaining fluid and electrolyte 
homeostasis.  The current studies do not elucidate the mechanism underlying the 
observed suppression of PRA; however, it is possible that suppressed PRA during high-
salt intake is mediated by a renal baroreceptor pathway or reflects a salt-evoked decrease 
in the number of renin-secreting cells present in the afferent arteriole. 
Central sympathoexcitation is implicated as the main driver of this hypertensive 
state, potentially due to the absence of PVN-mediated inhibition of sympathetic outflow. 
In support of these findings, it has been recently demonstrated that acute increases in 
blood sodium levels cause a decrease in renal SNA and that this renal sympathoinhibitory 
effect of sodium is mediated via a pathway that synapses in the PVN (Frithiof et al., 
2014). In the current study, impaired Gαi2 protein signal transduction in the PVN resulted 
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in sympathetically-mediated salt-sensitive hypertension and thus, suggests a critical role 
of PVN Gαi2 proteins in modulating changes in sympathetic outflow. Taken together, 
PVN Gαi2 protein-mediated signal transduction arises as a candidate driver of 
sympathoinhibition required for a normotensive state, with sympathoexcitation and 
hypertension resulting from the absence of these intracellular inhibitory proteins in the 
PVN.  
To determine whether the renal nerves are involved in the observed 
sympathoexcitatory drive, RDNX was performed in animals lacking PVN Gαi2 proteins 
and challenged by a high salt diet. Indeed, RDNX abolished salt-sensitive hypertension, 
suggesting that the integrity of the renal nerves is required for the development of this 
hypertensive state. A drawback to RDNX is that the relative contribution of the afferent 
vs. efferent renal nerves remains unknown in this paradigm, as the technique does not 
discriminate between fibers and all are ablated. Clinical studies utilizing renal 
denervation for the treatment of resistant-hypertension have yielded mixed outcomes and 
the antihypertensive effects of RDNX are still unclear (Esler et al., 2012; Davis et al., 
2013; Krum et al., 2014). In the Dahl salt-sensitive rat, it has been suggested that the 
antihypertensive effect of RDNX is likely due to reduced activity of the renin-angiotensin 
system (Foss et al., 2016), though the current study observed a HS-evoked suppression in 
PRA in all treatment groups. Renal denervation has also been shown to alter 
hypothalamic NE content (Winternitz et al., 1982) and cardiovascular responses to 
ganglionic blockade (Krueger et al., 1986) in several experimental hypertensive models.  
It is postulated that the interruption of the negative feedback circuit that exists 
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between these fibers may contribute to hypertension. Afferent-mediated inhibition of 
efferent nerve release of NE modulates homeostatic control of sympathetic nerve 
activity—removal of this inhibitory “brake” allows greater release of NE, and thus a 
sympathoexcitatory state. These data suggest that interruption of renal nerve traffic may 
alter central sympathetic nervous activity. Therefore, it is plausible that the renal nerves 
are involved in the mechanisms that alter sympathetic function during the development of 
hypertension, thereby preventing salt-sensitive hypertension when they are removed. 
The independent effects of the afferent and efferent renal nerves are not well defined, and 
development of future treatment modalities requires not only a deeper understanding of 
their separate roles, but their combined influences on one another. Future experiments 
will examine the blood pressure response to high dietary salt in animals lacking PVN 
Gαi2 proteins following selective afferent renal nerve denervation (Foss et al., 2015).  
The current studies are limited in that they do not allow us to ascertain the precise 
receptor systems within the PVN by which Gαi2 proteins are coupled to that mediate the 
observed responses to chronic dietary sodium. To speculate, a major factor leading to 
increased sympathetic outflow to the kidneys from the PVN is reduced inhibitory 
GABAergic input (Li and Patel, 2003). In fact, a loss of a loss of PVN inhibitory 
GABAergic tone has been demonstrated in multiple disease states (Ramchandra et al., 
2013). GABAB receptors play an increasingly significant role in tonic GABAergic 
inhibition of the excitability of PVN output neurons in hypertension (Chen and Pan, 
2006; Li and Pan, 2006). Therefore, increased excitability of PVN-RVLM neurons due to 
inadequate GABAergic inhibition (disinhibition) may play a role in the heightened 
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sympathetic vasomotor tone in adult hypertensive rats (Li and Pan, 2006). 
Collectively, the current study highlights the interaction between the central 
nervous system and kidney, as well as the role of the sympathetic nervous system, in the 
long-term regulation of MAP.  Future work will aim to determine the precise receptor 
systems localized at the level of the PVN that influence SNA to further understand the 
molecular mechanisms by which PVN Gαi2 protein downregulation results in salt-
sensitive hypertension. To emphasize the importance of understanding homeostatic 
antihypertensive mechanisms, a recent review (Fujita and Fujita, 2016) has concluded 
that further investigation is required to manage salt-sensitive hypertension effectively by 
targeting central sympathetic inhibition. 
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CHAPTER FIVE: Overall Discussion & Perspectives 
Overall Discussion 
The importance of elucidating the underlying cellular signaling pathways 
involved in the neural control of sodium excretion in health and disease is highlighted by 
the multiple pathophysiological disease states that exhibit sodium retention, including 
heart failure, certain models of hypertension, and particularly salt-sensitive hypertension 
(Bayorh et al., 1998; Ando, 2014). Our collective work sought to provide an enhanced 
understanding of the central biological mechanisms that regulate blood pressure and the 
pathological processes underlying the development of salt-sensitive hypertension. Our 
data demonstrate a pivotal role of PVN Gαi2 subunit proteins in mediating sympathetic 
outflow and natriuresis in response to acute and chronic challenges to sodium 
homeostasis. We have reported that high dietary salt-evoked upregulation of PVN Gαi2 
proteins is required to maintain salt-resistance, via a renal nerve dependent 
sympathoinhibitory pathway, in the salt-resistant SD and DSR rat, and that a failure of 
this response contributes to the pathophysiology of DSS hypertension. Further, it was 
observed Gαi2 protein signal transduction differentially influences PVN parvocellular 
neuronal activation, the high-pressure baroreflex, sympathetic outflow, and blood 
pressure in response to an acute increase in plasma sodium, independently of actions on 
magnocellular neurons and vasopressin release in the salt-resistant SD rat.113 Our work 
supports a PVN-specific Gαi2 subunit protein-gated signal transduction pathway that 
regulates sympathetic outflow in response to alterations in salt intake to maintain a salt-
resistant phenotype (Fig. 35). However, the impact of PVN Gαi2 proteins on the 
	 
136 
sympathoinhibitory neural mechanisms activated by acute and chronic challenges to 
sodium homeostasis in salt-resistant vs. salt-sensitive models remains unknown. 
 
Figure 35. Salt-Resistant versus Salt-Sensitive Phenotypes 
Schematic representation of the differential impact of elevated dietary sodium intake on PVN 
Gαi2 protein expression and the effect on central sympathetic outflow, sodium homeostasis, and 
blood pressure in salt-resistant versus salt-sensitive phenotypes.  
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Future Directions 
Future work of the laboratory will determine whether PVN Gαi2 proteins mediate 
sympathoinhibitory actions activated by acute and chronic sodium challenges in a salt-
resistant animal model, and whether impairment of this signal transduction pathway 
contributes to hypertension in salt-sensitive animal models. Future work will also further 
define the specific receptor systems that critically mediate physiological SNA and blood 
pressure responses through PVN Gαi2 protein-mediated signal transduction in salt-
resistant animal models. Increased neuronal activity and excitability (i.e., synaptic 
plasticity) in the PVN mediates elevated sympathetic drive in multiple hypertensive 
animal models. Pathophysiological changes in GPCR signaling can be probed to 
understand the mechanistic contributions to salt-sensitive hypertension. 
GABAB receptors play an increasingly significant role in tonic GABAergic 
inhibition of the excitability of the PVN output neurons in hypertension (Li and Pan, 
2006). Therefore, increased excitability of PVN-RVLM neurons due to inadequate 
GABAergic inhibition (disinhibition) may play a role in the heightened sympathetic 
vasomotor tone in adult hypertensive rats (Li and Pan, 2006). Plasticity of brain GABA 
receptors in PVN presympathetic neurons may contribute to hypertension development 
and are not merely an adaptation to elevations in arterial pressure. Alternatively, changes 
in the downstream signaling also can preferentially alter the GABAB receptor function in 
glutamatergic and GABAergic terminals in the PVN in the SHR (Li et al., 2008). Further, 
electrophysiological data suggest that GABAB receptors—metabotropic receptors coupled 
to intracellular Gαi2 proteins—greatly influence PVN presympathetic neurons in the 
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hypertensive state (Li and Pan, 2006). 
Lastly, basic science data generated by the laboratory thus far in salt-resistant and 
salt-sensitive phenotypes suggest that SNPs in the GNAI2 gene (Menzaghi et al., 2006; 
Kohara et al., 2008) could be utilized as a potential biomarker of salt-sensitivity, as well 
as to predetermine individuals at risk of salt-sensitive hypertension. To further pursue 
these findings, we have designed a translational study to interrogate polymorphic 
variance of GNAI2 as a biomarker of both hypertension and the salt-sensitivity of BP in 
human subjects in the GenSalt and HyperPATH cohorts. This work will directly address 
the need for standardized protocols to determine salt-sensitivity at an individual level.  
Perspectives 
The pathophysiological characteristics explored in salt-sensitive hypertension not 
only deepen our insight into the mechanisms underlying the relationship between salt and 
blood pressure regulation, but have broad relevance to other disease states. Central 
sympathoexcitation is a hallmark feature of a multitude of pathophysiological disorders, 
including obesity-induced hypertension (Ando, 2014), heart failure (Honda et al., 2013), 
and chronic intermittent hypoxia in sleep apnea (Shell et al., 2016). Adequate treatment 
options remain scarce for patients affected by these disorders, especially therapeutics that 
modify the course of the disease rather than simply treating the secondary symptoms 
associated with it. We hope that our work to define the central signal transduction 
mechanisms involved in elevated sympathetic nerve activity will provide a foundation for 
the development of novel treatments not only for salt-sensitive hypertension, but many 
other diseases featuring central sympathoexcitation. 
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The critical importance of this work and establishing new methodologies to 
identify the clinical phenotype of salt-sensitivity is underscored by 1) the excess of 
dietary salt consumed globally (Appel et al., 2011; WHO, 2013), 2) the absence of 
hypertension biomarkers  or a rapid method to ascertain the salt-sensitivity of blood 
pressure (Weinberger et al., 1986; Morimoto et al., 1997), and 3) the results of the 
SPRINT (The SPRINT Research Group, 2015) and PATHWAY-2 (Williams et al., 2015) 
trials, which support the benefits of significant blood pressure reduction and a primary 
role of sodium retention in resistant hypertension, respectively. Future work has the 
potential to substantially enhance our understanding of the mechanisms by which central 
Gαi2 proteins function to impact blood pressure during salt intake and potentially provide 
a methodology to identify patients at risk of developing salt-sensitive hypertension. We 
hope this work will result in a paradigm shift in the approach toward the treatment of 
hypertension from a non-specific treatment algorithm to a more precision-medicine based 
approach driven by each individuals’ underlying disease mechanism and genotype. This 
potential personalized approach will be groundbreaking in treating those with and at risk 
for hypertension.  
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APPENDIX 
Central Gαi2 Proteins, Sympathetic Nervous System, and Blood Pressure Regulation 
This section published previously as: J. Zicha (2016). Central Gαi2 proteins, sympathetic 
nervous system, and blood pressure regulation. Acta Physiologica 216(3), 258–259. 
 
Editorial Commentary on C. Y. Carmichael, A. C. T. Carmichael, J. T. 
Kuwabara, J. T. Cunningham, & R. D. Wainford (2016). Impaired sodium-evoked 
PVN neuronal activation underlies prolonged elevated blood pressure in 
conscious Sprague-Dawley rats lacking central Gαi2 proteins. Acta Physiologica 
216(3): 314-329. PMID: 26412230. 
 
Carmichael et al. (2016) demonstrated that the inactivation of brain Gαi2 proteins 
prolonged the duration of blood pressure response elicited by intravenous administration 
of hypertonic saline. Some of their findings indicated that brain Gαi2 protein inactivation 
altered the central mechanisms responsible for the suppression of sympathetic outflow, 
which occurs in intact rats challenged by hypertonic saline. These mechanisms involve 
sodium-evoked activation of parvocellular neurons in paraventricular nucleus. 
 This study on the role of Gαi2 protein-mediated signal transduction in the 
response of Sprague-Dawley rats to acute salt loading is an exciting paper, especially if 
we consider its results in the context of previous studies by Kapusta and Wainford. Brain 
Gαi2 subunit proteins participate in central sympathoinhibition in animals subjected to 
acute salt loading in which the inactivation of brain Gαi2 proteins causes sodium 
retention, sympathoexcitation, and blood pressure elevation (Kapusta et al., 2012). 
Highly important are also the findings that brain Gαi2 proteins are responsible for salt 
resistance in the rat. Recently, Wainford et al. (2015) reported that chronic 
intracerebroventricular infusion of targeted Gαi2 oligonucleotides enabled the 
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development of salt hypertension even in salt-resistant Dahl rats and the same 
phenomenon was also observed in Sprague-Dawley rats (Kapusta et al., 2013). Indeed, 
blood pressure effects resulting from the sympathoexcitation in animals subjected to the 
inactivation of brain Gαi2 proteins were confirmed by enhanced blood pressure response 
to ganglionic blockade (Kapusta et al., 2013; Wainford et al., 2015a; Carmichael et al., 
2016).  
 Another highly interesting part of the paper by Carmichael et al. concerns the 
impact of Gαi2 ODN pretreatment on the baroreflex function. Central 
Gαi2 downregulation, which is associated with facilitation of salt hypertension 
development, caused a moderate attenuation of baroreflex efficiency. There was a less 
steep slope of baroreflex curve (heart rate to mean arterial pressure relationship) in 
Gαi2 ODN pretreated rats, indicating decreased baroreflex sensitivity in Gαi2 ODN 
pretreated rats. This is clearly evident in high-pressure part of the analyzed baroreflex 
curve. It is generally accepted that baroreflex function is altered in hypertensive subjects 
and animals. These alterations appearing during hypertension development consist of the 
resetting of baroreflex set point to high blood pressure values and the decrease in 
baroreflex sensitivity. Nevertheless, this study shows that the inactivation of brain 
Gαi2 proteins caused the changes in baroreflex sensitivity without previous blood 
pressure changes. It would therefore be desirable to analyze the changes of baroreflex 
sensitivity prior to high blood pressure appearance in salt-sensitive Dahl rats developing 
salt hypertension as well as in salt-resistant Dahl rats in which salt hypertension 
development was enabled by Gαi2 ODN pretreatment (Wainford et al., 2015a).  
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 Thus, the altered function of central α2-adrenergic mechanism causing 
sympathoinhibition through the activation of Gαi2 protein-gated signal transduction 
pathways might be the key to better understanding of pathophysiology of salt 
hypertension in Dahl rats, which are characterized by enhanced sympathetic nerve 
activity and its augmented contribution to high blood pressure maintenance (Takeshita et 
al., 1979; Zicha et al., 2001) (for reviews, see also (Zicha et al., 2012) and (Mark, 1991). 
Further studies should be focused on possible alterations of Gαi2-dependent 
sympathoinhibitory mechanisms in other models of salt hypertension, as well as on the 
participation of these mechanisms in other forms of experimental hypertension. 
 It is of interest that Gi proteins participate not only in central but also peripheral 
mechanisms of blood pressure control, but blood pressure effects of their brain or 
peripheral inactivation are quite opposite. Blood pressure of spontaneously hypertensive 
rats (SHR), which is highly dependent on sympathetic vasoconstriction (for recent 
review, see e.g. (Pinterova et al., 2011), can be considerably lowered by peripheral Gi 
protein inactivation following intravenous pertussis toxin administration (Tabrizchi and 
Triggle, 1991; Pinterova et al., 2010). Chronic treatment of immature SHR with pertussis 
toxin retarded effectively the onset of genetic hypertension development (Li and Anand-
Srivastava, 2002). The contribution of peripheral mechanisms to blood pressure reduction 
elicited by Gi protein inactivation was studied by Pinterova et al. (2010) who reported the 
attenuation of sympathetic vasoconstriction in pertussis toxin-treated rats, the effects 
being substantially greater in hypertensive animals than in their normotensive controls. 
Using conscious rats subjected to acute ganglionic blockade, we demonstrated a 
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rightward shift of blood pressure response to noradrenaline in pertussis toxin-treated rats, 
indicating diminished vascular responsiveness to noradrenaline in animals with 
peripheral Gi protein inactivation. This shift of noradrenaline dose-response curve to the 
right was caused by the disappearance of nifedipine-sensitive component of vascular 
contraction in pertussis toxin-treated SHR, suggesting an important role of peripheral α2-
adrenergic mechanisms in the pathogenesis of genetic hypertension (Pinterova et al., 
2009; Pinterova et al., 2010).  
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